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Abstract!
Background 
Adoptive transfer of cells targeting viral infection or tumour following allogeneic 
transplantation is hindered by the requirement for immunosuppression. Reports 
of engineered resistance to calcineurin inhibitors have highlighted the potential 
of conferring immunosuppressive resistance in this setting. A commonly used 
immunosuppressant, mycophenolate mofetil (MMF) is a non-competitive 
inhibitor of inosine-5’-monophosphate dehydrogenase (IMPDH). I used T cells 
transduced with mutated IMPDH that confers >2000-fold resistance to MMF 
(IMPDH2R; T333I, S351Y).  
Methods 
IMPDH2R and IMPDH2 with a catalytic site mutation (IMPDH2CS; C331A) were 
cloned into retroviral vectors as fusions to eGFP reporter sequences. T cells 
were transduced with either vector, transferred to recipient mice and evaluated 
in the presence or absence of MMF.  
Results 
A selective advantage for IMPDH2R was demonstrated using a 1:1 mix of CD8 
T cells transduced with IMPDH2R and IMPDH2CS. These were injected into 
recipients distinguishable from the transferred cells using congenic markers. 
Transferred cells were stimulated by cognate peptide and MMF (0-
200mg/kg/day) was given daily. Selection of IMPDH2R transduced cells 
occurred following stimulation even without drug (Mann-Whitney Ratio 
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IMPDH2R:IMPDH2CS p=0.0356). MMF administered significantly increased 
selection (Mann-Whitney MMF 0 v 200 p=0.0365).  
To assess function, irradiated mice were injected with EL4.OVA tumour cells 
subcutaneously. After 10 days, either MMF or vehicle treatment was initiated 
and OT1 CD8 T cells transduced with either IMPDH2CS or IMPDH2R 
transferred. The combination of MMF and IMPDH2R transduced cells resulted 
in significantly improved survival over vehicle treated mice (log rank p<0.0001) 
with significantly smaller tumours at day 26 (Mann-Whitney p<0.0001). This 
effect was due to direct synergistic effects of both MMF and transferred T cells 
against tumour cells. 
Conclusions 
IMPDH2R confers cells with a selective advantage. Synergy with MMF resulted 
in improved tumour survival. In patients requiring on-going immunosuppression 
during adoptive immunotherapy, this combination has great therapeutic 
potential.   
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5 
Index 
 
Declaration and Dedication 
 
Abstract 
 
Index  
 
Abbreviations 
 
Page 
2 
 
3 
 
5 
 
14 
 
19 
 
19 
 
24 
 
25 
 
25 
 
26 
 
 
28 
 
 
28 
 
29 
 
29 
 
30 
 
31 
 
31 
 
34 
 
36 
 
38 
 
39 
 
41 
 
43 
 
45 
 Chapter 1. Introduction 
 
Background 
 
1.1  
 
1.1.1  
 
1.1.1.1  
 
1.1.2  
 
 
1.1.3  
 
 
1.1.3.1  
 
1.1.3.2  
 
1.1.3.3  
 
1.1.4  
 
1.1.5  
 
1.1.5.1  
 
1.1.5.2  
 
1.1.6  
 
1.1.6.1  
 
1.1.6.2  
 
1.1.6.3  
 
1.2  
 
1.2.1  
Adoptive Immunotherapy  
 
Specificity  
 
Selection and expansion of cells of required TCR specificity  
 
Clinical use of virus specific adoptive immunotherapy in stem cell 
transplantation 
 
Clinical Use of Virus specific adoptive immunotherapy in solid organ 
transplantation 
 
Autologous EBV-CTL  
 
Generation of EBV-CTLs from seronegative recipients  
 
Third party EBV-CTL  
 
Adoptive immunotherapy in non-transplant patients  
 
Redirection of lymphocytes  
 
Redirection – TCR transduction  
 
Redirection – CAR transduction  
 
In vivo expansion and engraftment - Lymphodepletion  
 
Lymphodepletion – elimination of regulatory T cells (Treg)  
 
Lymphodepletion – Cytokine sinks and homeostatic expansion 
 
Lymphodepletion – Competition for APC 
 
Post transplant Immunosuppressive Regimens  
 
Corticosteroids 
6 
1.2.2  
 
1.2.3  
 
1.2.4  
 
1.2.5  
 
1.2.6  
 
1.2.7  
 
1.2.8  
 
1.2.9  
 
1.2.10  
 
1.3  
 
1.4  
 
1.4.1  
 
1.4.2  
 
1.4.2.1  
 
1.4.3  
 
1.4.3.1  
 
1.4.3.2  
 
1.4.3.3  
 
1.4.3.4  
 
1.4.4  
 
1.4.4.1  
 
1.4.5  
 
1.4.6  
 
1.4.7  
 
1.4.7.1  
 
1.4.7.2  
 
1.4.7.3  
 
1.4.7.4  
 
 
Calcineurin inhibition – Ciclosporin 
 
MTOR Inhibition – Sirolimus 
 
Purine synthesis inhibition – MMF 
 
Pyrimidine synthesis inhibition – Azathioprine 
 
Biological agents – Antithymocyte globulin (ATG) 
 
Biological agents – Alemtuzumab 
 
Biological agents – Basiliximab and Daclizumab 
 
Biological agents – Rituximab 
 
Use of immunosuppressive agents in combination 
 
Effect of pharmacological immunosuppression on cellular therapy 
 
Mycophenolate Mofetil (MMF) 
 
Identification and development of MPA/MMF 
 
Purine metabolism 
 
Inherited defects of purine metabolism 
 
Inosine-5’-Monophosphate Dehydrogenase (IMPDH) 
 
IMPDH structure 
 
Enzymatic action of IMPDH 
 
Other functions of IMPDH 
 
Mutations in IMPDH 
 
Pharmacokinetics of MMF 
 
Clinical monitoring of MPA levels 
 
Antimicrobial activity of MPA 
 
Antineoplastic activity of MPA 
 
Immunosuppressive activity of MPA 
 
MPA reduces lymphocyte proliferation 
 
MPA causes a reduction in antibody formation 
 
MPA has minimal effect on cytokine production 
 
MPA in vitro reduces glycosylation and expression of adhesion  
molecules 
 
45 
 
46 
 
46 
 
46 
 
47 
 
48 
 
48 
 
48 
 
49 
 
50 
 
53 
 
53 
 
55 
 
57 
 
57 
 
59 
 
62 
 
64 
 
64 
 
65 
 
66 
 
67 
 
68 
 
69 
 
69 
 
69 
 
70 
 
70 
 
 
7 
1.4.7.5  
 
1.4.7.6  
 
1.4.8  
 
1.4.8.1  
 
1.4.9  
 
1.5  
 
1.6  
 
  
 
2.1  
 
2.1.1  
 
2.1.2  
 
2.2  
 
2.2.1  
 
2.2.2  
 
2.2.3  
 
2.2.4  
 
2.2.4.1  
 
2.2.4.2  
 
2.2.4.3  
 
2.2.4.4  
 
2.2.5  
 
2.2.6  
 
2.2.7  
 
2.3  
 
2.3.1  
 
2.3.2  
 
2.3.3  
 
2.3.4  
 
2.3.5  
MPA inhibits nitric oxide production  
 
MMF in models of allograft rejection  
 
Clinical studies of MMF 
 
Prevention of SOT allograft rejection 
 
Safety and tolerability of MMF  
 
Hypotheses 
 
Aims 
 
Chapter 2: Materials and methods  
 
Retroviral vectors 
 
Generation of wild-type IMPDH2 
 
Generation of catalytic-site mutant IMPDH2 
 
Cell culture 
 
Murine cells 
 
Cell lines 
 
Cell counting and viability 
 
Culture media 
 
Murine T cells – T cell media 
 
RMAS cells and BW cells – Cell line media 
 
EG7 cells – EG7 media  
 
Packaging cell media 
 
Cytokines 
 
Mycophenolic acid 
 
Peptides 
 
Retroviral transduction 
 
Transfection and retroviral particle production 
 
Magnetic bead selection and activation of CD8+ T cells 
 
Retronectin 
 
Transduction of CD8+ murine splenocytes 
 
Maintenance of murine cells in culture 
70 
 
71 
 
71 
 
71 
 
72 
 
74 
 
74 
 
75 
 
75 
 
76 
 
79 
 
82 
 
82 
 
82 
 
83 
 
84 
 
84 
 
84 
 
84 
 
84 
 
85 
 
85 
 
85 
 
86 
 
86 
 
86 
 
87 
 
87 
 
88 
8 
2.3.6  
 
2.3.7  
 
2.3.8  
 
2.4  
 
2.4.1  
 
2.4.2  
 
2.5  
 
 
2.5.1  
 
2.6  
 
2.6.1  
 
2.6.2  
 
2.6.3  
 
2.6.4  
 
2.7  
 
2.7.1  
 
2.7.2  
 
2.7.3  
 
2.8  
 
 
 
3.1  
 
3.2  
 
3.3  
 
3.3.1  
 
 
3.3.2  
 
 
3.3.3  
 
 
3.3.4  
 
 
Retroviral Transduction of BW cells 
 
Preparation of Human Peripheral Blood Mononuclear Cells (PBMC) 
 
Retroviral transduction of human PBMC 
 
Peptide restimulation 
 
Restimulation of transduced murine splenocytes 
 
Restimulation of transduced human PBMC 
 
Measurement of secreted IL-2 and IFN-γ by enzyme-linked 
immunosorbent assay (ELISA)  
 
Standards preparation 
 
Flow cytometry 
 
Cell surface staining  
 
Fluorescent labelled antibodies 
 
Detection of Apoptosis – Annexin V staining 
 
Analysis of Cell Cycling 
 
In vivo Experiments 
 
Mycophenolate mofetil 
 
Peptide 
 
Procedures 
 
Statistical analysis 
 
Chapter 3: In vitro functional analysis of IMPDH2R transduced cells 
 
Introduction 
 
Aims 
 
Results 
 
IMPDH2R expression increases the IC50 for MPA compared to IMPDH2CS, 
while IMPDH2WT confers an intermediate phenotype.  
 
IMPDH2R expression confers a selective advantage during MPA exposure 
compared to un-transduced cells 
 
IMPDH2R transduced BW cells overcome MPA-induced cell cycle 
blockade 
 
IMPDH2R transduced BW cells are protected against MPA-induced 
apoptosis 
 
88 
 
88 
 
89 
 
90 
 
90 
 
90 
 
91 
 
 
92 
 
93 
 
93 
 
93 
 
95 
 
95 
 
96 
 
96 
 
96 
 
97 
 
97 
 
98 
 
99 
 
100 
 
101 
 
101 
 
 
104 
 
 
107 
 
 
112 
 
 
9 
3.3.5  
 
3.3.6  
 
 
3.3.7  
 
3.3.8  
 
3.4  
 
 
 
4.1  
 
4.2  
 
4.3  
 
4.3.1  
 
4.3.2  
 
 
4.3.3  
 
 
4.3.4  
 
4.3.5  
 
 
4.3.6  
 
 
4.3.7  
 
 
 
4.4  
 
 
 
 
5.1  
 
5.2  
 
5.3  
 
5.3.1  
 
5.3.2    
 
 
 
 
Antigen dependent selection 
 
IMPDH2R transduced cells are progressively selected under antigen 
independent conditions 
 
Selection and expansion of TCR redirected PBMC 
 
Retention of function post MPA exposure 
 
Discussion 
 
Chapter 4: In vivo selection of IMPDH2R transduced cells 
 
Introduction 
 
Aims 
 
Results 
 
In vivo dosing and toxicity of MMF 
 
In vivo administration of MMF in mice not exposed to lymphodepleting 
irradiation reduces lymph node cellularity 
 
In vivo administration of MMF in mice not exposed to lymphodepleting 
irradiation reduces B220 cell numbers but not CD4 or CD8 T cells 
 
Development of a model of in vivo selection 
 
In non irradiated mice, selection of IMPDH2R requires both antigenic 
stimulation and high dose MMF 
 
Following TBI, selection of IMPDH2R is driven by antigenic stimulation and 
increased by MMF administration within the spleen 
 
Selection of IMPDH2R within the activated (CD44high) compartment occurs 
following TBI, but not the steady state, in both spleen and lymph nodes 
and is driven by both antigen and MMF  
 
Discussion 
 
Chapter 5: Effects of MMF post-lymphodepleting irradiation and 
tumour control during MMF treatment 
 
Introduction 
 
Aims 
 
Results 
 
Delaying initiation of MMF treatment after irradiation reduces toxicity 
 
Combination of IMPDH2R and MMF results in improved survival compared 
with vehicle treated mice 
 
 
 
115 
 
122 
 
 
126 
 
130 
 
132 
 
137 
 
138 
 
142 
 
143 
 
143 
 
146 
 
 
148 
 
 
154 
 
159 
 
 
161 
 
 
162 
 
 
 
166 
 
172 
 
 
173 
 
174 
 
176 
 
175 
 
178 
 
 
 
 
10 
5.3.3  
 
 
 
5.3.4  
 
 
5.3.5  
 
 
5.3.6  
 
 
5.4  
  
 
 
6.1  
 
 
6.2  
 
 
6.3  
 
6.4  
 
6.5  
 
6.6  
 
6.7  
 
6.7.1  
 
6.7.2  
 
 
6.7.3  
Mice receiving MMF and IMPDH2R transduced cells have increased 
percentages of transduced OT1 in peripheral blood than mice receiving 
vehicle or IMPDH2CS transduced cells 
 
Depletion of NK cells does not prevent improved tumour control when 
IMPDH2R transduced cells and MMF are combined 
 
MMF has different effects on reconstitution of several lymphocyte subsets 
and in different organs following lymphodepleting irradiation 
 
Tumour control by IMPDH2R transduced cells in the absence of 
endogenous lymphocytes 
 
Discussion 
 
Chapter 6: Discussion 
 
Synergy between IMPDH2R transduced adoptive immunotherapy and 
MMF 
 
Treatment of post-transplant viral infection with IMPDH2R transduced 
adoptive immunotherapy 
 
Effect of MMF on endogenous lymphocytes 
 
Selection of IMPDH2R transduced cells 
 
Safety 
 
Drug administration 
 
Future experiments 
 
Effects of MMF post lymphodepletion 
 
Confirmation of IMPDH2R transduced cell function in other adoptive 
immunotherapy models 
 
Development of new plasmids – Generation and testing of multi-
immunosuppressive agent resistance plasmids 
 
References 
181 
 
 
 
183 
 
 
190 
 
 
195 
 
 
199 
 
203 
 
204 
 
 
207 
 
 
207 
 
209 
 
210 
 
211 
 
211 
 
212 
 
212 
 
 
213 
 
 
214 
 
 
Tables!
Table 1.1 
 
Table 2.1  
 
Table 4.1  
 
Table 4.2 
Drugs used in Post-Transplant Immunosuppression   
 
Fluorescent-labelled antibodies     
 
Published MMF dosing from in vivo murine models  
 
Summary of MPA exposure methods    
 
44 
 
94 
 
138 
 
141 
11 
Figures!
Fig 1.1 
 
 
Fig 1.2 
 
Fig 1.3 
 
 
Fig 1.4 
 
 
Fig 1.5 
 
Fig 1.6 
 
 
Fig 2.1 
 
Fig 2.2 
 
Fig 3.1 
 
Fig 3.2 
 
 
Fig 3.3 
 
 
Fig 3.4 
 
 
Fig 3.5 
 
 
Fig 3.6 
 
 
Fig 3.7 
 
 
Fig 3.8 
 
 
Fig 3.9 
Mechanisms underlying the impact of lymphodepletion on adoptively 
transferred T cells  
 
Purine metabolism 
 
Chemical structure of mycophenolate mofetil, mycophenolic acid and 
mycophenolic acid glucuronide  
 
Amin acid sequence of murine and human Inosine-5’-
Monophosphate dehydrogenase  
 
Structure of Inosine-5’-Monophosphate dehydrogenase (IMPDH)  
 
The kinetic mechanism and conformational transitions of the Inosine-
5’-monophosphate dehydrogenase (IMPDH) reaction  
 
Cloning SFG.eGFP-IMPDH2WT  
 
Cloning SFG.eGFP-IMPDH2CS  
 
Transduced BW dose response 
 
BW cells transduced with IMPDH2R are selected when cultured in 
MPA  
 
IMPDH2R transduced BW cells overcome MPA-induced cell cycle 
blockade 
 
IMPDH2R transduction protects BW cells from MPA-induced 
apoptosis 
 
IMPDH2R transduced OT1 CD8 are selected when stimulated by 
cognate peptide in the presence of MPA 
 
IMPDH2R transduced OT1 CD8 are selected when exposed to non-
cognate peptide in the presence of MPA 
 
IMPDH2R transduced cells are progressively selected in antigen 
independent conditions in the presence of MPA 
 
Human PBMC dual transduced with IMPDH2R and LMP2 TCR are 
selected during restimulation with cognate peptide and MPA  
 
IMPDH2R transduced cells selected by exposure to MPA, produce 
interleukin 2 and interferon gamma in response to cognate peptide at 
a similar level to cells cultured in the absence of drug 
 
37 
 
 
54 
 
56 
 
 
58 
 
 
61 
 
63 
 
 
77 
 
80 
 
103 
 
106 
 
 
110 
 
 
114 
 
 
118 
 
 
120 
 
 
124 
 
 
128 
 
 
131 
Fig 4.1 
 
 
 
Fig 4.2 
 
In vivo MMF toxicity is manifested as dose dependent weight 
loss and is increased when combined with lymphodepleting 
irradiation 
 
MMF causes reduced lymph node cellularity  
 
145 
 
 
 
147 
 
12 
Fig 4.3 
 
 
 
Fig 4.4 
 
 
 
Fig 4.5 
 
 
Fig 4.6 
 
 
Fig 4.7 
 
 
Fig 4.8 
 
Fig 4.9 
 
 
Fig 4.10 
 
Fig 4.11 
MMF causes a dose-dependent reduction in lymphocytes 
within the bone marrow due to reduction in B220 positive B 
cells 
 
At maximum tolerated dose of MMF, there is no change in CD4 
or CD8 cells percentage but absolute numbers are decreased 
in lymph nodes 
 
Overview of protocol to investigate in vivo selection of 
IMPDH2R transduced cells 
 
Weight loss is increased at higher MMF doses when MMF and 
TBI are combined  
 
IMPDH2R cells are selected over IMPDH2CS cells during in vivo 
MMF administration 
 
Ratio of IMPDH2R:IMPDH2CS transduced cells 
 
Ratio of activated (CD44high) IMPDH2R:IMPDH2CS transduced 
cells 
 
Absolute numbers of CD44high IMPDH2R transduced cells 
 
MPA levels in murine blood measured after various delivery 
strategies 
 
149 
 
 
 
150 
 
 
 
153 
 
 
155 
 
 
158 
 
 
160 
 
164 
 
 
165 
 
169 
Fig 5.1 
 
Fig 5.2 
 
 
Fig 5.3 
 
 
 
Fig 5.4 
 
 
 
 
Fig 5.5 
 
 
 
 
Fig 5.6 
 
 
Fig 5.7 
 
 
Overview of in vivo tumour model 
 
Initiating MMF treatment 10 days after lymphodepleting 
irradiation does not result in toxicity 
 
Mice receiving IMPDH2R transduced T cells and MMF exhibit 
increased survival over mice receiving IMPDH2CS transduced 
cells or vehicle 
 
Mice receiving IMPDH2R transduced cells had significantly 
increased tumour regression when treated with MMF 
compared with mice receiving IMPDH2CS transduced cells or 
vehicle 
 
Mice receiving MMF and IMPDH2R transduced cells have a 
higher percentage of transduced OT1 T cells in peripheral 
blood than mice receiving vehicle or IMPDH2CS transduced 
cells 
 
Overview of model to investigate effects of MMF on different 
cell subsets in mice receiving lymphodepleting irradiation 
 
MMF has different effects on reconstitution of several 
lymphocyte subsets and in different organs following 
lymphodepleting irradiation  
176 
 
177 
 
 
179 
 
 
 
180 
 
 
 
 
182 
 
 
 
 
184 
 
 
185 
 
 
13 
Fig 5.8 
 
 
 
 
Fig 5.9 
 
Fig 5.10 
 
 
Fig 5.11 
 
 
 
Fig 5.12 
 
Fig 5.13 
MMF treatment after lymphodepleting irradiation does not 
significantly reduce the number of cells incorporating BrdU but 
does reduce the number of interferon gamma producing CD8 
and NK cells in the spleen 
 
Overview of NK depletion model 
 
In vivo antibody depletion of NK cells does not cause increased 
toxicity 
 
Antibody depletion of NK cells in vivo does not abrogate the 
improved control seen when mice receive IMPDH2R 
transduced cells and MMF 
 
Overview of Rag -/- model 
 
MMF significantly inhibits tumour growth even in the absence 
of adoptively transduced cells when treatment is started with 
less established tumours 
190 
 
 
 
 
191 
 
192 
 
 
193 
 
 
 
196 
 
198 
 
 !
14 
Abbreviations,used!
6-MP  6-Mercaptopurine 
7-AAD 7-Aminoactinomycin D 
ADP  Adenosine diphosphate 
ALL  Acute Lymphoblastic Leukaemia 
AMP  Adenosine Monophosphate 
APC  Antigen presenting cell 
ATG  Antithymocyte globulin 
ATP  Adenosine triphosphate 
BMT  Bone Marrow Transplant 
BrdU  Bromodeoxyuridine 
BSA  Bovine serum albumin 
BW  BW5247 thymoma cell line 
CAR  Chimeric Antigen Receptor 
CD  Cluster of differentiation 
cDNA  Complementary deoxyribonucleic acid 
CLL  Chronic Lymphocytic Leukaemia 
CMV  Cytomegalovirus 
ConA  Concanavalin A 
15 
CTL  Cytotoxic T Lymphocyte 
dADP  Deoxyadenosine disphosphate 
dGDP  Deoxyguanosine diphosphate 
dGTP  Deoxyguanosine triphosphate 
DLI  Donor lymphocyte infusion 
DNA  Deoxyribonucleic acid 
EBV  Epstein Barr Virus 
EDTA  Ethylenediaminetetraacetic acid 
ELISA  Enzyme-Linked ImmunoSorbant Assay 
FACS  Flow cytometry 
GDP  Guanosine diphosphate 
GFP  Green fluorescent protein 
GMP  Guanosine monophosphate 
GTP  Guanosine triphosphate 
GvHD  Graft versus Host Disease 
GvL  Graft versus Leukaemia 
HGPRT Hypoxanthine-guanine phosphoribosyltransferase 
HLA  Human Leukocyte Antigen 
HSCT  Haematopoietic Stem Cell Transplantation 
16 
IFA  Incomplete Freund’s adjuvant 
IFN  Interferon 
IL  Interleukin 
i.p.  Intraperitoneal 
i.v.  Intravenous 
IMP  Inosine Monophosphate 
IMPDH Inosine-5’-monophosphate dehydrogenase 
Ki  Dissociation constant 
LCL  Lymphoblastoid cell line 
LMP  Latent membrane protein 
MACS  Magnetic-activated cell sorting 
MFI  Median fluorescence intensity 
MHC  Major Histocompatibility Complex 
MMF  Mycophenolate Mofetil 
MPA  Mycophenolic acid 
MPAG Mycophenolic acid glucuronide 
mRNA Messenger ribonucleic acid 
MSC  Myeloid suppressor cells 
MTOR Mammalian target of rapamycin (Also known as mechanistic 
target of rapamycin) 
17 
NAD  Oxidised nicotinamide adenine dinucleotide 
NADH  Reduced nicotinamide adenine dinucleotide 
NK cell Natural Killer cell 
NO  Nitric oxide 
OVA  Ovalbumin 
PBMC  Peripheral Blood Mononuclear Cell 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PI  Propidium Iodide 
PRPP  5’-phosphoribosyl-1-pyrophosphate 
PTLD  Post-transplant Lymphoproliferative Disorder 
RNA  Ribonucleic acid 
s.c.  Subcutaneous 
SOT  Solid Organ Transplantation 
TAP  Transporter associated with protein 
TBI  Total Body Irradiation 
TCR  T cell receptor 
Tg  Transgenic 
Th cells T helper cells 
18 
TLR  Toll-like receptor 
TNF  Tumour necrosis factor 
TReg  Regulatory T cells 
XMP  Xanthine Monophosphate 
ZFN  Zinc finger nuclease 
  
19 
Chapter(1:(Introduction!
 
Background!
The effector cells of the adaptive immune system are activated in a targeted 
fashion when T cell receptors (TCR) on the lymphocyte cell surface bind to 
specific antigens presented by host major histocompatibility (MHC) molecules. 
Following recognition and lymphocyte activation, cytolytic activity is targeted 
towards cells presenting ‘foreign’ antigen such as virally derived antigens on 
infected cells or neo-antigens on tumour cells. Lymphocytes possessing a 
diverse repertoire of TCRs are generated but negative selection within the 
thymus removes lymphocytes expressing TCRs most likely to cause 
autoimmune disease while retaining cells with potential to respond to foreign 
antigen. This ability to act in such a specific, targeted fashion makes the use of 
lymphocytes an attractive therapeutic option for the treatment of malignancy or 
viral infection.  
All TCRs expressed by a single T cell are of the same specificity, directed to a 
specific combination of human leukocyte antigen (HLA) molecule and antigen. 
CD8 T cells express TCR specific for HLA class I molecules presenting 
peptides from cytosolic proteins. Class I molecules are found on the surface of 
all cells except red blood cells and platelets (Natali et al., 1984). Normal cells 
express peptides processed from self-antigen to which the CD8+ T cell 
repertoire is tolerised during negative selection within the thymus (Palmer, 
2003). Cells infected by virus will also present viral peptides and tumour cells 
20 
may present peptides from neoantigens. These can be recognised by CD8 T 
cells as foreign, resulting in a cytotoxic immune response.  
Whilst not as specific as the use of lymphocytes alone, the benefit of allogeneic 
stem cell transplantation in treating malignancy is due to the response of 
lymphocytes from the donor against malignant cells known as graft-versus-
leukaemia (GvL). This immunological action works in combination with the 
conditioning regimen of chemo-radiotherapy with the aim of eradicating 
disease. GvL effects of lymphocytes are clearly demonstrated in patients with 
chronic myeloid leukaemia, who have been successfully treated with infusions 
of donor lymphocytes following relapse post stem cell transplant (Kolb et al., 
1990). Non-myeloablative conditioning regimens where less intensive 
conditioning has enabled use of allogeneic transplant in more elderly patients 
due to reduced toxicity require the graft versus leukaemia effect to work to 
prevent disease relapse. 
GvL is the beneficial immunological effect of allogeneic stem cell transplant, 
however in addition to recognition of leukaemia cells, lymphocytes from the 
donor can recognise host cells as ‘foreign’.  This causes graft-versus-host 
disease (GvHD), which results in significant morbidity and potentially mortality 
(Ferrara et al., 2009). To prevent graft versus host disease, 
immunosuppressive medication is given which inhibits lymphocyte function. 
The same agents are used to prevent the recipient immune system rejecting 
solid organ transplants. While immunosuppression has allowed transplantation 
to become an established treatment modality, it also results in significant side 
effects. Some viral infections are not cleared following primary infection and are 
subsequently kept dormant by an intact cellular immune response (Steven, 
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1997, Sylwester et al., 2005). Immunosuppression enables reactivation of 
latent viral infections such as cytomegalovirus (CMV) and Epstein Barr virus 
(EBV), the latter of which can cause lymphoproliferative disorder (PTLD).  
CMV is a herpes virus that infects the majority of people; seroprevalence 
depends on socioeconomic status and is between 45 and 100% of the 
population (Cannon et al., 2010). Primary CMV disease is usually 
asymptomatic or produces a mild flu-like illness. It can cause pharyngitis, 
lymphadenopathy and fever of unknown origin. It is the largest herpes virus 
producing more than 200 proteins, of which several are involved in immune 
evasion thereby preventing clearance of virus (Miller-Kittrell and Sparer, 2009). 
Lifelong latency is established, primarily in myeloid cells (Poole et al., 2011). 
The size of the cellular response throughout the rest of an infected individuals 
life is enormous. CD4 and CD8 T cells with broad specificity for CMV increase 
throughout life accounting for 10-40% of the memory compartment (Ouyang et 
al., 2003, Sylwester et al., 2005).  
Following transplantation, anti-rejection and anti-GvHD regimens can result in 
reactivation of latent virus as well as increasing the risk of primary disease. 
Loss of immune containment allows uncontrolled viral replication with potential 
for disseminated disease and development of life-threatening end organ 
damage including pneumonitis, colitis and hepatitis. Up to 80% of seropositive 
bone marrow transplant recipients will reactivate CMV (Ljungman et al., 2011). 
Current antiviral therapies have significant side effects including renal 
dysfunction and suppression of bone marrow function. Mortality from CMV 
pneumonitis remains at over 50% despite these therapies. 
22 
Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of 
disease primarily arising from the malignant transformation of germinal centre 
B cells following solid organ transplantation (SOT) or haematopoietic stem cell 
transplantation (HSCT). The histology ranges from an indolent polyclonal 
expansion of B cells to the more common aggressive diffuse large B cell and 
Burkitt lymphoma types. There is an overall incidence of 1-15% following SOT 
and 0.5-25% following HSCT with the highest incidence following T-cell 
depletion and aggressive immunosuppression (Shapiro et al., 1988, Swinnen, 
2000, Cockfield, 2001, Domingo-Domenech et al., 2001, Opelz and Dohler, 
2003). The reported mortality is approximately 50% (Leblond et al., 1995, 
Newell et al., 1996, Opelz and Dohler, 2003). The pathogenesis results from 
the reactivation of the oncogenic virus EBV in 60-80% of cases (Allen et al., 
2001, Hoshida et al., 2001). Prior to development of PTLD, EBV infected B 
cells are seen in increased number within the blood and tissues (Stevens et al., 
2001, Muti et al., 2003). Within tumour cells the EBV infection is monoclonal 
(Capello et al., 2003). Several EBV genes expressed during latent infection 
have transforming activity for B cells (Cohen, 2003, Hsieh et al., 1999, Tanner 
and Alfieri, 2001, Kuppers, 2003, Thompson and Kurzrock, 2004). PTLD 
tumour cells express EBV latent proteins, an ideal immunogenic target for 
immunotherapy.  
Monitoring for EBV DNA in the circulation can identify patients at high risk of 
imminent PTLD. These patients can then be pre-emptively treated by reducing 
immunosuppression (if possible) and with rituximab, a human-murine chimeric 
monoclonal antibody that targets the CD20 positive B-lymphocytes in which 
EBV is found. Once PTLD has developed systemic chemotherapy must be 
given, causing greater morbidity and mortality. 
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Current therapy for CMV and EBV reactivation cause significant morbidity 
particularly due to renal toxicity and bone marrow suppression and therefore 
alternative therapy, either pre-emptive or acute, would be welcomed. Viral 
reactivation could be treated effectively by transferring viral-specific 
lymphocytes, a process called adoptive immunotherapy. It is possible to collect 
and expand virus specific donor cells (Heslop et al., 1994b, Rooney et al., 
1998, Gustafsson et al., 2000, Hale et al., 2008, Merlo et al., 2008) or redirect 
the specificity of lymphocytes by ex vivo insertion of genes encoding a virus 
specific TCR prior to transfer (Orentas et al., 2001, Mueller et al., 2012). When 
a patient still requires on-going immunosuppression following transplantation, 
to prevent rejection or GvHD, transferred lymphocytes will also be supressed, 
reducing efficacy.  
A potential strategy to circumvent the inhibitory effects of immunosuppression 
is to engineer therapeutic cells with resistance to immunosuppressive drugs ex 
vivo prior to transfer. Here I discuss the current use of adoptive immunotherapy 
and redirection of lymphocytes through transfer of specific TCRs. I will discuss 
the actions of immunosuppressive medication and the potential genes to confer 
drug resistance. I outline the aims of this research, in which I confer resistance 
to mycophenolate mofetil (MMF) and investigate the action of these resistant 
cells during MMF therapy in a murine tumour model. 
 !
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1.1!Adoptive!Immunotherapy!
Immunotherapy is a term defined as “the treatment of disease by inducing, 
enhancing or suppressing an immune response” (Dictionary, 2004). Adoptive 
immunotherapy involves the transfer of T cells to a recipient with the aim of 
producing a response against target cells, usually malignant or virally infected 
cells.  
Adoptive immunotherapy has several advantages over conventional 
therapeutic approaches; 
1) Specificity – targeting of tumour or virally infected cells via a specific 
receptor causing fewer side effects. 
2) Longevity – Transferred cells can establish immunological memory and 
persist to control disease long term.  
Effective adoptive immunotherapy requires that transferred cells are of the 
correct specificity and retain their cytotoxic function following transfer. In most 
settings it is also desirable for transferred cells to engraft and persist providing 
long-term immunological memory. Repeated administration of adoptive 
immunotherapy may also be used and if disease is cleared, memory is not an 
absolute requirement. 
 !
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1.1.1!Specificity!
The specificity of T lymphocytes is determined by their TCR in an HLA 
restricted fashion. This means that transferred cells need to be HLA compatible 
with the recipient, i.e. a lymphocyte with a TCR specific for a viral peptide will 
only work if the recipients HLA type is compatible. There are several options to 
either collect or engineer a cellular product of the desired specificity: 
• Selection and expansion of pre-existing autologous or allogeneic cells 
on the basis of their T cell receptor specificity (monoclonal or polyclonal) 
• Redirection of lymphocytes towards a specific target by introduction of a 
new TCR specific for the desired target antigen:MHC complex 
• Redirection of lymphocytes towards a specific target by introduction of a 
chimeric antigen receptor specific for cell surface antigens (not HLA 
restricted) 
1.1.1.1!Selection!and!expansion!of!cells!of!required!TCR!specificity!
If a donor is seropositive for a particular virus i.e. previously exposed, they will 
have generated virus-specific T cells during the infective episode. Following 
resolution of infection, some of these cells will persist as a long-lived memory 
population. When polyclonal T cells are incubated with viral peptides, only cells 
receiving necessary levels of stimulation will persist. This will result in selection 
of viral reactive cells that expand while alloreactive cells will not receive 
stimulation and will undergo apoptosis. After donation, therapeutic numbers of 
cells can be generated using repeated ex vivo stimulation with antigen 
presenting cells (APC) expressing the desired HLA:viral antigen and cytokine 
support. It is therefore necessary to identify the immunogenic viral antigen and 
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express that on an APC in the context of MHC in the presence of co-
stimulatory molecules.  
Immunodominant antigens have been described for CMV (Berger et al., 2009), 
EBV (Hislop et al., 2007), adenovirus (Leen et al., 2004), Human Herpes Virus 
6 (Gerdemann et al., 2013), BK (Blyth et al., 2011) and Varicella Zoster Virus 
(Blyth et al., 2012). This has allowed the use of overlapping peptide pools 
covering the whole viral protein rather than live viruses to be used (Trivedi et al., 
2005). Optimisation of protocols in terms of both antigen and cytokine support 
are reducing the length of ex vivo culture required and simultaneous stimulation 
with peptides from several viruses e.g. EBV, CMV and adenovirus has allowed 
multi-virus cytotoxic T lymphocyte (CTL) lines to be generated simultaneously 
(Zandvliet et al., 2011, Gerdemann et al., 2012). 
More rapid selection strategies are available and under investigation for clinical 
use. When there is a high frequency of specific T cells e.g. CMV- or EBV-
reactive, magnetically labelled peptide multimers bind to the TCR and allow 
selection of cells. The product will be specific only for the peptide multimer 
used, but avoids the need for culture with APCs. There is a requirement for 
both a high precursor frequency and a large volume of blood/apheresis product. 
Alternatively, selection of cells that produce interferon gamma (IFNγ) after 
stimulation with viral antigens allows selection of a broad range of virus 
reactive cells but still requires large donor blood volumes or apheresis product. 
1.1.2!Clinical!Use!of!Virus!specific!adoptive!immunotherapy!in!stem!cell!
transplantation!
The potential for adoptive immunotherapy to reconstitute specific immunity 
following stem cell transplantation has been studied. Reconstitution of anti-viral 
27 
immunity to CMV, using specific CTL, was first reported in 1992 (Riddell et al., 
1992). Lymphocytes were expanded using donor fibroblasts as the APC and 
antigen from the AD169 strain of CMV. The sibling donors were HLA-matched 
and transferred cells did not cause GvHD. Both CD4+ and CD8+ T cell CMV 
response was required for long-term persistence. Subsequently, several other 
groups using a variety of production techniques have successfully reconstituted 
CMV-specific responses in many patients (Walter et al., 1995, Einsele et al., 
2002, Peggs et al., 2003). It should be noted that when CMV antigen generated 
CD4 CTL were transferred alone the level of conferred immunity appeared 
much reduced with multiple failures and even death (Perruccio et al., 2005). 
Therefore it can be postulated that a broad polyclonal product of both CD4 and 
CD8 lymphocytes, which more closely resembles the endogenous response to 
CMV, may produce the best results.  
Therapy for PTLD was initially trialed with unmanipulated donor lymphocytes 
(DLI) that led to successful treatment in approximately 70% of patients 
(Doubrovina et al., 2012) but with a high incidence of GvHD (Heslop et al., 
1994b, Papadopoulos et al., 1994). Because up to 95% of adults worldwide 
have been exposed to EBV (Higgins et al., 2007) and up to 5% of their 
circulating CD8+ T cells target EBV (Bhaduri-McIntosh et al., 2008), it is an 
ideal target for collection and expansion of specific T cells. By stimulating donor 
peripheral blood mononuclear cells (PBMCs) with autologous EBV-transformed 
B cell lines ex vivo, EBV-specific, MHC-restricted cytotoxic T cell lines can be 
generated, without the auto-reactive T cells responsible for causing GvHD. 
After transfer these cells are well tolerated and successfully control active EBV 
replication and PTLD (Heslop et al., 1994a, Rooney et al., 1995).  
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In vivo persistence has been demonstrated by detection of a neomycin 
resistance gene retrovirally transduced into CTL ex vivo prior to infusion 
(Heslop et al., 2010). The ability to persist led to prophylactic adoptive 
immunotherapy for high-risk patients following HSCT, which was effective 
compared to historical controls (Rooney et al., 1998). Adoptive immunotherapy 
with EBV-specific CTLs is now an established therapeutic option (Gustafsson 
et al., 2000, Hale et al., 2008, Merlo et al., 2008) and provides safe and 
effective reconstitution of EBV immunity both preventing and treating EBV-
PTLD after T cell depleted stem cell transplant.  
1.1.3! Clinical! Use! of! Virus! specific! adoptive! immunotherapy! in! solid!
organ!transplantation!
EBV-PTLD following solid organ transplantation is recipient rather than donor in 
origin. Therefore autologous (recipient) EBV-CTLs, or HLA-matched allogeneic 
EBV-CTLs are required.  
1.1.3.1!Autologous!EBVHCTLs!
The feasibility and safety of CTL infusion following SOT has been established, 
using autologous EBV-CTLs generated from patient blood taken pre-
transplant(Haque et al., 1998). Subsequently EBV-CTL lines have been 
generated from patients receiving immunosuppressive therapy (Khanna et al., 
1999, Savoldo et al., 2001) and induced complete response (CR) in a patient 
with progressive PTLD. Unfortunately, secondary lesions developed in this 
patient implying lack of functional persistence of EBV-CTLs in the presence of 
immunosuppression. 
Further studies suggest that responses induced using autologous EBV-CTL for 
adoptive immunotherapy are often partial or temporary (Comoli et al., 2002, 
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Comoli et al., 2005, Savoldo et al., 2006, Sherritt et al., 2003). When used 
prophylactically, none of the first 21 patients treated developed PTLD. For 
treatment ~50% (19/39) achieved complete remission but 41% (16/39) had no 
response (Merlo et al., 2008). 
Following HSCT, transferred cells expand and persist. In contrast, following 
SOT, expansion appears more limited with levels dropping prior to the next cell 
infusion. It is possible that infused EBV-CTLs are unable to proliferate 
significantly due to immunosuppressive therapy in the absence of significant 
lymphodepletion. 
1.1.3.2!Generation!of!EBVHCTLs!from!seronegative!recipients!
Autologous memory EBV-CTLs cannot be collected for ex vivo expansion from 
EBV seronegative SOT recipients. These patients are at risk of developing 
primary infection with EBV and PTLD whilst immunosuppressed. Alternative 
expansion protocols using IL-12 and IL-7 (Comoli et al., 2006) or enrichment of 
activated CD25 positive cells (Savoldo et al., 2002) have enabled the 
generation of autologous EBV-CTLs in EBV-negative individuals. Generating 
sufficient numbers of autologous EBV-CTL takes about 10 weeks for each 
patient. Therefore another approach is to use pre-generated, allogeneic CTL 
lines from partially HLA matched third party donors. 
1.1.3.3!Third!party!EBVHCTLs!
Haque and colleagues have established a bank of 100 EBV-CTL lines that are 
immediately available (Wilkie et al., 2004). Cells are selected on the basis of 
the closest HLA match to the patient. Despite HLA mismatches, a phase II trial 
showed no toxicity or graft failure and responses in 21 of 33 patients refractory 
to conventional treatment. Of note, immunosuppression was reduced or 
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stopped in all patients which may have resulted in recovery of the patients EBV 
immunity as well as allowing transferred cells to function. Transferred cells do 
not appear to persist and one patient was shown to have antibodies against the 
mismatched allo-HLA antigens on the transferred cells (Haque et al., 1998, 
Haque et al., 2007). 
!
1.1.4!Adoptive!immunotherapy!in!nonHtransplant!patients!
Adoptive immunotherapy has also been successfully employed in the treatment 
of patients with malignancy. Cultured autologous EBV-specific T-cell lines were 
used by Bollard et al. to treat EBV-positive Hodgkin’s disease (Bollard et al., 
2004). The targeted antigens were only weakly immunogenic, consisting 
primarily of the latent membrane protein (LMP)1 and LMP2 antigens.  Despite 
this low immunogenicity, viral load decreased, demonstrating the biologic 
activity of the infused CTLs. The CTLs were able to expand by several log in 
vivo and persisted for over 12 months. EBV CTLs were well tolerated, could 
control B symptoms (fever, night sweats, and weight loss), and had antitumour 
activity. Five of fourteen patients entered complete remission, one had a partial 
response and a further five stable disease.  
In 1988, Rosenberg et al. used autologous tumour infiltrating lymphocytes to 
treat metastatic melanoma (Rosenberg et al., 1988). Lymphocytes were 
extracted from freshly resected melanomas and expanded in vitro. 20 patients 
were treated with these tumour-infiltrating lymphocytes and interleukin-2, 
resulting in regression of tumour in 60% of patients with the effect lasting up to 
13 months.  
 !
31 
1.1.5!Redirection!of!Lymphocytes!
When the donor is sero-negative i.e. lacking specific immune cells, or following 
umbilical cord stem cell transplant where donor cells are limited in number and 
are virus naïve, it is very challenging to select and expand specific T cells for 
transfer. An alternative option is to engineer cells ex vivo to express a specific 
receptor. Redirection is achieved by insertion of an alternative TCR or a 
chimeric antigen receptor (CAR) of known specificity (Sadelain et al., 2003). 
Redirecting the specificity of collected cells towards a specific target in this way 
also reduces the time needed to generate the required number of therapeutic 
cells through repeated cycles of expansion. 
1.1.5.1!Redirection!H!TCR!transduction!
TCR transduction requires transfer of genes encoding the α and β chains of a 
specific TCR, usually with high avidity for the antigen of interest, into a T cell 
(Dembic et al., 1986). To ensure stable expression, the introduced gene must 
be inserted into the cellular genomic DNA. This can be achieved using either a 
gamma-retrovirus, lentivirus or transposon system. Following transduction, 
large populations of antigen-specific T cells are generated (Stanislawski et al., 
2001, Xue et al., 2005, Morris et al., 2005, Thomas et al., 2007, Hart et al., 
2008, Perro et al., 2010, Tsang et al., 2008, Ahmadi et al., 2011).  
The therapeutic potential of such gene-modified T cells was shown by Morgan 
et al., who documented regression of metastatic melanoma in two out of fifteen 
patients treated with adoptively transferred autologous T cells transduced with 
a TCR specific for the tumour-associated antigen MART-1 (Morgan et al., 
2006). 
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TCRs specific for viral antigens have been cloned and shown to confer 
transduced T cells with antiviral specificity. Latent membrane protein 2 (LMP2) 
represents the immunodominant epitope following EBV infection. It is 
expressed on EBV-driven malignancies and is therefore a good candidate for 
adoptive immunotherapy. A HLA-A2 restricted, LMP2-specific TCR has been 
cloned and optimised for use in redirection of T cells (Hart et al., 2008). This is 
specific for EBV LMP2 426-434 (CLGGLLTMV) in the context of HLA A*02:01. 
Human CMV lower matrix protein pp65 contains the immunodominant epitope 
for CMV. A TCR specific for this epitope, pp65 protein 495-504 (NLVPMVATV), 
also in the context of HLA A*02:01 has been cloned and optimised for use 
following retroviral transduction (Schub et al., 2009). 
The strategy of redirecting T cells by transducing TCR genes has potential 
deficiencies and risk of complications. Because the TCR is HLA specific, 
different TCRs are needed for each different HLA-type. Techniques to identify 
TCRs of the correct specificity (peptide and HLA specific) have been developed 
with a much higher throughput, however this can still take some time. A recent 
technical report highlighted a high-throughput approach whereby rapid 
identification of TCR sequences from large collections of samples was enabled 
by capturing and sequencing the TCR variable regions (Linnemann et al., 
2013). A bait library was designed that targets each individual variable and 
joining element within both TCRα and TCRβ loci, resulting in selective isolation 
of TCR-encoding elements from sheared genomic DNA. Once isolated, paired-
end deep sequencing showed that as few as 500 cells were needed to 
correctly identify a rearranged TCR. Using this approach a library of tumour 
reactive TCRs from patient material has been generated. The technique is also 
able to identify TCRαβ pairs in bulk antigen-specific T cell populations and to 
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assess the TCR repertoire of intratumoral T cell subsets without knowledge of 
antigen specificity.  
Following transduction there is potential for the introduced genes to ‘mis’-pair 
with endogenous TCR chains. The resultant hybrid TCR is of unknown 
specificity and has potential to recognise ‘self’ antigen and cause GvHD. To 
avoid this several genetic optimisations are routinely utilised;  
1. The cassette of genes contains 2A DNA sequences between the α and 
β TCR genes to ensure equal production.  
2. The TCR genes are codon optimised to improve efficiency of translation  
3. Disulphide bonds introduced to promote binding between the introduced 
TCR genes.  
More recently methods have been described to delete the endogenous TCR 
thereby removing the possibility of mispairing (Provasi et al., 2012). By utilising 
zinc-finger nucleases (ZFN) designed to target conserved regions of the TCRβ 
and TCRα chain genes, endogenous TCR genes are deleted. This was 
achieved in a stepwise approach where cells were first exposed to adenoviral 
vectors containing a TCRα chain targeted ZFN. This is transiently expressed 
(two to three days) during which time the endogenous TCR gene is deleted. 
Successfully treated cells become CD3 negative allowing sorting five to eight 
days after transduction. TCRα deleted T cells are then stably transduced with a 
lentiviral vector containing a TCRα chain gene. This process can then be 
repeated for the TCRβ chain. Resultant cells express high levels of the 
transferred TCR and are both functional and highly specific. 
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1.1.5.2!Redirection!–!CAR!
As previously mentioned, redirection may also be achieved by the use of CARs. 
The introduced gene is engineered from the variable domains of an antibody 
heavy and light chain fused by a flexible linker sequence. This is grafted via a 
hinge and transmembrane region to TCR activation and costimulatory domains, 
usually CD3-zeta, CD28 and 41BB or OX40. Following ligation of the CAR to 
its target ligand, both a ‘signal 1’ and ‘signal 2’ are generated resulting in 
activation of the T cell with resultant cytokine production and lytic activity. 
Redirection with CARs has several advantages over TCR transduction; 
• the inserted gene is shorter and therefore easier to transduce 
• there is no mis-pairing of introduced TCR chains with endogenous TCR 
chains 
• the target is HLA independent, therefore one CAR will work in all 
patients 
CARs are only specific for cell surface target molecules and therefore will not 
be able to be used in the treatment of malignancies where the neoantigen is 
intracellular and targeted by TCR via presentation by HLA class 1 molecules. 
The first clinical trial of CAR-expressing T cells was in ovarian cancer, the 
target was the α-folate receptor (Kershaw et al., 2006), but no tumour 
regression was seen. Subsequently the design of CAR genes has changed 
significantly, particularly in the use of different and multiple co-stimulatory 
domains and T-cell-activation moieties. Much of this has been in the evaluation 
of CARs targeting CD19, a B-cell antigen (Kochenderfer et al., 2009, 
Kochenderfer et al., 2010b, Cheadle et al., 2005, Cheadle et al., 2010, 
Brentjens et al., 2003, Cooper et al., 2003, Rossig et al., 2006). CD19 is an 
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appealing target because it is uniformly expressed by the vast majority of B-cell 
malignancies (Nadler et al., 1983) and in normal tissue restricted to mature B 
cells, B-cell precursors, plasma cells and possibly follicular dendritic cells.  
CD19 CAR T cells have been used in the treatment of chronic lymphocytic 
leukaemia and follicular lymphoma with some patients achieving complete 
responses (Brentjens et al., 2010, Brentjens et al., 2011, Kochenderfer et al., 
2012, Kochenderfer et al., 2010b, Kochenderfer et al., 2010a, Kalos et al., 
2011, Porter et al., 2011).  
More recently CD19 CAR transduced T cells have been demonstrated to have 
clinical activity in the treatment of acute lymphoblastic leukaemia (ALL). CAR T 
cells were successfully used to treat two children with relapsed refractory pre-
B-cell ALL (Grupp et al., 2013). Both patients developed B-cell aplasia and 
cytokine-release syndrome requiring admission to intensive care. One child 
remains in complete remission over two years following treatment. 
Unfortunately the other patient relapsed 2 months after treatment with an 
escape variant that was CD19 negative. These results have resulted in intense 
study of CD19 CAR transduced T cells in the treatment of ALL with at least 30 
clinical trials in progress at the time of writing.  
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1.1.6!In!vivo!Expansion!and!Engraftment!H!Lymphodepletion!
Selection of cells with the correct specificity or redirection of cells by insertion 
of specific receptors is the first step to effective adoptive immunotherapy. It is 
also necessary for cells to expand in number and engraft within the recipient. 
Initial reports of adoptive immunotherapy in metastatic melanoma showed that 
in vivo persistence of cells was very short and clinical responses not sustained 
(Rosenberg et al., 1990).  
Use of immunodepleting conditioning chemotherapy and high-dose cytokine 
administration increase the efficacy of transferred cells significantly (Dudley, 
2002, Dudley, 2005). In clinical trials, a non-myeloablative regimen of 
cyclophosphamide and fludarabine has been used with additional total body 
irradiation (TBI) given to some patients. Following cell transfer, patients receive 
high-dose IL-2 for two to three days. Under these conditions, transferred cells 
expand and can account for up to 75% of peripheral blood CD8+ T cells six to 
twelve months after transfer. While not randomised, additional lymphodepletion 
in the form of TBI increased the response to adoptive immunotherapy with 
responses correlated with TBI dose (Dudley et al., 2008). The mechanisms by 
which lymphodepletion results in increased expansion and engraftment of 
transferred cells are discussed below and summarised in figure 1.1. 
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Figure 1.1 Mechanisms underlying the impact of lymphodepletion on 
adoptively transferred T cells 
A Adoptive Immunotherapy in a lymphoreplete host may be inhibited by: 
a) Competition for antigen at antigen-presenting cells (APCs) and 
inefficient lymphocyte activation in the absence of co-stimulation 
b) Reduced availability of activating cytokines by cellular ‘sinks’  
c) Suppressive activities of regulatory T (TReg) cells, myeloid suppressor 
cells (MSCs) and possibly Natural Killer (NK) cells 
B Prior systemic chemotherapy or radiation may overcome this by: 
a) Reducing competition for antigen at APC and activating dendritic cells  
b) Removal of cellular ‘sinks’ 
c) Removal of TReg, MSCs and NK cells 
  
  
Adapted from: Adaptive Immunotherapy for Cancer: Building on Success 
Gattinoni et al  Nature Reviews Immunology 2006: 6 (5); 383-393 
A"
B"
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1.1.6.1!Lymphodepletion!–!elimination!of!regulatory!T!cells!(TReg)!
TReg cells are a CD4+ population of lymphocytes that are crucial in maintaining 
peripheral tolerance to self-antigen through suppression of effector cells 
(Walker et al., 2003, Fisson et al., 2003, Bluestone and Abbas, 2003, Asano et 
al., 1996). One of the main theories to explain the benefit of lymphodepletion 
prior to adoptive cell transfer is that elimination of endogenous regulatory T 
cells removes suppression of the transferred cells. Antony et al (Antony et al., 
2005) showed that following lymphodepletion, co-transfer of CD8 T cells with 
CD4+CD25+ TReg prevented effective adoptive immunotherapy. They used a 
murine model of adoptive immunotherapy using a subcutaneous B16 tumour (a 
murine melanoma) to which lymphocytes from pmel-1 TCR transgenic mice are 
targeted. In Cd4-/- recipient mice, but not Cd8-/-, the anti-tumour effect of 
transferred CD8 T cells was enhanced. The enhanced anti-tumour was lost if 
either unselected CD4, which will include TReg, or selected TReg were co-
transferred with the CD8 T cell effectors. When CD4 T cells depleted of TReg 
were co-transferred with the CD8 T cells, there was enhancement of the anti-
tumour effect and significant autoimmunity. 
We can infer from these data that TReg cells inhibit the action of effector T cells 
against tumour; this finding is not surprising as several groups have reported 
that depletion of TReg cells enables endogenous immune cells to protect from 
tumour (Shimizu et al., 1999, Sutmuller et al., 2001, Golgher et al., 2002, Jones 
et al., 2002). Other cell subsets may be involved in suppression of transferred 
lymphocytes in lymphoreplete hosts including NK, NK-T and myeloid 
suppressor cells. 
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1.1.6.2!Lymphodepletion!H!Cytokine!sinks!and!homeostatic!expansion!
The beneficial effect of CD4+CD25- Th cells shown by Antony et al. was 
abrogated when IL-2 deficient CD4 Th cells were used, suggesting provision of 
cytokine support to CD8 T cells was required (Antony et al., 2005). Cytokine 
support from Th cells was superior to exogenously administered IL-2, which is 
commonly used in clinical trials. Lymphocyte number and activation state is 
regulated by homeostatic cytokines. These include the common gamma chain 
cytokines IL-2, IL-7 and IL-15. Cytokine availability is essential for both the 
normal maintenance and proliferation of memory CD8 T cells with IL-7 or IL-15 
deficiency causing reductions in the number of memory cells (Schluns et al., 
2000, Ku, 2000, Tan, 2002) and over-expression causing memory CD8 
expansion (Kieper, 2002, Marks-Konczalik et al., 2000). When cells are 
transferred in the absence of lymphodepletion, endogenous lymphocytes will 
compete for the limited amount of cytokine. It is therefore hypothesised that in 
addition to removal of regulatory cells, lymphodepletion will also remove 
competition for cytokines. 
Following the induction of lymphopenia, spontaneous expansion of any 
persisting peripheral lymphocytes restores the size of the T cell pool (Mackall 
et al., 1997). Homeostatic proliferation of lymphocytes is due to recognition of 
self-MHC/peptides in a process similar to thymic positive selection (Marrack et 
al., 2000, Surh and Sprent, 2000, Goldrath and Bevan, 1999, Ernst et al., 1999). 
When lymphocytes are transferred into a lymphopenic host, they also undergo 
homeostatic proliferation, the rate of which is reduced in a dose-dependent 
manner depending on the number of transferred cells (Cho et al., 2000, 
Dummer et al., 2001).  
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Dummer et al. hypothesised that induction of an autoimmune response against 
tumour associated self-antigens could be elicited by T cell homeostatic 
proliferation (Dummer et al., 2002). Following transfer of autologous or 
syngeneic T cells into mice lymphodepleted by sublethal irradiation, there was 
inhibition of tumour growth following challenge with melanoma or colon 
carcinoma. This depended on homeostatic expansion of transferred T cells in 
peripheral lymph nodes as the effect was reduced in the absence of lymph 
nodes (lymphotoxin-α gene knockout recipient mice) or if transferred cells 
lacked the ability to home to lymph nodes due to lack of β7 integrin and CD62L. 
Gattinoni et al. demonstrated the concept of cytokine sinks by showing 
lymphodepletion enhanced adoptively transferred CD8 T cell anti-tumour 
efficacy, even in the genetic absence of endogenous regulatory T cells 
(Gattinoni, 2005). The enhanced efficacy following lymphodepletion was lost in 
recipient mice congenitally deficient in IL-15 and IL-7. They also demonstrated 
enhanced tumour control when recipient NK cells were removed by 
administration of in vivo depleting antibody. It is postulated that NK cells are 
one of the lymphoid cell populations that compete with transferred T cells for 
limiting cytokines. The role of NK cells as cytokine sinks was also shown with 
experiments comparing Rag1-/- to Rag2-/-γc-/-. Rag1-/- lack B and T lymphocytes 
but retain NK cells, whereas Rag2-/-γc-/- lack NK cells as well as B and T cells. 
More extensive tumour regression was seen in Rag1-/- mice that were 
irradiated prior to adoptive cell transfer compared to non-irradiated recipients. 
In Rag2-/-γc-/- recipients, there was no detectable difference between irradiated 
and non-irradiated mice, however adoptive cellular therapy was very 
efficacious in all Rag2-/-γc-/- recipients. IL-15 is crucial for NK cell survival and 
proliferation in vivo, making NK cells likely candidates as cytokine sinks. 
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1.1.6.3!Lymphodepletion!–!Competition!for!Antigen!Presenting!Cells!(APC)!
In addition to competition with endogenous cells for limiting cytokines, 
adoptively transferred cells may also need to compete for antigen on the 
surface of antigen-presenting cells. Kedl et al. first demonstrated that T cells 
compete for access to antigen-bearing APCs (Kedl et al., 2000). They 
compared responses to the dominant ovalbumin epitope SIINFEKL and 
subdominant epitope KRVVFDKL in H-2b mice. Transferred OT1 cells, 
transgenic for a high affinity SIINFEKL specific TCR, completely inhibited host 
ovalbumin specific T cell responses. OT1 cells also inhibited responses to 
unrelated peptide, providing it was presented on the same dendritic cells.   
Lymphocyte activation, in the absence of lymphodepleting chemo-radiotherapy, 
will also be inefficient due to the absence of co-stimulatory molecules on 
immature dendritic cells. Lymphodepleting irradiation can reduce the absolute 
number of APCs in vivo, but also results in their activation. Within 6 hours of 
irradiation, C57Bl/6 spleens contain activated CD11c+ DC aggregated in the T 
cell areas (Zhang et al., 2002). Irradiation has also been shown to increase the 
frequency of APC producing the inflammatory cytokine TNFα (Brown et al., 
2004, Hill et al., 1997), to upregulate surface expression of CD86 and I-Ab 
(MHC class II molecule) and DCs to release substantially more IL-12 (Zhang et 
al., 2002). Potential mechanisms for activation of APC include; translocation of 
Toll-like receptor agonists into the blood after mucosal damage (Hill et al., 
1997) and increased levels of pro-inflammatory cytokines such as TNF 
(Sherman et al., 1991), IL-1 (Xun et al., 1994) and IL-4 (Rigby et al., 2003).  
Systemic chemotherapy or irradiation prior to adoptive immunotherapy for 
malignant disease can result in apoptosis or necrosis of tumour cells. Russo et 
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al. showed that when attempting transduction of dendritic cells (DC) with a 
retroviral vector coding a cytoplasmic tumour antigen, there was dissociation 
between integration of vector DNA and the ability to stimulate a tumour-antigen 
specific response (Russo et al., 2000). DCs cultured with irradiated MAGE-3-
expressing cells could stimulate a response against this tumour antigen in T 
cells obtained from a patient with MAGE-3 positive melanoma.  
 
 !
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1.2!Post!transplant!Immunosuppressive!Regimens!
To use adoptive immunotherapy in the post transplant setting it is important to 
understand the actions of immunosuppressive medication used in these 
patients. The ability to transplant solid organs and haematopoietic stem cells 
has reduced mortality and morbidity for a number of conditions. It is the 
discovery and refinement of immunosuppressive medication that has enabled 
transplantation to become a standard treatment. Following SOT, the aim of 
immune suppression is to reduce the risk of the transplanted organ being 
recognised and rejected by the recipient’s immune system. Following HSCT, 
the aim of immunosuppression is to reduce the graft recognising the recipient 
as foreign and causing graft versus host disease as well as preventing graft 
rejection by host immune cells recovering after conditioning. 
Immunosuppressive regimes vary depending on multiple factors including the 
organ transplanted, the degree of HLA-match, the toxicity of specific 
immunosuppressive agents as well as the consequences of rejection e.g. 
immunosuppression following a heart transplant is greater than following a 
renal transplant. In HSCT, conditioning therapy and immunosuppression will 
depend on the disease for which the transplant is being performed, patient age 
and co-morbidities, the stem cell source, risk of GvHD and viral reactivation. 
Examples of immunosuppressive agents in common use are shown in table 1. 
Here I briefly discuss some of the most commonly used drugs, their 
mechanism of action, side effects and use in post-transplant 
immunosuppression.  
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Table 1.1 Drugs used in Post-Transplant Immunosuppression 
  
Class of drug Example 
Glucocorticoids  Prednisolone 
Small molecules 
  
  
  
Calcineurin inhibitors Ciclosporin 
Tacrolimus 
Mammalian Target Of 
Rapamycin inhibitors 
Sirolimus 
Purine synthesis inhibitors MMF 
Pyrimidine synthesis 
inhibitors 
Azathioprine 
Biological agents 
  
Depleting antibodies ATG (polyclonal) 
Alemtuzumab (CD52) 
Rituximab (CD20) 
Muromonab (CD3) 
Non-depleting antibodies and 
fusion proteins 
Daclizumab (CD25) 
Basiliximab (CD25) 
Belatacept (CTLA-4) 
C5 Inhibitor Eculizumab 
Protease Inhibitor Bortezomib 
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1.2.1!Corticosteroids!
Corticosteroids are a mainstay of immunosuppressive regimen both in 
induction and maintenance as well as in acute rejection and GvHD. They are 
agonist of the glucocorticoid receptor and prevent production of cytokines 
(including IL-1, IL-2 and TNF-α) and vasoactive substances (e.g. 
prostaglandins). Steroids have many unwanted side-effects and newer 
regimens in SOT have been designed to reduce or completely remove their 
usage (Guerra et al., 2011, Chhabra et al., 2012, Rajab et al., 2006, Oaks et al., 
2001, Xing et al., 2013). The side effects include glucose intolerance, 
hypertension, cataracts, psychiatric disturbance, osteoporosis, avascular 
necrosis and development of cushingoid features (Veenstra et al., 1999, 
Stanbury and Graham, 1998). 
1.2.2!Calcineurin!inhibition!–!Ciclosporin!
Ciclosporin has been a mainstay of transplantation for over 40 years and has 
been utilised in both induction and maintenance of immunosuppression. It is an 
11 amino acid cyclic peptide produced by the fungus Tolypocladium inflatum 
(Borel et al., 1976). It binds to cyclophilin and subsequently calcineurin, 
abolishing its dephosphorylation activity.  Inhibition of calcineurin prevents IL-2 
production and T-cell activation. Close monitoring of trough levels is necessary 
with adjustment in dosing. The main side effects of nephrotoxicity and 
hypertension have resulted in many investigators trialling regimes without 
ciclosporin or with reduced dosing (Ekberg et al., 2007). In renal transplantation 
a randomised trial comparing the three most common immunosuppressive 
regimen (ciclosporin and sirolimus, MMF and tacrolimus, tacrolimus and 
sirolimus) showed the combination of MMF and tacrolimus to be most 
favourable, with lower levels of acute rejection and better graft function (Guerra 
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et al., 2011). Following heart transplant reducing the use of ciclosporin, 
particularly during maintenance immunosuppression, has also been shown to 
be advantageous (Aleksic et al., 2000, Baryalei et al., 2003, Zuckermann et al., 
2001, Hamour et al., 2007) however there are data to contradict this (Hunt et 
al., 2007). 
1.2.3!MTOR!Inhibition!–!Sirolimus!
Sirolimus, also known as rapamycin, binds to FK-binding protein 12 which 
inhibits the mammalian target of rapamycin complex 1, resulting in inhibition of 
signal 3 by stopping RNA translation and preventing G1-S phase progression. It 
also inhibits IL-2 and IL-4 dependent proliferation of lymphocytes. It causes 
minimal nephrotoxicity, which makes it an attractive option in patients with 
impaired renal function. It can cause impaired wound healing and 
thrombocytopenia. Potentially severe lung toxicity precludes its use following 
lung transplantation. 
1.2.4!Purine!synthesis!inhibition!–!MMF!
MMF inhibits production of guanine nucleotides. It significantly reduces renal 
transplant loss (Ojo et al., 2000) and its use has generally replaced 
azathioprine, which was used in the first renal transplants. This was due to 
limited toxicity and a reduction in acute rejection rates in renal transplant 
recipients (Knight et al., 2009). The actions and use of MMF are described in 
section 1.4 (pp. 51). 
1.2.5!Pyrimidine!synthesis!inhibition!–!Azathioprine!
Azathioprine, in combination with glucocorticoid, was the first 
immunosuppressive agent used in transplantation (Murray et al., 1963). It is a 
prodrug that is converted to 6-Mercaptopurine (6-MP) by non-enzymatic 
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cleavage of a thioether group. 6-MP undergoes further metabolism to form 
several metabolites. The main active metabolite, methyl-thioinosine 
monophosphate is a pyrimidine synthesis inhibitor that blocks the enzyme 
amidophosphoribosyltransferase. Another metabolite, thioguanosine 
triphosphate is incorporated into and interferes with RNA. A further metabolite, 
thio-deguanosine triphosphate, is incorporated into DNA, impeding synthesis.  
The main adverse effect of azathioprine is myelosuppression, which is a 
potentially lethal complication. The degree of suppression is related to dose 
and is most marked in people with a genetic deficiency of thiopurine S-
methyltransferase.  Cessation of drug can result in recovery of marrow function, 
however to avoid this side effect, azathioprine has generally been replaced by 
ciclopsorin and MMF. Ciclosporin results in longer survival times when 
compared to azathioprine in heart transplantation (Modry et al., 1985). MMF 
has been shown to cause less bone marrow suppression, fewer infections and 
less acute rejection.  Despite this many studies suggest little overall benefit of 
MMF compared to azathioprine and it remains cheaper than MMF. 
1.2.6!Biological!agents!–!Antithymocyte!globulin!(ATG)!
Polyclonal antithymocyte globulins, raised in rabbits or horses, have been used 
in induction immunosuppressive regimen since the 1970s. They result in the 
depletion of thymocytes in the recipient. In general, ATG is being replaced by 
newer monoclonal antibodies in SOT regimen (Hao et al., 2012) particularly 
those with a low risk of rejection, but its use continues in HSCT regimen 
(Bacigalupo, 2005). During infusion the xenogenic proteins can cause allergic 
reactions including anaphylaxis. There is an associated increased risk of CMV 
infection and post-transplant malignancy. 
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1.2.7!Biological!agents!–!Alemtuzumab!
Alemtuzumab is a humanized monoclonal anti-CD52 antibody that is 
lymphocyte-depleting. It is used in HSCT reduced intensity conditioning 
regimes where it can deplete both recipient and donor lymphocytes, reducing 
GvHD and treatment related mortality (Poire and van Besien, 2011). Its use is 
increasing in SOT, where it has been shown to reduce the incidence of acute 
rejection compared to conventional therapy (Hanaway et al., 2011). 
1.2.8!Biological!agents!–!Basiliximab!and!Daclizumab!
Anti-CD25 antibodies (Basiliximab and Daclizumab) are chimeric humanized 
monoclonal antibodies. CD25 is the IL-2 receptor α chain found on activated T 
cells. Ligation inhibits T cell activation and can result in depletion. They are well 
tolerated and are established as first line treatment for induction of 
immunosuppression for SOT. While they have been shown to reduce acute 
rejection episodes, there is no increase in kidney or patient survival. Their use 
may enable elimination or reduction of more toxic immunosuppressive agents 
(Salis et al., 2008). 
1.2.9!Biological!agents!–!Rituximab!
Rituximab is a monoclonal anti-CD20 molecule that depletes B cells. It is not 
used as a routine part of post-transplant immunosuppressive regimen but can 
be added pre transplant in patients with preformed alloantibodies (Vo et al., 
2010). It has also been used for the treatment of antibody-mediated rejection, 
however data from larger studies is needed to prove efficacy (Becker et al., 
2004, Roberts et al., 2012). 
 !
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1.2.10!Use!of!immunosuppressive!agents!in!combination!
Since the first SOT, combinations of different immunosuppressive drugs rather 
than single agents have been given to prevent rejection. Different drugs are 
used in the induction/conditioning phase, immediately prior to and after 
transplantation, compared to long-term maintenance immunosuppression. In 
renal transplantation, international guidelines recommend combination therapy 
including a biologic agent (CD25-antibody or ATG) at induction, followed by 
glucocorticoids, calcineurin inhibitor and anti-proliferative agent (Kasiske et al., 
2010). The recommended calcineurin inhibitor is tacrolimus and MMF is the 
suggested anti-proliferative agent. There is significant variability in practice 
and, as discussed previously, attempts to reduce toxicity by reduction or 
elimination of glucocorticoids and ciclosporin from the immunosuppressive 
regime.  
Similarly for heart transplantation, a combination regimen of calcineurin 
inhibitor (tacrolimus) and anti-proliferative agent (MMF) or MTOR inhibitor are 
recommended with biological agent induction especially to enable more rapid 
reduction in other agents (Costanzo et al., 2010).  
In HSCT, many chemo-radiotherapy induction regimes contain a lymphocyte-
depleting biological agent such as alemtuzumab or ATG. Other techniques, 
such as immunomagnetic selection of CD34 positive stem cells, have been 
used to deplete T-cells from the graft prior to transfer to the recipient. A survey 
of European transplant centres, showed wide variability of agents used for 
prophylaxis. Ciclosporin and MMF were the two most commonly used drugs for 
GvHD prophylaxis (Ruutu et al., 2012). 
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1.3! Effect! of! pharmacological! immunosuppression! on! cellular!
therapy!
The discovery and development of immunosuppressive medication has been 
instrumental in the treatment of autoimmune disease and has allowed millions 
of patients worldwide to receive HSCT and SOT from both related and 
unrelated donors. Despite the clear benefits, suppressing the immune system 
also results in many side effects. The individual characteristics of each drug 
determine the side effect profile but increased rates of infection and malignancy 
relate to the unavoidable reduction in immunosurveillance by suppression of 
lymphocytes.  
Post-SOT adoptive immunotherapy for EBV and CMV has not been as 
successful as that post-HSCT. Two possible explanations are: 
1) Pre-transplant lymphodepletion - Conditioning for HSCT causes 
lymphodepletion providing an immunological niche for transferred cells 
to expand into with reduced competition from other lymphocytes. EBV-
CTLs administered post-SOT enter a lymphocyte replete patient and 
therefore more competition for cytokines.  
2) Ongoing immunosuppression – patients receiving EBV-CTLs post-HSCT 
had ceased immunosuppression, while post-SOT immunosuppression 
was usually continued.  
Although CMV-specific CD8+ T cells can be detected at normal levels in 
patients receiving immunosuppressive therapy, these cells display impaired 
functionality as shown by reduced IFN-γ secretion (Engstrand et al., 2003). 
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This supports the hypothesis that immunosuppression will inhibit transferred 
cells.  
Immunosuppression is also able to impair adoptive immunotherapy with CD4+ 
T cells. A study investigating the effect of standard immunosuppressants 
(Ciclosporin, MMF, glucocorticoids and rapamycin) on Anti-Aspergillus TH1 
cells showed that all doses of ciclosporin, MMF and glucocorticoids used 
significantly decreased the number of viable anti-aspergillus cells in culture 
(Tramsen et al., 2014). The doses reflected target doses in serum and doses 
above and below this, however it is uncertain whether this effect will also occur 
in vivo. 
If transferred cells were conferred with resistance to immunosuppressants, it is 
hypothesised that they would improve the outcome of adoptive immunotherapy 
post-SOT and allow immunosuppression to continue post-HSCT. Two groups 
have published strategies to engineer cells with resistance to calcineurin 
inhibitors prior to adoptive transfer. Brewin et al. (Brewin et al., 2009) 
transduced cells with calcineurin mutants which conferred resistance to 
tacrolimus and/or ciclosporin and demonstrated in vitro efficacy of the 
resistance gene. Continuation of this work was presented recently showing 
efficacy in a xenogenic mouse model (Ricciardelli et al., 2014). De Angelis et al 
(De Angelis et al., 2009) knocked down a binding protein (FKBP12) on which 
tacrolimus depends using a specific small interfering RNA and demonstrated 
activity in a xenogenic mouse model of PTLD during tacrolimus therapy.  
As outlined in section 1.2, many other immunosuppressants are in common 
usage either as monotherapy or in combination. Strategies to provide 
resistance to additional immunosuppressants would expand the potential for 
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adoptive immunotherapy post transplant and during therapy for autoimmune 
disease. Several teams have investigated engineering resistance to 
mycophenolate mofetil (MMF). A mutant form of the enzyme targeted by the 
drug was identified from a murine cell line exposed to increasing 
concentrations of MMF (Hodges et al., 1989, Lightfoot and Snyder, 1994). 
Initial work focused on enabling selection of transduced cells (Yam et al., 2006, 
Sangiolo et al., 2007). During preparation of this manuscript, a further report 
using the same gene alongside a gene conferring methotrexate resistance 
combined in the same vector has also been published (Jonnalagadda et al., 
2013). In this work, I look to assess the utility of this MMF resistance gene for 
adoptive immunotherapy during immunosuppressive therapy. 
 !
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1.4!Mycophenolate!Mofetil!!
The immunosuppressant mycophenolate mofetil (MMF) is routinely used in the 
prevention of allograft rejection (Matas et al., 2013) and treatment of 
autoimmune diseases (Appel et al., 2005, Richardson et al., 2000, Boehm and 
Bieber, 2001, Moore and Derry, 2006). Mycophenolic acid (MPA), the active 
metabolite of MMF, non-competitively inhibits Inosine-5’-monophosphate 
dehydrogenase (IMPDH).  
1.4.1!Identification!and!development!of!MPA/MMF!
MPA was originally identified in 1896 as a fermentation product of penicillium 
brevicompactum (Gosio, 1896), having been isolated from spoiled corn during 
investigations into the cause of pellagra. Gosio showed that the acidic 
fermentation product he had isolated was able to inhibit the growth of anthrax 
bacillus. The same compound was ‘re-discovered’ by Alsberg and Black in 
1913, when they isolated it from deteriorated Italian corn and named the 
compound mycophenolic acid. They established the chemical formula C17H20O6. 
The chemical structures of MMF, MPA and the inactive degradation product 
MPA glucuronide are shown in figure 1.2.  
The action of MPA on IMPDH, and its ability to inhibit nucleic acid synthesis in 
eukaryotic cells was established in 1969 (Franklin and Cook, 1969). The lethal 
dose for an adult mouse was determined to be ~10mg when administered 
intravenously (~500µg/g) and 40mg orally (Florey et al., 1946). Initial 
investigations showed that MPA had antimicrobial, antineoplastic and 
immunosuppressive activity in vitro.  
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Figure 1.2 Chemical structure of mycophenolate mofetil, mycophenolic 
acid and mycophenolic acid glucuronide 
The chemical structure of MMF (2-morpholinoethyl (E)-6-(1,3-dihydro-4- 
hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate) 
is shown (A). MMF has a molecular formula of C23H31NO7 and a molecular 
weight of 433.5 Daltons. Following intravenous or oral administration, MMF is 
rapidly hydrolysed to MPA by serum and tissue esterases. MPA has the 
molecular formula C17H20O6 and its chemical structure is shown (B). MPA is 
metabolised in the liver by glucuronosyl transferase to form the inactive 
Mycophenolic acid glucuronide (C).  
  
esterase 
Mycophenolic acid – MPA 
Mycophenolic acid  
glucuronide – MPAG 
glucuronosyl transferase 
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1.4.2!Purine!metabolism!
There are two major pathways of purine synthesis, de novo and salvage 
(Figure 1.3). In the de novo pathway, ribose-5-phosphate and adenosine 
triphosphate (ATP) are converted to 5-phosphoribosyl-1-pyrophosphate 
(PRPP) catalyzed by the enzyme PRPP synthetase. PRPP is then converted to 
inosine monophosphate (IMP), from which guanine or adenine nucleotides can 
be synthesized.  
The conversion of IMP to XMP, catalyzed by IMPDH, is the first committed and 
rate-limiting step in guanine nucleotide biosynthesis. Guanosine 
monophosphate (GMP) is synthesized from XMP catalyzed by GMP 
synthetase. Guanine nucleotides serve as precursors for RNA and DNA, the 
energy source for translation, the co-factor for G-proteins, precursors for 
glycosylation, the precursor for tetrahydrobiopterin synthesis as well as 
important allosteric regulators and signaling molecules (Allison and Eugui, 
2000).  
To generate adenosine monophosphate (AMP), IMP undergoes a two-step 
conversion, catalyzed by adenylosuccinate synthetase and adenylosuccinate 
lyase respectively. Generation of dGTP and dATP involves reactions catalysed 
by ribonucleotide reductase.  
The guanine salvage pathway involves the formation of GMP from guanine and 
PRPP, a reaction catalyzed by hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT).  
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Figure 1.3 Purine metabolism 
The two major pathways of purine synthesis, de novo and salvage are shown. 
In the de novo pathway, 5-phosphoribosyl- 1-pyrophosphate (PRPP) is formed 
from ribose-5-phosphate and adenosine triphosphate (ATP) by PRPP 
synthetase. PRPP is then converted to inosine monophosphate (IMP). 
Adenosine monophosphate (AMP) is synthesized from IMP in two steps, 
catalyzed by adenylosuccinate synthetase and adenylosuccinate lyase 
respectively. Guanosine monophosphate (GMP) is converted from IMP by the 
action of two enzymes, IMPDH and GMP synthetase. GMP is also generated 
via the salvage of guanine nucleotides catalyzed by hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT). Adenosine diphosphate (ADP) and 
guanosine diphosphate (GDP) are converted to deoxyadenosine diphosphate 
(dADP) and deoxyguanosine diphosphate (dGDP) respectively by 
ribonucleotide reductase.  
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Feedback within the purine synthesis pathway occurs via two routes. When 
adenosine nucleotides exceed guanosine nucleotides, PRPP synthetase is 
inhibited (Garcia et al., 1977). Excess dATP, compared to dGTP, causes 
inhibition of ribonucleotide reductase (Kashlan et al., 2002). 
1.4.2.1!Inherited!defects!of!purine!metabolism!
Inherited deficiency of adenosine deaminase (de novo pathway) causes severe 
immunodeficiency (Giblett et al., 1972), but Lesch-Nyhan syndrome caused by 
HGPRT deficiency (salvage pathway) results in severe neurological symptoms 
but no immunodeficiency (Seegmiller et al., 1967). This suggested that human 
lymphocytes are relatively dependent on the de novo pathway of purine 
synthesis whereas the salvage pathway catalyzed by HGPRT is not essential.  
1.4.3!InosineH5’HMonophosphate!Dehydrogenase!(IMPDH)!
With the exception of protozoan parasites such as Giardia lamblia (Morrison et 
al., 2007) and Trichomonas vaginalis (Carlton et al., 2007), the IMPDH 
pathway appears to be present in every organism. The human and murine 
sequences differ by only six amino acids (figure 1.4). Moreover, many 
organisms contain multiple genes encoding IMPDH. Two distinct cDNAs of 
human IMPDH have been cloned, producing two isoforms, designated types 1 
and 2 (Collart and Huberman, 1988, Natsumeda et al., 1990). The genes are 
encoded on chromosomes 7 and 3 respectively. Both isoforms contain 514 
amino acids, of which 84% are identical (Natsumeda et al., 1990), and are 
almost indistinguishable in their kinetic properties.   
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Figure 1.4 Amino acid sequences of murine and human Inosine-5’-
Monophosphate Dehydrogenase (IMPDH2) 
Green highlights the six differences between the amino acid sequence of 
murine top and human bottom IMPDH2  
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Type I, the preponderant isoform in the retina, spleen and resting peripheral 
blood mononuclear cells, is constitutively expressed and is not inducible (Nagai 
et al., 1991). Type 2 is selectively up-regulated in neoplastic (Natsumeda et al., 
1990) and replicating cells and emerges as the dominant species (Nagai et al., 
1991, Nagai et al., 1992). Most tissues express both isozymes to varying 
extents (Jain et al., 2004, Senda and Natsumeda, 1994, Bowne et al., 2006a). 
IMPDH1 knockout mice display mild retinopathy, however IMPDH2 null mice 
die during embryogenesis. A recent report shows that the isoforms display 
different nucleotide binding with differential regulation by a mechanism 
involving binding to the subdomain by AMP (IMPDH2) and ATP (IMPDH1) 
(Thomas et al., 2012). 
The type 2 isoform was found to be 4.8 times more sensitive to MPA than the 
type 1 isoform (Carr et al., 1993). The fact that the type 2 isoform of IMPDH is 
predominantly expressed in activated lymphocytes may partly explain why 
MPA is relatively selective for lymphocytes. 
1.4.3.1!IMPDH!structure!
IMPDH proteins form stable tetramers with square planar geometry that may 
contain both isoforms. The x-ray crystal structure identifies monomers 
containing two domains: the core catalytic domain, which is a (α/β)8 barrel, and 
the flanking subdomain containing two CBS domains (Carr et al., 
1993),(Nimmesgern et al., 1999, Gan et al., 2002).  
CBS domains are conserved sequences found in a wide range of proteins in all 
species. The secondary structure, β1α1β2β3α2, folds into a globular structure 
with three antiparallel β sheets together and the two α-helices on the other 
side. CBS domains are always found in pairs that tightly associate via their β-
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sheets in what is termed a Bateman domain. ATP binds to the Bateman 
domains of tetrameric IMPDH in a positive, cooperative way (Cornuel et al., 
2002, McLean et al., 2004, Mortimer and Hedstrom, 2005, Bowne et al., 
2006b). ATP binding activates IMPDH catalytic activity (Scott et al., 2004). ATP 
binding and activation is abolished by a single amino acid mutation in the 
second CBS domain (R224P) which when present in IMPDH 1 is a cause of 
autosomal dominant retinitis pigmentosa. In addition to activation of the 
enzymatic domain, the CBS subdomains have also been shown to: 
1) regulate nucleotide pools (Pimkin and Markham, 2008).  
2) associate with polyribosomes, suggesting involvement in the regulation 
of translation (Mortimer et al., 2008).  
The junction between the catalytic domain and the subdomain is flexible and 
the relative orientation can vary by as much as 120 degrees in different crystal 
structures (Figure 1.5) (Colby et al., 1999).  
The enzymatically active site of the catalytic domain is located in the loops on 
the C-terminal ends of the β sheets. The catalytic loop, the C-terminal segment 
and a flap segment display structural mobility. This is critical for enzymatic 
activity, with a different conformation generated for each step of the catalytic 
cycle. A large segment between β8 and α8 forms a flap, the distal portion of 
which moves in and out of the active site during the catalytic cycle; the open 
conformation is required for the dehydrogenase reaction while the closed 
conformation is used in the hydrolysis step (Hedstrom and Gan, 2006). Both 
the key catalytic residue Cys319 and most of the residues that interact with 
IMP are conserved across species. However, the NAD site and the flap are 
highly divergent. 
61 
Figure 1.5 Structure of Inosine-5’-Monophosphate Dehydrogenase 
(IMPDH) 
(A) An IMPDH2 monomer is shown as a ribbon diagram with IMP bound in the 
enzymatic domain. (B) Human Type II IMPDH tetramer with bound dinucleotide 
analogue (circled, red) and substrate analogue (circled, green). The 
dinucleotide binds at the monomer–monomer interface (dotted lines). The 
following structures are illustrated: catalytic β-barrel domain (blue), flanking 
domain (magenta), active site loop (yellow) and active site flap fragments 
(white). IMP – Inosine monophosphate, NAD – Nicotinamide adenine 
dinucleotide 
 !NAD Binding Pocket A 
B 
From Colby et al. Crystal structure of human type II inosine monophosphate 
dehydrogenase: implications for ligand binding and drug design  
PNAS 1999;96 (7) 3531-3536 
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1.4.3.2!Enzymatic!action!of!IMPDH!
IMPDH catalyzes the nicotinamide adenine dinucleotide (NAD)-dependent 
oxidation of IMP to xanthosine monophosphate (XMP), which is the committed 
step in the de novo biosynthesis of guanine nucleotides (Crabtree and 
Henderson, 1971, Jackson et al., 1975). The reaction is irreversible and was 
initially thought to follow bi-bi sequential ordered kinetics (Carr et al., 1993); 
however, more recently a more random mechanism has been shown to occur 
(Heyde et al., 1976, Heyde and Morrison, 1976). The mechanism of action of 
IMPDH is shown diagrammatically in Figure 1.6. IMPDH catalyzes two 
chemical transformations: firstly following IMP binding a dehydrogenase 
reaction to form NADH and the covalent intermediate E-XMP* and then a 
hydrolysis reaction which converts E-XMP* into XMP.  
MPA and the nicotinamide portion of NAD+ have similar volumes and 
electronic properties(Makara et al., 1996). Mycophenolic acid (MPA) traps E-
XMP* within IMPDH, the crystal structure of the E-XMP*•MPA complex has 
been solved (Sintchak et al., 1996, Fleming et al., 1996, Link and Straub, 1996) 
which shows that MPA stacks against the purine ring in a similar manner to the 
nicotinamide ring of NAD+ (Sintchak et al., 1996). The strong preference for E-
XMP* makes MPA an uncompetitive inhibitor with respect to both IMP and 
NAD+.  
 !
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Figure 1.6 The kinetic mechanism and conformational transitions of the 
Inosine-5’-Monophosphate Dehydrogenase (IMPDH) reaction.  
The pathway where IMP binds first is depicted for clarity. The Cys319 loop and 
the flap are initially disordered (denoted by the dashed lines). When IMP binds, 
the loop becomes more ordered. NAD+ binds and the dehydrogenase reaction 
occurs rapidly to produce E–XMP*!NADH. The release of NADH is slower than 
hydride transfer. MPA binds to the vacant NADH site of E–XMP*. Alternatively, 
the flap folds into the NADH site, positioning Arg418 to activate water. The 
hydrolysis of E–XMP* is rate-limiting, and is believed to trigger the release of 
K+ and the opening of the flap and loop.  
IMP - Inosine monophosphate; MPA – Mycophenolic acid; NAD - Nicotinamide 
adenine dinucleotide; XMP – Xanthine monophosphate  
 !
Adapted from L Hedstrom and Lu Gan IMP dehydrogenase: structural 
schizophrenia and an unusual base  
Current Opinion in Chemical Biology 2006, 10:520–525  ! 
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1.4.3.3!Other!functions!of!IMPDH!
In addition to the enzymatic function of IMPDH, several other functions have 
been proposed. Kozhevnikova et al. showed that in Drosophila IMPDH not only 
controls cell proliferation by controlling the guanine nucleotide pool but is also a 
DNA-binding transcriptional repressor, binding to CT-rich DNA elements 
(Kozhevnikova et al., 2012). DNA binding by IMPDH reduces cell proliferation 
by reducing histone gene and E2f expression. DNA binding is through the CBS 
domain. 
IMPDH2 has been shown to rapidly recruit to lipid raft after Toll-like receptor 2 
(TLR2) activation. It causes increased phosphatase activity of SHP1 resulting 
in inactivation of PI3K and thereby negatively regulation TLR2 signalling 
(Toubiana et al., 2011).  
IMPDH is a rate-determining factor in the regulation of proliferation by p53 (Liu 
et al., 1998). Constitutive IMPDH expression prevents growth suppression 
while inhibition of IMPDH mimics over-expression of p53. 
1.4.3.4!Mutations!in!IMPDH!
As stated in section 1.4.3.1, the R224P mutation of IMPDH1 causes autosomal 
dominant retinitis pigmentosa as does D226N and V268I (Mortimer and 
Hedstrom, 2005). Additionally two mutations have been linked to Leber 
congenital amaurosis, R105W and N198K. While IMPDH2 has low genetic 
diversity, one variant (L263F) displays marked reduction in enzymatic activity 
(Wang et al., 2007). 
Within this work I have used a mutant form of IMPDH generated by incubation 
of murine neuroblastoma cells in increasing concentrations of MPA (Hodges et 
al., 1989). The resulting cells were 10,000 fold more resistant to MPA induced 
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growth inhibition. The cells had increased expression of IMPDH due to 
increased copy number resulting in 10-20 fold increase in IMPDH mRNA and 
IMPDH accounted for 20% of soluble proteins. MPA resistance was also 
caused by mutation in the IMPDH gene. 4 nucleotide changes were identified, 
one of which was present in the parental tumour cell line and another did not 
result in a codon change. The remaining 2 mutations caused 2 amino acid 
substitutions, T333I and S351Y, that result in 2400-fold increased resistance to 
MPA (Lightfoot and Snyder, 1994). The mutations also cause a reduction in 
enzymatic activity, with the estimated Kcat 10% of wild-type enzyme. 
Mutational analysis of the IMPDH catalytic domain has identified mutants with 
reduced enzymatic activity (Futer et al., 2002). I have used a mutant with 
unrecordable catalytic activity, C331A, which is designated IMPDH2CS and the 
wild-type gene IMPDH2WT. 
1.4.4!Pharmacokinetics!of!MMF!
MMF is rapidly absorbed following oral administration. After oral or intravenous 
administration, MMF is hydrolysed to pharmacologically active MPA by serum 
and tissue esterases. Following oral administration, MMF itself is not 
measurable in transplant patients or animals (Lee et al., 1990). Up to 98% of 
MPA binds to albumin, with only the free portion being active (Nowak and 
Shaw, 1995). MPA is metabolised in the liver by glucuronosyl transferase to 
form the inactive mycophenolic acid glucuronide (MPAG) (Sweeney et al., 
1972). MPAG is primarily eliminated in the urine. MPA also exhibits 
enterohepatic recirculation where inactive MPAG is excreted in bile (Shaw and 
Nowak, 1995). This is metabolised by intestinal bacteria to reform MPA and 
both MPA and MPAG are reabsorbed in the gut (Bullingham et al., 1998).  
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Peak MPA levels typically occur between 20 and 40 minutes after 
administration but there is significant inter- and intra-patient variability in 
pharmacokinetics. The half-life of MPA is approximately 18 hours and 
enterohepatic recirculation can result in a small secondary peak in MPA levels 
approximately 16 hours post administration. Dosing schedules require 
administration of MMF two or three times daily. MPA levels are usually 
assessed pre-dose (trough). The therapeutic range for pre-dose levels, 
calculated from reported successful immunosuppression, is given as 1-3.5mg/l, 
equating to a concentration of 3.1-10.9µM.  
1.4.4.1!Clinical!monitoring!of!MPA!levels!
A 2008 review for the US Department of Health concluded that routine 
monitoring of MPA levels was not recommended (Oremus et al., 2008). There 
is however evidence that monitoring MPA levels and appropriate adjustment of 
doses may improve outcomes (Neumann et al., 2008, Le Meur et al., 2007, 
Hiwarkar et al., 2011, Tredger et al., 2004, Borrows et al., 2006). Monitoring of 
MPA is usually performed by high performance liquid chromatography, an 
EMIT immunoassay is also available but this reacts with both MPA and MPAG 
which further complicates interpretation of results (Weber et al., 2002). 
 !
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1.4.5!Antimicrobial!activity!of!MPA!
Following the discovery of penicillin, many fungal metabolites were investigated 
for their antibiotic properties. Rapid proliferation is a characteristic of microbial 
infections, so IMPDH is an attractive antimicrobial target. Antimicrobial utility 
may be limited by salvage of xanthine in addition to guanine and/or guanosine 
by many pathogens. Xanthine salvage enables several bacteria to retain 
normal virulence even in the absence of IMPDH (Ivanovics et al., 1968, 
McFarland and Stocker, 1987, Noriega et al., 1996, Straley and Harmon, 
1984). Inhibition of IMPDH has been shown to inhibit the growth of 
Staphylococcus aureus (Abraham, 1945, Harris, 1943), Plasmodium falciparum 
(Webster and Whaun, 1982), Eimeria tenella (Hupe et al., 1986), 
Tritrichomonas foetus (Hedstrom et al., 1990), Leishmania donovani (Wilson et 
al., 1991), Trypanosoma brucei (Wilson et al., 1994) Candida albicans (Kohler 
et al., 1997) and Cryptosporidium parvum (Striepen et al., 2004). Drug 
resistance has been demonstrated in vitro, by both amplification (Wilson et al., 
1991, Wilson et al., 1994, Lightfoot and Snyder, 1994) and drug resistance 
mutations (Kohler et al., 1997, Lightfoot and Snyder, 1994, Farazi et al., 1997) 
in the IMPDH gene.  
Additionally, MPA was shown to have in vitro anti-fungal (Florey et al., 1946, 
Noto et al., 1969) and anti-viral (Florey et al., 1946, Williams et al., 1968, Cline 
et al., 1969, Neyts et al., 1998) activity. However, MMF is not licensed for use 
in the treatment of fungal or viral infection. During MMF treatment, patients are 
at risk of primary viral infections and viral reactivation. 
 !
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1.4.6!Antineoplastic!activity!of!MPA!
Rapidly dividing cells have a high demand for guanine nucleotides. This 
requirement cannot be sustained by salvage pathways and explains the 
importance of IMPDH in cancer. Tumour cells have been shown to contain 
increased levels of IMPDH mRNA, protein and activity (Collart et al., 1992, 
Nagai et al., 1991). 
Early in vitro studies identified the anti-neoplastic activity of MPA (Williams et 
al., 1968, Carter et al., 1969, Suzuki et al., 1969). Additionally, MMF’s 
antiangiogenic activity (Chong et al., 2006, Domhan et al., 2008) is desirable in 
treating malignancy. MPA induces differentiation and/or apoptosis of several 
cancer cell lines, including breast (Bacus et al., 1990), prostate (Floryk and 
Huberman, 2006, Floryk et al., 2004), melanoma (Kiguchi et al., 1990), 
leukemia (Collart and Huberman, 1990) and neuroblastoma (Messina et al., 
2004, Messina et al., 2005).  
Due to its anti-neoplastic action in vitro, MPA was investigated both in murine 
tumour models and clinical trials as a cancer chemotherapeutic agent. MPA 
was found to have variable efficacy in in vivo murine models (Suzuki et al., 
1969, Planterose, 1969) and results from early clinical trials showed no benefit 
from MPA (Brewin et al., 1972). The antineoplastic efficacy of MPA in vivo is 
limited by glucuronidation of phenolic oxygen, inactivating the drug (Franklin et 
al., 1996). Cancer cells appear to have a higher capacity for glucuronidation 
than normal cells.  
 !
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1.4.7!Immunosuppressive!activity!of!MPA!
The first indication that MPA had immunosuppressive activity was seen in 
experiments performed by Planterose (Planterose, 1969). He used an in vivo 
tumour model triggered by mouse sarcoma virus and noted that splenomegaly 
only occurred when mice were treated with known immunosuppressants or 
MPA. Along with other findings detailed below and from knowledge of inherited 
defects in purine metabolism (section 1.4.2.1), development of MPA as an 
immunosuppressive drug began in the early 1980s (Allison and Eugui, 1993a). 
1.4.7.1!MPA!reduces!lymphocyte!proliferation!
As predicted from its mechanism of action, MPA reduces the proliferation of T 
and B lymphocytes following stimulation by several mitogens or in mixed 
lymphocyte reactions (Eugui et al., 1991b). Lymphocyte proliferation in 
response to tumour or vaccine is attenuated by MPA (Eugui et al., 1991b). 
Proliferation is limited by MPA induced G1-S phase cell cycle blockade (Cohn 
et al., 1999) and although the principal mode of action is cytostatic, MPA can 
induce apoptosis (Cohn et al., 1999).  
1.4.7.2!MPA!causes!a!reduction!in!antibody!formation!
MPA reduces B cells number and inhibits antibody formation. This has been 
demonstrated in vitro following activation of human B cells by Staphylococcus 
protein A sepharose (Allison et al., 1991), tetanus toxoid (Burlingham et al., 
1991) or stimulation by interleukin (IL)-4 and IL-13 (Chang et al., 1993). The in 
vivo murine antibody response to sheep erythrocytes was significantly reduced 
by MPA (Mitsui and Suzuki, 1969, Eugui et al., 1991b). 
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1.4.7.3!MPA!has!minimal!effect!on!cytokine!production!
Several groups have studied the effect of MPA on cytokine production. No 
inhibition has been demonstrated for IL-2 and IL-2R (Eugui et al., 1991a), IL-4, 
IL-5, interferon gamma (IFN-γ) and granulocyte macrophage colony stimulating 
factor (GM-CSF) (Chang et al., 1993) IL-1α, IL-1β, IL-3, IL-6, IL-10, tumor 
necrosis factor (TNF)-α and TNF-β (Nagy et al., 1993). A 40% reduction in GM-
CSF production in response to superantigen was seen following MPA 
exposure. 
1.4.7.4!MPA!in!vitro!reduces!glycosylation!and!expression!of!adhesion!molecules!
Adhesion molecules, such as selectins and integrins, required for recruitment 
of leukocytes to sites of inflammation require GTP for their synthesis. By 
reducing GTP, MPA reduces transfer of mannose to these membrane 
glycoproteins resulting in reduced expression (Allison and Eugui, 1993b). 
1.4.7.5!MPA!inhibits!nitric!oxide!production!
Nitric oxide (NO) is an important signaling molecule and mediator of the 
immune response. One of the co-factors required for its synthesis, 
tetrahydrobiopterin (Moncada et al., 1991) is in turn dependent on GTP for its 
synthesis. MPA has been shown to reduce production of NO in mouse and rat 
brain endothelial cells that had been stimulated with a combination of IFN-γ 
and TNF-α (Senda et al., 1995). 
In vivo, MPA has been shown to reduce levels of inducible NO synthase mRNA 
in the renal cortex of MRL/lpr mice (Yu et al., 2001). 
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1.4.7.6!MMF!in!models!of!allograft!rejection!
MMF reduces acute rejection in a variety of in vivo models. This has been 
demonstrated for transplanted pancreatic islets (Hao et al., 1990), heart 
(Tanabe et al., 1994, Fujino et al., 1994, Morris et al., 1990, Morris et al., 
1991), kidney (Platz et al., 1991), small bowel (Nakajima et al., 1993) and liver 
(Bechstein et al., 1993). Many of the studies showed additional benefit from 
combination therapy with other immunosuppressants. MMF is also effective in 
the treatment of models of chronic rejection of transplanted aorta (Raisanen-
Sokolowski et al., 1994), heart (Morris et al., 1991) and kidney (Azuma et al., 
1995). 
1.4.8!Clinical!studies!of!MMF!
MPA has been used in humans as sodium mycophenolate and a 
morpholinoethyl ester (MMF) with improved bioavailability (Lee et al., 1990). 
MPA has also been used in the treatment of several autoimmune diseases 
including Systemic Lupus Erythematosis (Karim et al., 2002, Moore and Derry, 
2006) and Multiple Sclerosis (Michel et al., 2013).  
1.4.8.1!Prevention!of!SOT!allograft!rejection!
An initial trial in 48 primary cadaveric renal transplant recipients receiving MMF 
(doses 0.1g to 3.5g/day) (Sollinger et al., 1992) showed efficacy in the absence 
of toxicity with 1-year actuarial graft survival of 95% (Deierhoi et al., 1993). In 
this study patients also received cyclophosphamide and prednisolone. With 
escalating doses of MMF, only one patient experienced an adverse event 
possibly related to the drug (haemorrhagic gastritis). There was a significant 
correlation between rejection episodes and dose of MMF (p=0.022). 
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Subsequently three multi-centre prospective, randomized, double-blinded 
placebo controlled trials of MMF for the prevention of acute rejection post renal 
transplant were performed (European Mycophenolate Mofetil Cooperative 
Study Group, 1995, Sollinger, 1995, The Tricontinental Mycophenolate Mofetil 
Renal Transplantation Study Group, 1996). Pooled analysis of 1493 renal 
transplant recipients from these trials showed that at one year, MMF 
significantly reduced the incidence of acute rejection. Overall graft survival 
rates were higher with MMF but did not reach statistical significance (Halloran 
et al., 1997). These results formed the basis for approval of MMF for prevention 
of acute rejection in renal transplant recipients. 
MMF also exhibits efficacy in the treatment of refractory acute cellular rejection 
in renal allografts recipients. As discussed in section 1.2, MMF is commonly 
given in combination with glucocorticoids and other immune suppressants such 
as calcineurin inhibitors or biological agents. 
1.4.9!Safety!and!tolerability!of!MMF!
Information on the safety and tolerability of MMF is mainly derived from three 
large clinical trials in renal transplantation (European Mycophenolate Mofetil 
Cooperative Study Group, 1995, Sollinger, 1995, The Tricontinental 
Mycophenolate Mofetil Renal Transplantation Study Group, 1996) and one 
large clinical trial in heart transplantation (Kobashigawa et al., 1998). 
MMF is generally well tolerated but can cause gastrointestinal and 
hematological side effects. The leading adverse gastrointestinal events are 
diarrhoea, abdominal pain, nausea and vomiting. Leukopenia and anemia are 
the most frequently encountered hematological adverse events. These adverse 
events are dose-dependent and are readily reversible upon dose reduction or 
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discontinuation. As with other immunosuppressive drugs, MMF treatment is 
associated with a higher risk of opportunistic infection. In particular, there is a 
tendency for a slight increase in the incidence of tissue-invasive 
cytomegalovirus infection, especially at the higher dose of 3g/day.  
There is no clear evidence for increased incidence of malignancy. Investigation 
of the effects of different immunosuppressants in a murine model of hepatic 
metastasis in colon cancer demonstrated reduction in tumour growth in mice 
receiving therapeutic concentrations of MMF but enhanced tumour growth 
when ciclosporin or tacrolimus were given (Yokoyama et al., 1995). In patients 
receiving immune suppression, there is data suggesting reduced rates of 
malignancy when MMF is used in comparison to other agents. Analysis of 
registry data in renal transplant recipients has shown a trend towards reduced 
incidence and a significant increase in time to onset of post-transplant 
malignancy compared to other immunosuppressive regimen (Robson et al., 
2005). Post-transplant Kaposi sarcoma has been shown to regress when 
immunosuppression was changed from ciclosporin to MMF (Hussein et al., 
2000), however another reports suggest an increased risk of Kaposi sarcoma 
while taking MMF (Eberhard et al., 1999).   
74 
1.5!Hypotheses!
In this work I will use a retroviral vector to transduce cells with a mycophenolic 
acid resistant mutant of inosine-5’-monphosphate (IMPDH2R) to test the 
following hypotheses: 
1. Transduction with IMPDH2R will confer a selective advantage compared 
to untransduced cells or cells transduced with wild-type or 
hypofunctional IMPDH2 in the presence of mycophenolic acid. 
2. IMPDH2R will confer a selective advantage due to protection from MPA 
induced cell cycle blockade and apoptosis. 
3. IMPDH2R transduced cells will persist and function in vivo during 
treatment with Mycophenolate Mofetil. 
1.6!Aims!
1. To generate IMPDH2CS, IMPDH2WT and IMPDH2R transduced cells and 
investigate their phenotype in vitro in the presence and absence of MPA. 
2. To investigate in vivo selection of IMPDH2R versus IMPDH2CS 
transduced CD8 T cells following antigenic stimulation in the presence 
or absence of MMF. 
3. To investigate the function of IMPDH2R in vivo during MMF therapy 
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Chapter(2:#Materials)and)Methods!
 
2.1!Retroviral!Vectors!
A retroviral vector (SFG) containing human IMPDH2 with the double-mutation 
T333I and S351Y in frame with eGFP at its N-terminus (IMPDH2R) had 
previously been cloned and was a gift from Dr Martin Pule, UCL. In order to 
assess whether any advantage seen in cells transduced with IMPDH2R was 
due to expression of increased levels of IMPDH2 rather than the resistance 
phenotype, a plasmid containing a wild-type IMPDH2 gene was cloned from 
the mutant form (IMPDH2WT). Additionally, an enzymatically hypofunctional 
plasmid (IMPDH2CS) was generated by insertional mutagenesis to act as a 
control. A plasmid containing eGFP alone was also used as a control.  
pCl-Eco is a retroviral packaging vector, which is used to enhance retroviral 
titres produced by Ph-Eco cells by encoding retroviral gag, pol and ecotropic 
envelope proteins. These were used to generate retroviral supernate for the 
transduction of murine cells. pCl-Ampho was used with Ph-Ampho cells to 
generate retroviral supernate for the transduction of human cells. 
 !
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2.1.1!Generation!of!wildHtype!IMPDH2!!
Using the two sets of overlapping primers (sequences below) we generated 
two DNA fragments (Figure 2.1A) that were subsequently fused to create a 
fragment in which the T331I and S351Y mutations had been repaired (Figure 
2.1B). This was then cloned back into the original mutant vector using 
Sbf1/BamHI enzyme digestion of the parental plasmid and PCR fusion to 
generate a plasmid containing wild-type IMPDH2.GFP fusion (Figure 2.1C). 
The alignment of Primers 2 and 3 to IMPDH2WT is shown (Figure 2.1D). 
Primer 1: 5’-CCCAAGGATCGCGTGCGGGATG-3’ 
Primer 2: 5’-GTTGCTTGGGGCCGCCCACAGGCCAGCACTTCCTGCGTA 
ATGCAGATGGAGCCACTTCCCATGC-3’ 
Primer 3: 5’-CCTGTGGGCGGCCCCAAGCAACAGCAGTGTACAAGGTGT 
CAGAGTATGCACGGCGCTTTGGTG-3’ 
Primer 4: 5’-GGCACCAATGTCCTGGCATGAGTGTTG-3’ 
 !
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Figure 2.1 Cloning SFG. eGFP-IMPDH2WT 
(A) An SFG plasmid containing an eGFP-IMPDH2R fusion was used as a 
template for cloning. Two PCR reactions were performed to cover an 
overlapping 600 base pair region of the IMPDH2 gene contain a BamH1 and 
Sbf1 restriction site and the 2 mutations S351Y and T333I.  
(B) The two overlapping PCR products were separated on a 1% agarose gel 
and extracted. A secondary PCR reaction using the outermost primers (1 and 
4) was performed and the resulting product separated on a 1% agarose gel 
and extracted. 
(C) Both the PCR product and the SFG.eGFP-IMPDH2R plasmid were digested 
using BamH1 and Sbf1 and a PCR reaction run using primers 2 and 3 to fuse 
the secondary PCR product into the SFG plasmid. Successful generation of an 
SFG.eGFP-IMPDH2WT plasmid was confirmed by DNA sequencing. 
(D) The sequences of the overlapping primers 2 and 3 and the aligned 
IMPDH2R sequence are shown. 
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Figure 2.1 !
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2.1.2!Generation!of!catalyticHsite!mutant!IMPDH2!
Futer et al identified a C331A mutation in IMPDH (IMPDH2CS) that results in an 
enzyme with a Kcat <0.00007/s compared to 1.51/s for the wild type 
enzyme(Futer et al., 2002). I generated this hypofunctional mutant of IMPDH2 
by insertional mutagenesis using QuickChange® Mutagenesis XL kit (Agilent) 
as per the manufacturers instructions (Figure 2.2). The C331A mutant required 
a two base pair mutation T991G and G992C. Primers (Invitrogen Life 
Sciences) were designed using the online Stratagene Quickchange primer 
design program. 
5'-GGGAAGTGGCTCCATCGCCATTACGCAGGAAGTG-3' 
5'-CACTTCCTGCGTAATGGCGATGGAGCCACTTCCC-3' 
 
A PCR reaction was set up using the two primers highlighted above, pfu turbo-
polymerase, the SFG.eGFP-IMPDH2WT plasmid, quick solution, dNTP mix and 
B˚. The PCR product was incubated in DpnI to digest the parental plasmid but 
not the unmethylated PCR product. XL-10 Gold cells were transformed using 
the DpnI treated DNA and then grown on agar plates containing ampicillin. The 
resultant colony was expanded and DNA extracted using a miniprep kit 
(Qiagen). Sequencing was performed which confirmed the insertion of the 
C331A mutation. 
 !
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Figure 2.2 Cloning SFG.eGFP-IMPDH2CS 
Using a QuickChange® Mutagenesis XL kit, a PCR reaction with the placental 
plasmid SFG.eGFP-IMPDH2WT and mutagenic primers was performed. 
Parental plasmid was digested with Dpn1, which does not digest the 
unmethylated PCR product containing the mutagenic primers. XL10 Gold cells 
were transformed with this mutated plasmid. Successful mutation was 
confirmed by DNA sequencing. 
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Figure 2.2 
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2.2!Cell!culture!
2.2.1!Murine!cells!
C57Bl/6, OT1 TCR Tg Rag-/-(Hogquist et al., 1994) (CD45.1, CD45.1xCD45.2 
or CD45.2), Thy1.1 (C57Bl/6 background), CD45.1 and CD45.1xCD45.2 mice 
(C57Bl/6 background) were obtained from breeding colonies established at our 
on-site animal facility.  
2.2.2!Cell!lines!
The Phoenix Ecotropic (Ph-Eco) Packaging cell line (Nolan Laboratory, 
Stanford, CA) is an adherent cell line used as the packaging line to generate 
high concentrations of retroviral particles following transient transfection. 
Phoenix Eco cells stably express from gag, pol and env the proteins required 
for packaging, processing, reverse transcription and integration of retroviral 
genomes, and include selectable markers for gag-pol expression (hygromycin 
resistance) and env expression (diphtheria toxin resistance).  In addition 
Phoenix Amphotrophic (Ph-Ampho) Packaging cells were used which are very 
similar to Ph-Eco cells, but their env gene produces supernate that is trophic 
for human cells. 
RMAS cells were used as antigen presenting cells to murine lymphocytes as 
they do not present endogenous antigen, but after temperature induction 
express high levels of empty MHC class I on their surface, which can be loaded 
with peptide (Ljunggren et al., 1990, Esquivel et al., 1992, De Bruijn et al., 
1991). A T2 cell line, generated from fusion of a human B-Lymphoblastoid cell 
line (LCL) and T-LCL, is deficient in transporter associated with protein (TAP) 
but still express low amounts of MHC class I on the surface of the cells (Salter 
and Cresswell, 1986, Salter et al., 1985). After loading with peptide these cells 
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were used in restimulation of TCR transduced human peripheral blood 
mononuclear cells. 
A CD8+ variant of the BW5147 thymoma cell line (BW) was used to assess 
transduction, confirm phenotype and to ensure larger numbers of analyzable 
cells (Wegener et al., 1992, Letourneur and Malissen, 1989). 
The EG7 cell line was used in in vivo tumour experiments. EG7 was generated 
by transfection of the C57BL/6 (H-2b) derived cell line EL4 with a plasmid 
containing a complete cDNA copy of the chicken ovalbumin (OVA) mRNA and 
a neomycin resistance gene which allows for selection of transfected cells by 
G418 (Moore et al., 1988). EG7 cells form solid tumours in mice (Zhou et al., 
1992) and present the immunodominant peptide epitope of OVA257-264 
(SIINFEKL) in the context of Kb, which is recognised by the OT1 TCR(Shastri 
and Gonzalez, 1993, Rotzschke et al., 1991). 
Adherent cells were cultured in T75 and non-adherent cell lines in T25 or T75 
tissue culture flasks (Helena Biosciences, UK). All tissue culture procedures 
were performed in a class II tissue culture cabinet. 
2.2.3!Cell!counting!and!viability!
Cells were counted using a disposable Neuberger improved haemocytometer 
under a light microscope. Cell viability was assessed using 0.4% trypan blue 
(Sigma); live cells are capable of excluding the trypan blue dye. 
 !
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2.2.4!Culture!media!!
2.2.4.1!Murine!T!cells!–!T!cell!media!
Medium used comprised RPMI-1640 (Roswell Park Memorial Institute - Lonza) 
with 10% heat inactivated foetal bovine serum (Sigma), 100Units/mL penicillin, 
100µg/mL streptomycin (Invitrogen), 2mM L-glutamine (Sigma-Aldrich) and 
0.05mM 2-mercaptoethanol.  
2.2.4.2!RMAS!cells!and!BW!cells!–!Cell!line!media!
Medium used comprised RPMI-1640 (Roswell Park Memorial Institute - Lonza) 
with 10% heat inactivated foetal bovine serum (Sigma), 100Units/mL penicillin, 
100µg/mL streptomycin (Invitrogen) and 2mM L-glutamine (Sigma-Aldrich). 
2.2.4.3!EG7!cells!–!EG7!media!
Medium comprised of DMEM with 10% heat inactivated foetal bovine serum 
(Sigma) and 2mM L-glutamine (Sigma-Aldrich). G418 (400µg/ml) was added to 
the culture to select OVA transfected cells. 
2.2.4.4!Packaging!cell!media!
Medium used comprised IMDM (Iscove’s Modified Dulbecco’s Medium - Lonza) 
with 10% heat inactivated foetal bovine serum (Biowest), 100Units/mL 
penicillin, 100µg/mL streptomycin (Invitrogen) and 2mM L- glutamine (Sigma-
Aldrich).  
 !
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2.2.5!Cytokines!
Interleukin-2 (IL2) (Chiron) was reconstituted in PBS and aliquots stored at -
20˚C. IL-7 (R&D) was reconstituted in PBS + 2% Fetal calf serum at 1ng/µl and 
aliquots stored at -20˚C. IL-15 (Peprotech) was reconstituted in PBS + 2% 
Fetal calf serum at 10ng/µl and aliquots stored at -20˚C. Concanavalin A 
(ConA) (Sigma-Aldrich) was reconstituted at 2µg/µl. Aliquots were stored at -
20˚C and diluted 1:1000 in culture media for usage. 
2.2.6!Mycophenolic!acid!
Mycophenolic acid (Sigma-Aldrich) was reconstituted in Methanol at 50mg/ml 
(156mM) and stored at -20˚C.  
2.2.7!Peptides!
All peptides were obtained from Proimmune, UK. Ovalbumin peptide 
(SIINFEKL) is presented in the context of H2-Kb. MDM2 peptide was used as a 
control. Peptides were reconstituted in phosphate buffered saline (PBS) to a 
stock concentration of 2mM and stored at -20°C. 
 !
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2.3!Retroviral!transduction!!
2.3.1!Transfection!and!retroviral!particle!production!!
Cells were seeded on tissue culture-treated 10cm dishes at 1.5 x 106 in 8mL of 
culture medium. After 24 hours the medium was replaced with 5ml culture 
medium and the Phoenix Eco cells transfected using the lipid-based Fugene-
HD transfection reagent (Roche) in serum-free Opti-MEM medium with 2.6µg 
relevant plasmid DNA and 1.5µg pCl Eco DNA. After a further 24 hours the 
medium was replaced with 5.5ml T-cell medium. 24 hours later this retroviral 
particle-containing medium was collected and centrifuged at 1500rpm for 5 
minutes to remove cellular debris. The retroviral supernatant was then either 
used directly for transduction of activated murine splenocytes or stored at -
80˚C for later use.  
2.3.2!Magnetic!bead!selection!and!activation!of!CD8+!T!cells!!
CD8+ T cells were purified from the spleens of C57Bl/6 mice, using anti-CD8α 
(Ly-2, Miltenyi) MACS beads and LS magnetic columns (Miltenyi). Purification 
was carried out by positive selection according to manufacturer’s instructions. 
Briefly, up to 2 x 108 splenocytes were washed in MACS buffer (2% Bovine 
Serum Albumin (BSA), 2mM EDTA in PBS) and resuspended in 90µL MACS 
buffer and 10µL anti-CD8α MACS beads per 107 cells. The suspension was 
incubated for 20 minutes at 4°C. Cells were washed with MACS buffer, 
resuspended in minimum of 500µL for up to 1x108 cells and applied to a 
prepared LS column in a MACS generated magnetic field. The column was 
washed with 3 x 3ml of MACS buffer before being removed from the MACS 
magnet. The CD8+ T cells were then eluted from the column with 5ml of MACS 
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buffer. Purity was checked by FACS analysis and was consistently greater than 
90% for CD8+ T cells (data not shown).  
The eluted cells were counted and resuspended at 1.5 x 106/ml in T cell media 
containing 1ng/ml IL-7 and 2µg/mL Concanavalin A (ConA). The cells were 
incubated for 24-26 hours prior to retroviral transduction 
2.3.3!Retronectin!
Retronectin (Takara Bio, Japan) was made up as per manufacturers 
instructions and stored at -20˚C. Retronectin was re-used up to 10 times. 
2.3.4!Transduction!of!CD8+!murine!splenocytes!
Non-tissue culture treated 24 well plates (Cellstar) were coated with 750µl 
retronectin/well and incubated at room temperature for 2-3 hours.  Retronectin 
was removed and plates were blocked for 30 minutes at room temperature with 
filter sterilized 2% BSA/PBS (2.5ml per well).   1 x 106 activated splenocytes 
were re-suspended in 750µl viral supernatant and added to one well of a 
retronectin-coated plate. For mock transduction, 1 x 106 activated splenocytes 
were re-suspended in 750µl conditioned T-cell media.  Cells were centrifuged 
at 2000g for 90 minutes at 4 ˚C with no brake and then incubated at 37°C, 5% 
CO2.  On the day following transduction (Day 1), the media in each well was 
replaced with 2ml fresh T-cell media with IL-2 100u/ml, IL-7 1ng/ml, and IL-15 
10ng/ml. On day 3 the cells were aspirated and counted, then resuspended in 
fresh media at 1 x 106/ml. Transduction efficiency was assessed by FACS 
analysis for GFP.  
!
!
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2.3.5!Maintenance!of!murine!cells!in!culture!
For experiments with long-term in vitro culture of primary murine CD8+ cells, 
media was refreshed on alternate days with IL-2, IL-7, and IL-15 unless 
otherwise specified. When mycophenolic acid was also present, a working 
stock solution was made and added at appropriate concentration to media prior 
to resuspension of cells. 
2.3.6!Retroviral!Transduction!of!BW!cells!
BW cells do not require activation prior to transduction. Following the protocol 
above, using retronectin, results in very high rates of stable transduction >80%. 
To test batches of frozen retroviral supernate and for enrichment experiments, 
5 x 105 BW cells/well were plated into a 96 well plate in 200µl retroviral 
supernate. Cells were centrifuged at 2000g for 90 minutes at 4 ˚C with no 
brake and the contents of each well were aspirated, added to 5ml cell line 
media in a T25 flask and transferred to an incubator. Transduction was 
assessed 3 days later. 
2.3.7!Preparation!of!Human!Peripheral!Blood!Mononuclear!Cells!(PBMC)!
Human PBMC were generated from cones of donor blood by the protocol 
detailed below and stored in our institutions Biobank. Blood was layered on top 
of Lymphoprep (Ficoll) in a 50ml falcon tube at a ratio of 1:2 to the blood 
sample volume. The falcon was then centrifuged at 1600 rpm for 20 min with 
no break. The interphase was careful aspirated with a Pasteur pipette into 
another falcon tube and washed with PBS. The collected cells were typed for 
HLA-A2 by flow cytometry (only HLA-A2 positive cells used) and then 
resuspend cells in freezing medium. 
!
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2.3.8!Retroviral!transduction!of!human!PBMC!
Transduction of human PBMC closely follows the protocol used for murine 
CD8+ splenocytes. Defrosted cells are resuspended at 1 x 106/ml in T cell 
media and activated with OKT3 (CD3 Antibody) at 30ng/ml and IL-2 (Chiron) 
600 units/ml 48hours prior to transduction.  Retronectin coated plates are used 
with 750µl viral supernatant per well for 1 x 106 activated PBMC. For dual 
transduction, 750µl of each supernate are used. Unlike with murine cells, the 
plate is not centrifuged.  Approximately 3-4 days following transduction the 
media is replaced with 2ml fresh T-cell media with IL-2 100u/ml.  
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2.4!Peptide!restimulation!
2.4.1!ReHstimulation!of!transduced!murine!splenocytes!
Following transduction, murine CD8+ T cells were cultured in T-cell media with 
IL-2, IL-7 and IL-15 for 7 days. On day 6 RMAS were resuspended at 1 x 
106/ml in a 25-cm2 non-filter flask. The cap was loosened and flask transferred 
to an incubator for 5 hours. The cap was fastened and flask transferred to 26˚C 
water-bath overnight. RMAS cells were resuspended at 1 x 106/ml in fresh T 
cell media with 10µM peptide and incubated for 2 hours. Concurrently, a single 
cell suspension of C57Bl/6 splenocytes was made to produce feeder cells. The 
RMAS and feeder cells were irradiated for 14 and 7 minutes respectively. In a 
24 well plate, 5 x 105 CD8+ T cells, 2 x 106 irradiated feeder cells and 1 x 105 
RMAS cells/ well were suspended in 2ml T cell media + 20/ml Roche IL-2 +/- 
mycophenolic acid. Wells were assessed daily and split 1:2 with fresh media 
after 3 days. Analysis was performed 7 days after restimulation. 
2.4.2!ReHstimulation!of!transduced!human!PBMC!
7 days following transduction transduced human PBMC underwent stimulation 
with peptide loaded feeder cells in a 24 well plate. T2 cells were peptide loaded 
with EBV LMP2426-434 CLGGLLTMV peptide or CMV pp65495-503 NLVPMVATV 
peptide for 2 hours. 2 x 105 T2 cells per well were incubated with 100µM 
peptide and then irradiated for 14 minutes. Additionally, PBMC from the same 
donor were defrosted and irradiated for 7 minutes to act as feeder cells, with 2 
x 106 required for each well. The irradiated peptide-loaded T2 cells and PBMC 
feeders were cultured with 5 x 105 transduced cells in a total of 2ml T cell 
media with 2 units/ml of IL2 (Roche). The colour of media was monitored and 
media replenished as required. Restimulation was repeated every 7-10 days. 
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For measurement of cytokine production, 5 x 105 transduced PBMC were 
cultured with 5 x 105 peptide loaded T2 cells in 200µl media overnight in a 96 
well round bottomed plate. Supernate was aspirated and stored at -20˚C prior 
to measurement. 
2.5!Measurement!of!secreted!ILH2!and!IFNHγ!by!enzymeHlinked!
immunosorbent!assay!(ELISA)!
!The concentration of IL-2 and IFN-γ in culture supernatants was determined 
using OptEIA ELISA kits (BD – IL-2 555190, IFN-γ 555142) according to the 
manufacturer’s instructions summarised below. The reagents used were 
supplied in the kit unless otherwise specified and included:  
• Coating buffer – 0.1M sodium carbonate 
• Assay diluent – PBS with 10% Fetal Bovine Serum (FBS)  
• Wash buffer – PBS with 0.05% Tween-20 
• Working detector – biotin-linked detection antibody and streptavidin-
linked horseradish peroxidase 
• BD substrate solution (BD – 51-2607/6) 
• Stop solution (1M sulphuric acid – Fisher Scientific, Loughborough, UK).  
96 well Nunc-Immuno™ polystyrene Maxisorp ELISA flat bottom plates were 
coated with 100µL of appropriate capture antibody diluted 1:250 in coating 
buffer and incubated overnight at 4°C. The plates were aspirated and washed 
three times. Wells were block with 100µl Assay Diluent and incubated for 1 
hour at room temperature. The plates were aspirated and washed three times. 
100µl standard or sample (diluted in assay diluent) was added to each well and 
the plate incubated for 2 hours at room temperature. The plates were aspirated 
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and washed five times. 100µl prepared Working Detector was added to each 
well and incubated for 1 hour at room temperature. The plates were aspirated 
and washed seven times. 100µl TMB One-Step Substrate Reagent was added 
to each well and the plate incubated in the dark for 30 minutes at room 
temperature (no plate sealer). 50µl Stop Solution was added to each well and 
the plate read at 450 nm within 30 minutes, λ correction 570nm using a 
Multiskan EX photometer (Thermo Scientific, Basingstoke, UK) 
2.5.1!Standards!preparation!
Lyophilised recombinant IL-2 (BD – 554603) and lyophilised recombinant IFN-γ 
(BD – 554617) were dissolved in assay diluent and diluted to 1000pg/ml. 
Successive doubling dilutions standards were prepared in duplicate from 
1000pg/mL to 3.125pg/mL. 
For each assay a standard curve was derived by log-log regression analysis 
using Excel 2011 (Microsoft). 
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2.6!Flow!cytometry!!
Samples were acquired on an LSRII or Fortessa flow cytometer (BD 
Biosciences, USA) and analysed using FlowJo software (Tree Star, Oregon). 
All buffers were kept at 4°C.  
2.6.1!Cell!surface!staining!!
0.25-0.5x106 cells/well 96 well plate were washed with FACS buffer (2% FBS in 
PBS) and resuspended in 50µL of FACS buffer with appropriate amount of 
fluorochrome-conjugated antibody, determined by prior titration. Suspensions 
were incubated in the dark for 15-20 minutes at 4°C, washed in 150µL then 
200µL of FACS buffer and resuspended in 200µL of FACS buffer. Multimer 
staining was performed in 50µl FACS buffer at room temperature, prior to 
washes and further surface staining. 
2.6.2!Fluorescent!labelled!antibodies!!
Table 2.1 contains a list of all the fluorescent-labelled antibodies used in the 
experiments detailed within this work. In addition, in most experiments, cells 
were positive for GFP and fluorescence from this was detected in FL-1. 
 !
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Table 2.1 Fluorescent-labelled antibodies  
Antigen Fluorochrome Clone Supplier Catalog'No 
B220 PerCP"Cy5.5 RA3"6B2 eBioscience 45"0452"82 
B220 BIOTIN RA3"6B2 eBioscience 13"0452"85 
CD19 FITC ID3 BD 553785 
CD335 PE"Cy7 29A1.4 eBioscience 25"3351"80 
CD4 PerCP RM4"5 BD 553052 
CD44 PE IM7 Pharmigen 553134 
CD45.1 APC"eFluor'780 A20 eBioscience 47"0453"82 
CD45.2 PerCP"Cy5.5 104 BD 552950 
CD62L APC MEL"14 BD 553152 
CD8a%(Ly"2) APC 53"6.7 BD 553035 
CD8a%(Ly"2) PE 53"6.7 eBioscience 12"0081"83 
CD8a%(Ly"2) V450 53"6.7 BD 560469 
FC#BLOCK  
93 eBioscience 14"0161"85 
IFN"GAMMA APC !4S.B3 BD 554413 
NK1.1 PE PK136 eBioscience 12"5941"81 
NK1.1 PE"Cy7 PK136 eBioscience 47"5941"80 
NK1.1 BIOTIN PK136 BD 553163 
STREPTAVIDIN APC  
BD 554067 
TCR–β"constant APC H57"597 eBioscience 17"5961"81 
THY"1.1#(CD90.1) PE"Cy7 HIS51 eBioscience 25"0900"82 
THY"1.2$(CD90.2) PE"Cy7 53"2.1 eBioscience 25"0902"81 
VA2 PE B20.1 BD 553289 
Vα2 BIOTIN B20.1 BD 553287 
Vβ5.1/5.2 FITC MR9"4 BD 553189 
Vβ5.1/5.2 PE MR9"4 BD 553190 
Human&CD4 APC"Cy7 RPA"T4 BD 557871 
Human&CD8 PE"Cy7 RPA"T8 BD 557746 
LMP2426"434#(CLGGLLTMV)! 
HLA$A*02:01$pentamer 
PE  ProImmune F042"2A 
  !
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2.6.3!Detection!of!Apoptosis!–!Annexin!V!staining!
Apoptosis was detected with an Annexin V APC staining kit (BD). Briefly, 1.5-3 
x 105 cells were surface stained as above and then washed twice in cold PBS. 
Resuspended in 50µL of Annexin V Binding buffer with 2µL Propidium iodide 
(PI) and 1.25µL Annexin V APC. Suspensions were incubated at room 
temperature, protected from light for 20 minutes. Each sample was made up to 
200 µL with Annexin V Binding buffer and analysed by flow cytometry within 1 
hour. 
2.6.4!Analysis!of!Cell!Cycling!
Cells were replated at 5 x 105/well 96 well plate in media containing 10µM 
Bromodeoxyuridine (BrdU; BD). Following 30-60 minutes incubation at 37˚C, 
5% CO2 cells were washed with FACS buffer and surface stained as above. 
Staining for BrdU and 7-Aminoactinomycin D (7-AAD) was carried out using a 
BrdU-APC kit (BD Pharmingen). Cells were fixed and permeabilised, treated 
with DNAse and then stained for BrdU incorporation and with 7-AAD as per the 
kit instructions. 
 !
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2.7!In!vivo!Experiments!
Females of 8-10 weeks of age were used as splenocyte donors for in vitro and 
in vivo experiments; females of 10 weeks or older were used as recipients. All 
procedures were carried out in accordance with United Kingdom Home Office 
regulations. To assess cell turnover, BrdU was added to the drinking water to a 
final concentration of 0.8M and replenished every 3-4 days. Irradiated mice 
received 21 days of Baytril starting 7 days prior to irradiation. Following 
irradiation mice were fed millet and wet feed in order to maintain weight. 
2.7.1!Mycophenolate!mofetil!
Mycophenolate mofetil (Cellcept) was reconstituted in either 5% dextrose 
(Baxter) or a resuspension vehicle (CMC) containing 0.9% sodium chloride, 
0.5% Tween 80, 0.5% benzyl alcohol and 0.8% carboxymethylcellulose. In 5% 
dextrose MMF was administered within 60 minutes of reconstitution, aliquots of 
MMF in CMC where stored at 4˚C for up to 5 days prior to administration. MMF 
was administered daily via intraperitoneal (i.p.) injection in 200μl diluent for 7 to 
21 days. Dose was adjusted according to body weight.  
2.7.2!Peptide!
Peptide was administered in vivo via subcutaneous (s.c.) injection at the base 
of the tail. Prior to injection an emulsion of peptide and incomplete Freund’s 
adjuvant (IFA; Sigma) was made at a concentration of 200µM and 100µl was 
injected. 
 !
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2.7.3!Procedures!
In cell transfer experiments, cells were injected intravenously (i.v.) via the tail 
vein suspended in 200μl phosphate buffered saline.  
EG-7 cells were suspended in 100µl of matrigel (BD) and remained on ice until 
immediately prior to s.c. injection. Measurement of tumour was with callipers to 
record perpendicular measurements of diameter. 
Blood was taken by capillary action following of the tail tip. Following collection 
the tail tip was cauterised with silver nitrate.  
Mice were checked 5 minutes after all procedures. 
2.8!Statistical!analysis!
GraphPad Prism version 6.0 for Mac OsX (GraphPad Software, San Diego, 
USA) was used for statistical analyses. P values of 0.05 or less were 
considered statistically significant. Comparisons between groups were carried 
out using two-tailed, paired Student’s t-test for in vitro experiments and Mann-
Whitney test for in vivo experiments.  
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Chapter( 3:( In" vitro! functional) analysis) of)
IMPDH2R!transduced*cells!
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3.1!Introduction!
 
By culturing a murine neuroblastoma cell line in increasing concentrations of 
mycophenolic acid (MPA), Hodges et al. developed a cell line resistant to MPA 
(Hodges et al., 1989). This resistance was shown to be due to cells exhibiting 
both gene amplification of inosine-5’-monophosphate dehydrogenase (IMPDH), 
resulting in a 200-500 fold increase in protein levels as well as mutations in 
isoform 2 of the IMPDH gene (IMPDH2). Of the four mutations identified, one 
was present in the parental cell line and another did not result in an amino acid 
change (Lightfoot and Snyder, 1994). The remaining 2 mutations, T333I and 
S351Y (IMPDH2R), are found in the nicotinamide adenine dinucleotide (NAD) 
binding pocket of IMPDH2, which is also the site of MPA binding.  Purification 
of the mutant enzyme showed an unchanged Michaelis constant for inosine 
monophosphate (IMP) but a 4-fold increase in the Michaelis constant for NAD. 
The dissociation constant (Ki) of IMPDH2R for MPA was shown to be 2400 fold 
higher than wild-type IMPDH2 (IMPDH2WT).  
Intracellular nucleotide levels govern the ability of a cell to proliferate due to 
DNA replication. Adequate GTP levels are also important to enable normal 
cellular signalling through G-coupled proteins. When GTP is depleted, a cell 
will initially undergo cell cycle arrest and with increased depletion undergo 
apoptosis. As previously described, MPA inhibits the de novo synthesis of 
guanosine nucleotides. MPA has been shown to block cell cycle progression 
from G1 to S phase and with increasing concentrations of drug causes cell 
death by apoptosis (Cohn et al., 1999). 
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MPA has been shown to act via inhibition of IMPDH (Franklin and Cook, 1969), 
which is required for de novo synthesis of GTP. A second pathway (salvage 
pathway), where HGPRTase converts guanine into guanosine monophosphate 
that can subsequently be metabolised to GTP and dGTP, is present in almost 
all cell types. The salvage pathway helps to protect most cell types from the 
effects of MPA. Lymphocytes express little HGRPTase, relying almost entirely 
on IMPDH for synthesis of guanosine nucleotides and therefore MPA is 
lymphocyte specific. In addition, when activated and requiring increased levels 
of GTP there is an isoform shift from primarily IMPDH1 to IMPDH2 (Nagai et 
al., 1992). IMPDH2 is 4 times more sensitive to MPA than IMPDH1 (Carr et al., 
1993) and MPA has most effect against proliferating cells. 
!
3.2!Aims!
• To generate plasmids encoding the wild-type and enzymatically 
hypofunctional (Futer et al., 2002) IMPDH2 genes 
• To demonstrate the selective advantage conferred to cells by IMPDH2R 
transduction in the presence of MPA 
• To investigate the protective effect of IMPDH2R against MPA induced 
apoptosis and cell cycle arrest 
• To test the ability of IMPDH2R cells cultured in MPA to produce 
cytokines in response to antigenic stimulation 
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3.3#Results!
In!vitro!investigation!of!IMPDH2R!phenotype:!Murine!cell!line!
To investigate the selective advantage conferred by IMPDH2R, I used the 
vectors generated in figures 2.1 (pp. 75) and 2.2 (pp. 78) to produce retroviral 
supernate for transduction. I first transduced a CD8+ variant of the murine 
BW5147 thymoma cell line with IMPDH2CS, IMPDH2WT or IMPDH2R. 
Additionally, an SFG vector containing eGFP alone was also used.! Initial 
transduction efficiency ranged from 21-58%. Transduced BW cells were FACS 
sorted to obtain pure populations of GFP expressing cells (purity >95%), which 
stably expressed the transduced construct during prolonged culture. These 
were used in the experiments outlined in sections 3.3.1, 3.3.3 and 3.3.4. 
3.3.1! IMPDH2R! expression! increases! the! IC50! for! MPA! compared! to!
IMPDH2CS,!while!IMPDH2WT!confers!an!intermediate!phenotype.!
Sorted transduced BW cells were cultured in concentrations of MPA from 0-
1mM. Cell counts were performed at 48 hours and normalised to the count 
without drug. Dose response curves were modelled and are shown with IC50 
calculated for each IMPDH2 construct (Figure 3.1). Cells transduced with 
IMPDH2CS showed suppression of cell growth at similar doses of MPA as 
untransduced BW cells seen in pilot experiments (data not shown) with a 
calculated IC50 of 252nM. IMPDH2R transduced cells continued to expand, 
compared to baseline, up to MPA concentrations several log higher than 
IMPDH2CS with a significantly increased IC50 calculated at 5499nM (Extra sum-
of-squares F test; F value CS v R = 351.4 p<0.0001). IMPDH2R transduced 
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cells also maintained similar cell expansion with or without MPA to a MPA 
concentration >1log higher than IMPDH2CS transduced cells. IMPDH2WT 
demonstrated an intermediate phenotype with a calculated IC50 767nM, 
significantly greater than IMPDH2CS and less than IMPDH2R (F values CS v 
WT = 103.7, WT v R = 332.4; both p<0.0001). 
This demonstrates an advantage, in terms of cell expansion, for IMPDH2R 
transduced BW cells cultured in MPA. 
 !
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Figure 3.1 Transduced BW dose response  
BW cells were transduced with IMPDH2CS, IMPDH2WT or IMPDH2R and FACS 
sorted for GFP. 1 x 106 cells were suspended in 5ml media with MPA at 
concentrations 0, 45, 150, 450, 1500, 4500, 15000, 45000, 150000 and 
450000nM. Cell counts were taken at 48 hours and normalised to the cell count 
in the absence of drug. Data from 3 independent experiments was combined 
and plotted as cell count at each concentration as a percentage of count in the 
absence of drug, with mean and standard deviation plotted. Dose response 
curves for the 3 constructs were modelled in GraphPad Prism. The modelled 
IC50 for each construct is shown. 
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3.3.2! IMPDH2R! expression! confers! a! selective! advantage! during! MPA!
exposure!compared!to!unHtransduced!cells!
As previously shown (Sangiolo et al., 2007, Yam et al., 2006), I hypothesised 
that IMPDH2R would confer a selective advantage to transduced cells in 
comparison to untransduced cells when cultured in MPA. Unsorted transduced 
BW cells were cultured in the presence or absence of two concentrations of 
MPA (450nM and 4500nM). FACS was performed at baseline and at 48 hours 
to ascertain percentage of GFP positive cells. Example plots indicative of 4 
independent experiments are shown (Figure 3.2A). Cell counts were performed 
and the fold change in transduced cells calculated and normalised to the fold 
change without drug (figure 3.2B).  
Cells transduced with GFP alone or IMPDH2CS exhibited a significant decrease 
in transduced cells at both concentrations of MPA (paired t-test GFP 0 v 450 
p=0.0334; G0 v 4500 p=0.0014; CS 0 v 450 p=0.0148; CS 0 v 4500 p=0.001; 
Means GFP 0 MPA=2.216, 450nM MPA=1.171, 4500nM MPA=0.01223, 
IMPDH2CS 0 MPA=2.285, 450nM MPA=1.157, 4500nM MPA=0.006385). 
Changes in transduced cell number were not different between the two 
constructs at either dose. IMPDH2WT transduced cell numbers were non-
significantly decreased at both doses (WT 0 v 450 p=0.1517; v 4500 p=0.0894; 
Means 0 MPA=2.265, 450nM MPA=2.172, 4500nm MPA=0.508).  
Only IMPDH2R resulted in a fold increase in transduced cells significant at the 
lower but not higher dose of MPA used (paired t-test R 0 v 450 p=0.0465; R 0v 
4500 p=0.0905; Means 0 MPA=2.369, 450nM MPA=3.722, 4500nM 
MPA=3.684). At both doses of MPA, IMPDH2R transduced cells were selected 
to significantly greater extent than GFP alone or IMPDH2CS transduced cells 
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(paired t test R450 v GFP450 p=0.0065; R4500 v GFP4500 p=0.0033; R450 v 
CS450 p=0.0051; R4500 vs CS4500 p=0.0032). Compared to IMPDH2WT 
transduced cells there was a significant increase at 450nM but significance was 
lost at 4500nM (R450 v WT450 p=0.0465; R4500 v WT4500 p=0.0905). 
These data demonstrate that IMPDH2R confers transduced cells with a 
selective advantage over untransduced cells. The number of transduced cells 
increases to a greater extent with MPA exposure than without. This is due to 
death of untransduced cells reducing competition for transduced cells. 
 !
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Figure 3.2 BW cells transduced with IMPDH2R are selected when cultured 
in MPA 
1.5 x 106 transduced BW cells were cultured in 10ml media containing 0, 450 or 
4500nM MPA. After 44 hours cell counts were performed and FACS analysis 
for GFP performed. (A) FACS plots shown were gated on viable cells and are 
representative of 4 independent experiments. (B) Data are summarised for 
each group as fold change in the total number of transduced cells normalised 
to observed change with no drug. 
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3.3.3! IMPDH2R! transduced! BW! cells! overcome!MPAHinduced! cell! cycle!
blockade!
I explored potential mechanisms by which IMPDH2R could confer a selective 
advantage. Because MPA is known to induce cell cycle arrest, I investigated 
the ability of transduced cells to progress through the cell cycle by staining for 
incorporated bromodeoxyuridine (BrdU) and deoxynucleic acid (DNA). Sorted 
transduced cells were cultured in a range of MPA concentrations for 20 hours. 
An equal number of cells from each condition were then cultured with BrdU (+/- 
MPA as appropriate) for 20 minutes and then stained for BrdU and 7-
Aminoactinomycin D (7-AAD). Example plots (Figure 3.3A) and summary data 
(Figure 3.3B) are shown. 
Cells that are dead or undergoing apoptosis (>G1) are located in the gate to the 
extreme left of each plot. Cells in G0/G1 have not undergone DNA replication 
during BrdU exposure and are BrdU negative with an intermediate 7-AAD 
fluorescence corresponding to a diploid cell. During S phase (top gate), BrdU is 
incorporated and as DNA is duplicated the 7-AAD signal increases up to twice 
the baseline level. Cells in G2 and M phase have high 7-AAD because they 
have double the number of chromosomes prior to cell division but are BrdU 
negative because DNA replication has occurred prior to BrdU exposure.  
The example plots (figure 3.3A) show that in the absence of MPA, 
approximately 50% of cells are in S phase and <5% of cells in <G1 during the 
20 minutes of BrdU exposure. When MPA 4500nM is added, IMPDH2CS 
transduced cells show a reduction in cells in S phase with an associated 
increase in cells in G1 phase or that were dead. IMPDH2R transduced cells 
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maintain similar percentages of cells within each stage of the cell cycle while 
IMPDH2WT has an intermediate appearance.   
Data summarising the effects on cell cycling for each construct at several MPA 
concentrations is shown separated into plots for <G1, G0/G1, S and G2+M 
phases (figure 3.3B).  A significant increase in the percentage of cells in <G1 
phase occurred for both IMPDH2CS transduced cells (paired t-test CS 0 v 1500 
p=0.0382) and IMPDH2WT transduced cells (paired t-test WT 0 v 4500 
p=0.287). The percentage of cells in <G1 phase was greater for IMPDH2CS than 
both IMPDH2R and IMPDH2WT except at the highest investigated dose (paired 
t-test CS450 v WT450 p=0.0492, v R450 p=0.0434; CS1500 v WT1500 
p=0.0237, v R1500 p=0.005; CS4500 v WT4500 p=0.102, v R4500 p=0.0354). 
IMPDH2WT showed significantly increase percentages of cells in <G1 compared 
to IMPDH2R (paired t-test WT v R 450nM p=0.0172, 1500nM p=0.0317, 
4500nM p=0.0365). 
G0/G1 percentages did not significantly increase for IMPDH2CS and IMPDH2R 
but there was a significant increase at the highest dose of MPA for IMPDH2WT 
transduced cells (paired t-test WT0 v 4500 p=0.0165). This indicates that cells 
are accumulating in G0/G1 phase. 
At the highest concentration of MPA investigated, there is clear maintenance of 
the percentage of cells in S phase for IMPDH2R transduced cells compared to 
those cultured without MPA i.e. preservation of cells entering the cell cycle 
(Paired t-test R0 v R4500 p=0.706). IMPDH2CS or IMPDH2WT transduced cells 
show a marked reduction in the percentage of cells in S phase, occurring at a 
lower dose of MPA for IMPDH2CS (paired t-test CS0 v 1500 p=0.0482; CS0 v 
4500 p=0.0351; WT 0v v 1500 p=0.3846, WT 0 v 4500 p=0.0423).  
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Compared to IMPDH2CS, a higher percentage of IMPDH2R transduced cells are 
in S phase at both 1500 and 4500nM MPA (paired t-test CS1500 v R1500 
p=0.0479; CS4500 v R4500 p=0.0248). More IMPDH2WT transduced cells are 
in S phase at the lower but not higher concentration of MPA (paired t-test 
CS1500 v WT1500 p=0.0412, CS4500 v WT4500 p=0.0999). There is a non-
significant trend to reduction in IMPDH2WT compared with IMPDH2R (paired t-
test WT1500 v R 1500 p=0.3877, WT4500 v R4500 p=0.0709). G2 + M phase 
percentages remained similar with all doses of MPA and all three IMPDH2 
constructs.  
These data show that IMPDH2R protects BW cells from MPA induced cell cycle 
arrest. IMPDH2WT confers protection from MPA at low concentrations of MPA 
but the effect is lost as MPA concentration increases. 
 !
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Figure 3.3 IMPDH2R transduced BW cells overcome MPA-induced cell 
cycle blockade 
5 x 106 transduced sorted BW cells were cultured in 10ml media with 0, 450, 
1500, 4500nM MPA for 20 hours. 1x106 cells from each condition were 
transferred to a 96 well plate and cultured in media containing BrdU and the 
appropriate concentration of MPA for 20minutes. Cells were then stained for 
BrdU and 7-AAD using a BrdU staining kit (BD).  
(A) Example plots indicative of 3 independent experiments are shown. The 
plots are otherwise ungated and show the percentages of cells in G0/G1 
(bottom right), S (top), G2+M (lower right) and <G1 phases (bottom left).  
(B) Data are summarised to show the percentage of cells in each phase of the 
cell cycle at each dose of MPA. 
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Figure 3.3 
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3.3.4!IMPDH2R!transduced!BW!cells!are!protected!against!MPAHinduced!
apoptosis!
Following cell-cycle arrest, further reduction in IMPDH activity by MPA induces 
apoptosis. I investigated whether IMPDH2R protects against MPA-induced 
apoptosis, by culturing transduced BW cells with or without MPA and staining 
for Annexin V and propidium iodide (PI) at both baseline and after 20 hours. 
Apoptosis is accompanied by a loss of membrane phospholipid asymmetry, 
resulting in the exposure of phosphatidylserine (PS) on the cell surface. 
Annexin V covalently binds to exposed PS and if conjugated to a fluorescent 
label, can be detected by FACS(Koopman et al., 1994). Of note, cells 
undergoing apoptosis decrease in size and therefore plots are not pre-gated 
prior to analysis  
 The percentage of apoptotic cells (figure 3.4A) and all apoptotic and dead cells 
(figure 3.4B) are shown. IMPDH2CS transduced cells exhibited a significant 
increase in apoptosis when exposed to MPA (paired t-test p=0.0037; Mean No 
MPA=8.9%, MPA=26.6%) that accounted for most of the change in total 
apoptotic and dead cells (paired t-test p=0.0027; Mean No MPA=16.4%, 
MPA=39.9%). IMPDH2WT transduced cells cultured with MPA also underwent 
increased apoptosis (paired t-test p=0.0343; Mean No MPA=14.5%, 
MPA=21.0%), which again accounted for the majority of the total annexin V 
positive cells (paired t test p=0.0102; Mean No MPA=23.86%, MPA=33.87%). 
MPA did not increase the apoptotic or total annexin V positive percentage of 
IMPDH2R transduced cells (paired t-test apoptosis p=0.815; Mean No 
MPA=13.6%, No MPA=13.4%; Total annexin V positive p=0.3273; Mean No 
MPA=23.94%, MPA=22.52%).  
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There was a significant increase in apoptosis for IMPDH2CS cells compared to 
IMPDH2R cells (paired t-test p= 0.015). Apoptotic percentage was not different 
for IMPDH2WT cells compared to IMPDH2CS or IMPDH2R transduced cells 
exposed to MPA (paired t-test CS v WT p=0.604; WT v R p=0.434). 
 !
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Figure 3.4 IMPDH2R transduction protects BW cells from MPA-induced 
apoptosis  
5 x 106 transduced sorted BW cells were cultured in 10ml media with or without 
MPA (4500nM) for 20 hours. 2.5x105 cells were stained with Annexin V and PI 
as per the Annexin V staining kit (BD). The percentage of apoptotic cells 
(Annexin V positive PI negative cells) is plotted for each of 3 independent 
experiments (A). All annexin V positive cells are also plotted (B). 
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In! vitro! investigation! of! IMPDH2R! phenotype:! Primary!murine!
cells!
3.3.5!Antigen!dependent!selection!
To investigate the effects of IMPDH2R in primary cells, I used a model antigen 
system where all cells express the same T cell receptor (TCR). CD8 T cells 
from OT1 (Ovalbumin (OVA) TCR 1) TCR transgenic Rag-/- mice were 
transduced with retrovirus and rested for one week. The OT1 TCR is specific 
for the chicken OVA257-264 peptide SIINFEKL presented in the murine H2-Kb. To 
provide an antigenic stimulus, I used a cell line (RMAS) that expresses class I 
molecules devoid of peptide at the cell surface, when pre-cultured at low 
temperature (22˚C), and can be loaded with exogenous peptide(Ljunggren et 
al., 1990).  RMAS were loaded with either relevant (SIINFEKL) or irrelevant 
(MDM2, a ubiquitous cell surface protein) peptide and irradiated. Irradiated 
splenocytes, acting as feeder cells, were cultured with transduced OT1 CD8 
and the irradiated RMAS in media containing interleukin 2 in the presence or 
absence of MPA (450 or 1500nM). Media was checked daily and wells were 
split as necessary, with media refreshed on all wells at the same time. 
Selection was investigated by FACS analysis (GFP expression) at both 
baseline and 7 days after stimulation. Three independent experiments were 
performed and example plots and summary data shown for relevant peptide 
(Figure 3.5) and irrelevant peptide (Figure 3.6).  
Of note, cells cultured with relevant peptide loaded RMAS cells required more 
media changes than those with irrelevant peptide and when cell counts were 
performed had a much greater number of trypan blue stained dead cells. When 
cultured in MPA, very few cells transduced with IMPDH2CS or IMPDH2WT 
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remain alive at day 7, which is reflected in the example plots shown (Figure 
3.5A). This is in contrast to IMPDH2R transduced cells, which persist and 
exhibit strong selection for transduced cells.  
Comparing the fold change in transduced cells (figure 3.5B), in the absence of 
MPA there is similar expansion of transduced cells with all 3 vectors. 
IMPDH2CS transduced cells are significantly reduced In the presence of MPA 
(paired t-test p=0.0191; Mean - No MPA=2.27, MPA=0.35). IMPDH2WT 
transduced cells exhibit a non-significant reduction in number in MPA 
compared to no drug and remain static over baseline (paired t-test p=0.074; 
Mean - No MPA=2.68, MPA=1.00). By contrast, IMPDH2R transduced cells are 
significantly increased in the presence of MPA over both baseline and cells 
cultured in the absence of drug (paired t-test p=0.011; Mean - No MPA=2.326, 
MPA=4.852).  
IMPDH2CS cells are significantly reduced in comparison to both IMPDH2WT and 
IMPDH2R transduced cells when cultured with MPA (paired t-test p= 0.047 and 
0.006 respectively). IMPHD2WT numbers are significantly reduced compared to 
the expansion seen with IMPDH2R (paired t-test p= 0.016). 
When cultured with irrelevant peptide loaded RMAS cells (figure 3.6), a similar 
trend in selection is seen. MPA was added at both the concentration used with 
relevant peptide and a higher concentration (1500nM). In contrast to 
stimulation with relevant peptide, IMPDH2CS transduced cells expand in 450nM 
of MPA and are only significantly reduced at the higher concentration (paired t-
test 0 v 450 p=0.1672, 0 v 1500 p=0.0498; Mean No MPA=3.02, MPA 
450nM=2.11, 1500nM=0.516). IMPDH2WT transduced cells increase over 
baseline even at the higher concentration of MPA but a non-significant trend to 
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reduced expansion with MPA is seen (paired t test 0 v 1500 p=0.0958; Mean 
No MPA=3.886, 1500nM MPA=1.231). IMPDH2R transduced cells exhibit non-
significantly increased expansion at both doses of MPA (paired t-test 0 v 450 
p=0.0552, 0 v 1500 p=0.0514; Mean No MPA=3.656, 450nM MPA=6.3, 
1500nM MPA=5.723). None of the differences between transduced groups 
achieved significance at either dose of MPA used (paired t-test MPA 450nM 
CS v WT p=0.0675, CS v R p=0.0612, WT v R 0.0618; MPA 1500nM CS v WT 
p=0.0714, CS v R p=0.0553, WT v R 0.0655).  
Comparing stimulation with relevant versus irrelevant antigen, there were no 
significant differences. At the 450nM concentration of MPA, there was a non-
significant trend to greater fold change of IMPDH2CS transduced cells with 
irrelevant antigen compared to relevant (paired t-test p=0.0673; Mean Relevant 
antigen=2.11, Irrelevant antigen=0.3549). 
To investigate whether cells with more copies of the transduced gene are 
preferentially selected, I analysed the median fluorescence intensity (MFI) for 
GFP (Figures 3.5C and 3.6B). When stimulated with cognate peptide, 
IMPDH2R transduced cells exhibit a non-significant increase in GFP MFI 
following MPA exposure than cells transduced with IMPDH2CS or IMPDH2WT 
(paired t-test CS v R p=0.0675; WT v R p=0.0633; CS v WT p=0.2626; Mean 
CS=320, WT=858, R=21567). A non-significant trend was also seen at the 
higher concentration of MPA when irrelevant peptide was used (paired t-test 
CS v R p=0.1718; WT v R p=0.1751; CS v WT p=0.0768; Mean CS=329, 
WT=437, R= 3835). There was no significant difference between relevant and 
irrelevant antigen for any of the IMPDH2 groups. 
 !
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Figure 3.5 IMPDH2R transduced OT1 CD8 are selected when stimulated by 
cognate peptide in the presence of MPA 
CD8 T cells were MACS sorted from OT1 TCR Tg Rag-/- spleens and 
stimulated overnight with Con-A and IL7 and subsequently transduced with 
IMPDH2CS, IMPDH2WT or IMPDH2R. A group was mock transduced to 
determine GFP gating on subsequent FACS analysis. The cells were rested for 
6 days prior to restimulation with peptide-loaded RMAS cells. Each group was 
cultured with relevant peptide with or without MPA for 7 days, Cells were 
counted and FACS analysis for CD8 and GFP performed.  
(A) Example plots indicative of 3 independent experiments are shown. The 
plots are pre-gated on viable lymphocytes.  
(B) Results are summarised from 3 independent experiments and given as a 
fold change in the number of transduced cells.  
(C) The median fluorescence intensity of GFP is plotted for each group in the 
presence or absence of MPA. Mean and standard deviation are given. 
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Figure 3.5 
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Figure 3.6 IMPDH2R transduced OT1 CD8 are selected when exposed to 
non-cognate peptide in the presence of MPA 
CD8 T cells were MACS sorted from OT1 TCR Tg Rag-/- spleens and 
stimulated overnight with Con-A and IL7 and subsequently transduced with 
IMPDH2CS, IMPDH2WT or IMPDH2R. A group was mock transduced to 
determine GFP gating on subsequent FACS analysis. The cells were rested for 
6 days prior to restimulation with peptide-loaded RMAS cells. Each group was 
cultured with irrelevant peptide with or without MPA for 7 days, Cells were 
counted and FACS analysis for CD8 and GFP performed.  
(A) Example plots indicative of 3 independent experiments are shown. The 
plots are pre-gated on viable lymphocytes.  
(B) Results are summarised from 3 independent experiments and given as a 
fold change in the number of transduced cells.  
(C) The median fluorescence intensity of GFP is plotted for each group in the 
presence or absence of MPA. Mean and standard deviation are given. 
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Figure 3.6 
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3.3.6!IMPDH2R!transduced!cells!are!progressively!selected!under!antigen!
independent!conditions!
I hypothesised that selection would occur following antigenic stimulation of 
transduced cells exposed to MPA. Therapeutic IMPDH2R transduced cells will 
not always be stimulated by antigen. I therefore investigated whether IMPDH2R 
transduced cells are selected under conditions more analogous to homeostatic 
proliferation. I hypothesised that selection would occur when transduced 
murine cells were maintained in culture by common gamma chain cytokines. 
C57Bl6/J CD8 T cells were transduced and after 3 days cultured with IL-2, IL-7 
and IL-15 in the presence or absence of MPA. Cell counts and percentage of 
GFP positive cells were assessed over the next 10 days. The fold change in 
transduced cell number is summarised in figure 3.7. 
In the absence of MPA, the cell number changes are not significantly different 
at any time point for IMPDH2CS, IMPDH2WT or IMPDH2R transduced cells. 
There is an initial expansion (two-fold) in the number of transduced cells by day 
3 followed by contraction to approximately 75% of baseline at day 10 (figure 
3.7A). The reduction in transduced cell is a result of the GFP positive 
percentage reducing in the absence of MPA while the total number of cells 
under these conditions remains or static or reduces slightly. 
At the lower concentration of MPA used (450nM), the same concentration used 
in experiments outlined for cognate antigen in section 3.3.5, IMPDH2R but not 
IMPDH2CS or IMPDH2WT transduced cells undergo significant expansion 
(paired t-test compared to Baseline IMPDH2CS p=0.1739, IMPDH2WT p=0.1329, 
IMPDH2R p=0.0285; Mean IMPDH2CS=1.255, IMPDH2WT=1.536, 
IMPDH2R=2.140). Transduced cell numbers reduce in all groups, with 
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IMPDH2R transduced cells remaining at higher levels than IMPDH2CS 
transduced cells with IMPDH2WT transduced cells in between. At day 10, 
IMPDH2CS transduced cells are significantly reduced in MPA with greater 
reduction with higher MPA concentration (paired t-test 0 v 450nM MPA 
p=0.0129, 0 v 1500nM MPA p=0.0103, 450 v 1500nM MPA 0.0236; Mean No 
MPA 0.75, 450nM MPA 0.44, 1500nM MPA 0.12). IMPDH2WT transduced cells 
at the same time point are not significantly reduced at the lower dose of MPA 
compared to no drug but are reduced by the higher dose (paired t-test 0 v 
450nM MPA p=0.9843, 0 v 1500nM MPA p=0.0277, 450 v 1500nM MPA 
0.0286; Mean No MPA 0.69, 450nM MPA 0.69, 1500nM MPA 0.45). IMPDH2CS 
transduced cells are not significantly reduced compared to IMPDH2WT 
transduced cells (paired t-test p=0.0765) but IMPDH2R transduced cells are 
higher than both the other constructs (paired t-test IMPDH2R v IMPDH2CS 
p=0.0367, v IMPDH2WT p=0.045). 
At the higher concentration of MPA (1500nM), both IMPDH2WT and IMPDH2CS 
transduced cells are significantly reduced by day 3 (paired t-test compared to 
baseline, IMPDH2CS p=0.0074, IMPDH2WT p=0.0206). In contrast, IMPDH2R 
numbers increase steadily over the course of MPA exposure and are 
significantly increased over baseline by day 3 (paired t-test p=0.0226). At day 
10, IMPDH2CS transduced cells are significantly reduced compared to 
IMPDH2WT and IMPDH2R transduced cells (paired t-test IMPDH2CS v IMPDH2R 
p=0.0362, IMPDH2CS v IMPDH2WT p=0.0109) but IMPDH2R was not 
significantly increased compared to IMPDH2WT (paired t-test p=0.0544). 
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Figure 3.7 IMPDH2R transduced cells are progressively selected in 
antigen independent conditions in the presence of MPA. 
CD8 T cells were MACS sorted from C57Bl6/J splenocytes and stimulated with 
ConA and IL7. They were transduced with IMPDH2CS, IMPDH2WT or IMPDH2R 
and subsequently rested for 3 days. Cells were cultured in media containing IL-
2, IL-7 and IL-15 in the presence or absence of MPA. Media was refreshed 
every other day. Transduction was assessed by FACS for GFP and monitored 
over 10 days of culture. Data from 3 independent experiments summarising the 
fold change in transduced cell number are shown for cells culture in the 
absence of MPA (A), 450nM MPA (B) and 1500nM MPA (C). Mean and 
standard deviation are shown. 
Red = IMPDH2R; Green = IMPDH2WT; Blue = IMPDH2CS 
  !
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Figure 3.7 
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In! vitro! investigation! of! IMPDH2R! phenotype:! Human!
Peripheral!Blood!Mononuclear!Cells!
3.3.7!Selection!and!expansion!of!TCR!redirected!PBMC!
Having demonstrated both antigen dependent and independent selection of 
IMPDH2R transduced murine CD8 T cells, I investigated whether IMPDH2R 
would provide a selective advantage to cells whose specificity had been 
redirected by transduction with a specific TCR. I used human peripheral blood 
mononuclear cells (PBMC) prepared from donor buffy coats and co-transduced 
LMP2 TCR (specific for the EBV peptide CLG) along with either IMPDH2CS, 
IMPDH2WT or IMPDH2R. After transduction cells were rested in culture for 7 
days and then underwent 3 stimulations with peptide loaded T2 cells at 7-10 
day intervals in the presence or absence of MPA. Selection of TCR and GFP 
was determined by FACS analysis. Example plots and summary data (Figure 
3.8) are shown. 
Dual transduced cells were only a minor population at baseline, accounting for 
approximately 5% of CD8 T cells. Repeated stimulation with peptide resulted in 
selection and expansion of TCR transduced cells in all groups. When cultured 
with MPA, cells transduced with IMPDH2CS and IMPDH2WT underwent high 
levels of cell death and insufficient cells were available in both groups to 
complete more than the first 1 or 2 stimulations. IMPDH2R was strongly 
selected when exposed to MPA with the majority of remaining cells GFP 
positive prior to the second stimulation. Overall the total number of dual LMP2 
TCR and IMPDH2R transduced cells was similar with or without MPA, however 
the purity was higher when cultured under the selective pressure of MPA. In 
second and subsequent stimulations, I cultured a group of cells without MPA 
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that had been MPA selected during the first stimulation. The IMPDH2R 
selection reduced slightly but was not significantly different (Figure 3.8B). 
 !
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Figure 3.8 Human PBMC dual transduced with IMPDH2R and LMP2 TCR 
are selected during restimulation with cognate peptide and MPA. 
Human donor peripheral blood mononuclear cells were prepared from buffy 
coats and stimulated with OKT3 and IL-7 prior to transduction with LMP2 TCR 
and either IMPDH2CS, IMPDH2WT or IMPDH2R. One week after transduction, 
FACS for GFP and pentamer for LMP2 TCR determined the baseline 
percentage of transduced cells. Cells were then stimulated with peptide-loaded 
T2, human PBMC and IL2 in the presence or absence of MPA. (A) Example 
plots gated for viable CD8 lymphocytes are shown at baseline and after 1 and 
3 rounds of stimulation for cells transduced with both LMP2 TCR and 
IMPDH2R. Summary data from 3 independent experiments are given with (B) 
the fold change in total dual transduced cell number and (C) the fold change in 
the percentage of TCR positive cells expressing GFP. 
  !
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Figure 3.8 !
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3.3.8!Retention!of!function!post!MPA!exposure!
To assess the ability of IMPDH2R cells cultured in MPA to function, cells were 
stimulated overnight with peptide loaded T2 cells +/- MPA as appropriate.  
Supernate was collected and tested by ELISA for IL-2 (figure 3.9A) and IFN-
gamma (figure 3.9B). Due to insufficient numbers of cells surviving to this time 
point, analysis could not be performed for IMPDH2CS or IMPDH2WT transduced 
cells exposed to MPA. For both IL-2 and IFN-gamma the level of production is 
similar for all groups tested. This implies that IMPDH2R treated cells maintain 
function despite MPA exposure. 
 !
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Figure 3.9 IMPDH2R transduced cells selected by exposure to MPA, 
produce Interleukin 2 and interferon gamma in response to cognate 
peptide at a similar level to cells cultured in the absence of drug. 
Following 3 rounds of stimulation, 5 x 105 dual transduced PBMC were cultured 
with 5 x 105 peptide loaded T2 cells overnight. Supernate was stored and levels 
of IL-2 and IFN gamma measure by ELISA as per kit instructions. Summary 
data from 3 independent experiments are shown for (A) IL2 and (B) IFN 
gamma. 
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3.4!Discussion!
Here I have demonstrated that a murine cell line can be successfully 
transduced with IMPDH2R and that IMPDH2R transduction confers a selective 
advantage to these cells in the presence of MPA. The BW cell line divides 
rapidly and therefore was ideal to demonstrate that this selective advantage 
occurs due to cells overcoming both cell cycle arrest and apoptosis, known 
actions of MPA.  
The increase in calculated IC50 for IMPDH2R over IMPDH2CS transduced BW 
cells was only 20 fold rather than 2400 fold previously calculated for the 
mutated enzyme. The previously reported increase in IC50 was calculated using 
protein purified from both wild-type and MPA-resistant neuroblastoma cell lines. 
In the work presented in section 3.3.1, I determined the IC50 by studying the 
effect of MPA on the growth of cells transduced with IMPDH2R, IMPDH2WT or 
IMPDH2CS. Determining the IC50 under these conditions is likely to more 
accurately reflect the level of resistance potentially conferred by transduction. 
Within cells, variability such as the availability of substrate or the amount of 
mutated IMPDH2 compared to the amount of wild-type enzyme will impact the 
IC50, effects not seen when investigating purified enzyme alone. 
When investigating apoptosis, cells transduced with either IMPDH2WT or 
IMPDH2R cultured in the absence of MPA exhibited higher percentages of 
apoptotic cells than those transduced with IMPDH2CS. During prolonged culture 
of sorted transduced BW cells, there was no apparent difference in the rate of 
proliferation of cells transduced with the different constructs. Additionally, no 
difference in the numbers of non-viable cells was seen. 
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I have also successfully transduced primary murine lymphocytes and 
demonstrated selection during MPA exposure of IMPDH2R but not IMPDH2CS 
transduced cells. To enable selection, I induced proliferation by either antigenic 
stimulation or cytokine. The concentration of MPA required to induce selection 
depended on the proliferative drive applied to the cells, with higher MPA 
concentrations required for cytokine than antigen driven proliferation. Selection 
was progressive throughout the period of MPA exposure and cells with higher 
copy numbers of the introduced gene appear to be preferentially selected as 
evidenced by higher MFI, however this did not achieve statistical significance 
when results from 3 independent experiments were combined. Using T cells 
from OT1 TCR transgenic mice provided a model where all IMPDH transduced 
cells are also of known antigen specificity. This does not occur when dual 
transducing cells with both TCR and IMPDH2 encoding retroviruses.  
Overall expansion of transduced OT1 cells was greater when exposed to an 
irrelevant antigen rather than with SIINFEKL. This appeared to be due to 
increased cell death following stimulation with cognate antigen. Activation 
induced cell death is a well described consequence of TCR ligation (Green et 
al., 2003). In these experiments, the use of TCR transgenic cells and saturating 
levels of peptide may have contributed to this. The culture conditions included 
both addition of exogenous IL-2 and irradiated feeder cells, which in the 
absence of cognate antigen may have been sufficient for T cells to both persist 
and proliferate but at reduced rates compared to cells stimulated by cognate 
antigen. The requirement for guanosine nucleotides within these cells would 
have been lower and therefore MPA had less effect on these cells. 
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Under conditions where exogenous IL-2, IL-7 and IL-15 were added to the 
culture medium, there is an initial expansion of cells.  However, the conditions 
used do not stimulate high levels of cell activation and expansion. The initial 
expansion phase seen is likely to relate to activation for transduction 4 days 
earlier with Con-A and IL7 rather than the common gamma chain cytokines 
used. IMPDH2R confers a selective advantage at all concentrations of MPA 
used compared to IMPDH2CS and IMPDH2WT. However, IMPDH2R transduced 
cells only continue to expand in number at the higher MPA concentration used 
(1500nM). At a higher concentration of MPA, GTP levels in control (IMPDH2CS 
and IMPDH2WT) cells decrease to a level that results in cell death. In contrast, 
IMPDH2R confers a significant advantage to transduced cells at this 
concentration. By the end of the experiments outlined in section 3.3.6, the vast 
majority of cells were GFP positive in the group of IMPDH2R transduced cells 
exposed to 1500nM MPA. At the lower dose of MPA only 30-50% of the cells 
were GFP positive reflecting the ability of untransduced cells to persist and in 
fact proliferate at this concentration of drug. 
Using primary murine cells in vitro led to some difficulties. The main difficulties 
were limiting survival of cells post transduction and reduction in the percentage 
of IMPDH2 transduced cells during culture in the absence of MPA. In almost 
every experiment there was a decline in the percentage of transduced cells in 
all groups when not exposed to MPA. Despite a decline in percentage, there 
was still an overall increase in transduced cell number because the total cell 
count increased. The transduced cells were outcompeted by untransduced 
cells within the same culture. In order to achieve successful retroviral 
transduction, cells are activated prior to incubation with retroviral supernate. It 
is likely that the successfully transduced cell population differs from 
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untransduced cells i.e. cells that do not transduce may have received lower 
levels of initial activation. This may subsequently enable an increased rate of 
activation and cell division during the subsequent experimental timeframe.  
In analysing my data, I have presented my findings as changes in total number 
of transduced cells to allow both percentage of transduced cells and expansion 
or contraction of cell numbers to be taken into account. In addition, I have 
normalised numbers to those at baseline to account for differences in initial 
transduction rates. This has allowed results from independent experiments to 
be combined. 
During these experiments, I purified populations of CD8 T cells prior to 
activation and transduction. Following transduction, cells were cultured for 3 
days with only the addition of exogenous IL-2 to T cell media. The resulting 
rates of cell death meant that some experiments were limited by the number of 
viable cells available either at baseline or during the experiment. Addition of 
exogenous IL-7 and IL-15 to the culture media maintained and expanded cell 
numbers, ensuring adequate numbers were available to initiate experiments. 
I have demonstrated selection of dual-transduced TCR redirected human 
PBMC i.e. transduced with a known TCR (LMP2) and IMPDH2R. My aim, using 
human cells, was to develop an experimental protocol that would mimic the ex 
vivo manipulation of cells that could subsequently be used therapeutically. The 
LMP2 TCR is specific for the immunodominant epitope of EBV and is an 
attractive TCR to use in treatment of post-transplant lymphoproliferative 
disorder (PTLD). While not shown here, I found similar results in one 
experiment in which I used a TCR specific for the NLG peptide of CMV. 
Despite work to optimise dual transduction, only 4-7% of cells were 
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successfully dual transduced at baseline. Selection for IMPDH2R was almost 
complete after 1 round of stimulation with MPA and large numbers of dual-
transduced cells could be selected after 3 rounds of stimulation. Once 
IMPDH2R was selected, cell expansion in the absence of drug does not lead to 
a significant decrease in the percentage of IMPDH2R transduced cells. 
Importantly, for therapeutic use, I have also demonstrated that cells cultured 
and selected in MPA retained function. While killing was not assessed, levels of 
cytokine production (Interleukin-2 and interferon-γ) were equivalent to those 
seen in cells never exposed to drug. 
These data support a strategy to generate adequate numbers of TCR 
redirected IMPDH2R transduced cells by ex vivo expansion of under the 
selective pressure of MPA for adoptive immunotherapy. I have shown that an 
adequate number of cells could be produced ex vivo and that these cells retain 
function in terms of cytokine production when exposed to antigen.  
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4.1!Introduction!
 
I have demonstrated the protective effect of IMPDH2R during MPA exposure in 
vitro. For adoptive immunotherapy with IMPDH2R transduced cells to be 
translated for therapeutic use in humans, the protective effects seen must also 
be demonstrated in vivo at concentrations relevant to the clinical setting.  
There has been significant variation in published reports regarding the dosing, 
diluent and route of administration of MMF in vivo. Different reported dosing 
strategies are summarized in table 4.1.  
 
Table 4.1 Published MMF dosing from in vivo murine models  
Route Diluent Dose (µg/g) Frequency Reference 
i.p. CMC 90 Daily (Van Bruggen et al., 1998) 
i.p. DMSO/PBS 
(1:10) 
30 Daily (Mehling et al., 2000) 
Oral gavage CMC 100 Daily (Izeradjene and Revillard, 
2001) 
i.p. CMC 30 or 100 Daily (Ramos et al., 2003) 
Oral gavage CMC 50, 100 or 150 12 hourly (Padalko et al., 2003) 
i.p. 5% Dextrose 28, 90, 120 or 200 Daily (Shapira et al., 2004) 
i.p. PBS 100 12 hourly (Quéméneur et al., 2004) 
i.p. 5% Dextrose 40 or 80 Daily (Koehl et al., 2007) 
i.p. 5% Dextrose 50 12 hourly 
Oral Specially 
formulated 
feed 
 Continuous 
i.p. 5% Dextrose 80 Daily (Guo et al., 2010) 
 
CMC - 0.5%Carboxymethyl cellulose /0.9% sodium chloride/0.4% Tween 80/0.9% 
benzylalcohol in distilled water @ 4.3 mg/ml; i.p. – intraperitoneal; DMSO – dimethyl sulfoxide; 
PBS – phosphate buffered saline  
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These studies looked at a range of in vivo models investigating a range of MMF 
effects. In particular, models of autoimmune disease e.g. SLE in (NZB x NZW 
F1) (Ramos et al., 2003), have been shown to respond well to MMF. In some 
studies, in vitro effects have not been replicated in vivo e.g. anti-tumour and 
anti-angiogenesis effects (Koehl et al., 2007). There is no clear correlation 
between different dosing strategies and positive results. 
Part of the difficulty in establishing dosing for in vivo models is that there 
remains much debate regarding what constitutes a therapeutic dose of MMF. 
The therapeutic range for MMF will vary depending on the indication and the 
use of concomitant immunosuppression.  
A therapeutic range following renal transplantation was proposed in 2006 (van 
Gelder et al., 2006) from data that showed AUC0-12h under 30mg!h/L identified 
87% of patients who will develop acute rejection in the first 3 months after 
transplant. From their data, an upper limit was set at 60 mg!h/L due to lack of 
additional efficacy rather than increased toxicity. Prospective trials have now 
shown that leukopenia and anaemia related to MMF could be reduced using 
dose adjustments based on the AUC0-12h upper limit of 60 mg!h/L(Kuypers et 
al., 2008). Gastrointestinal toxicity has also been shown to relate to AUC0-12h >60 
mg!h/L confirming the benefit of the maximum AUC0-12h target. Trough 
concentrations of 1.3mg/L with CsA and 1.9mg/L with tacrolimus were 
proposed to ensure >80% of patients would achieve the desired AUC0-12h. !
Following liver transplantation, clinical practice suggests that a target trough 
level 1 mg/L is important in the first year after transplantation to minimize 
rejection, whereas levels should be kept below approximately 3.5 mg/L 
subsequently to reduce the incidence of adverse effects (Tredger et al., 2004). 
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But following cardiac transplantation, target MPA trough concentrations >2 
mg/L when MMF is combined with tacrolimus are associated with reduced 
levels of rejection (Yamani et al., 2000).  
 A consensus report on therapeutic MMF monitoring was published in 2010 
(Kuypers et al., 2010). Table 4.2 summarizes their recommendations of how 
best to measure MPA exposure in clinical practice. At present routine 
monitoring of MPA levels is not recommended. Fixed MMF dosing is used; 
however large variability in pharmacodynamics and pharmacokinetics (Zeng et 
al., 2010) may result in significant under or overdosing. In renal transplant 
recipients the most important determinants of variability are renal function, 
albumin and calcineurin inhibitor therapy (van Hest et al., 2005, Le Guellec et 
al., 2004, van Hest et al., 2006).  A prospective trial of fixed dose versus 
concentration controlled MMF dosing showed no difference in treatment failure 
between the groups (van Gelder et al., 2008). This appeared to be due to 
failure of dose adjustments in patients assigned to the concentration controlled 
group. Approximately a third of patients on current initial MMF dosing are 
underexposed and at increased risk of acute rejection. 
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 Table 4.2 Summary of MPA exposure methods  
Adapted from Consensus report on therapeutic drug monitoring of 
mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol, 5, 
341-58. 
Exposure 
Measure 
How Assessed Advantages  Disadvantages  
Trough 
concentration (C0)  
Plasma concentration of 
MPA measured 
immediately before 
dosing  
Easy to obtain in clinical 
practice 
Requires only single 
sample  
Timing may vary from the 
“ideal” 12-hour dose 
interval  
Not a particularly strong 
association to full AUC 
Single 
concentration time 
points (e.g., C2 or 
C4)  
Plasma concentration of 
MPA measured at the 
exact time after dosing 
The single concentration 
can be used to estimate 
full AUC (regression 
equation)  
Relatively easy to obtain 
but requires more patient 
education Requires only 
single sample  
Usually better association 
to full AUC than trough 
concentration  
Timing may not be 
accurate  
Not a particularly strong 
association to full AUC 
Only for predetermined 
population  
Multiple 
concentration time 
points (several 
specific timed 
points after 
dosing, also called 
LSSs)  
Plasma concentrations 
of MPA measured at the 
exact and predefined 
times after dosing 
The concentrations can 
be used to estimate full 
AUC (multilinear 
regression equations)  
Relatively easy to obtain 
but requires more 
resources 
Better association to full 
AUC than single 
concentrations  
Requires longer stay for 
multiple samples  
Errors in timing lead to 
errors in estimations  
Only for the population in 
which regressions have 
been developed 
Single or multiple 
concentration time 
points, for 
Bayesian analysis  
Plasma concentration(s) 
of MPA measured at the 
predefined time(s) after 
dosing  
The concentrations are 
used in a Bayesian 
estimator to model the 
data (i.e., calculation of 
pharmacokinetic 
parameters and 
exposure indices)  
As above for single or 
multiple time points 
Bayesian approach is 
flexible with respect to 
sampling times because it 
can accommodate any 
time point or deviation 
from recommended time 
points  
Better estimate of 
individualized AUC  
As above for single or 
multiple time points 
Mathematically more 
complex, requires 
preexisting population 
pharmacokinetic model 
and knowledge of 
covariates Computer 
model based and requires 
interpretation for dosing 
advice 
Full AUC (AUC0 to 
12 hours, dose-
interval AUC)  
Plasma concentrations 
of MPA measured at 
exact predefined times 
after dosing allowing 
AUC to be calculated 
As above for multiple time 
points 
Best relationship to 
clinical outcomes  
As above for multiple time 
points 
Requires patient to be 
available for the complete 
dosing interval (12 hours)  
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A new, novel approach to monitoring has been investigated in patients treated 
with MMF post HSCT (Li et al., 2014). They analysed IMPDH activity to use as 
a marker of MPA activity. Mass spectrometric detection was used in an assay 
measuring the conversion of IMP to XMP. Patients were sampled at five time 
points after drug administration 21 days after their transplant. As seen in 
previous studies (Li et al., 2013), substantial variability in pharmacokinetics and 
pharmacodynamics was seen between patients. The IC50 was 3.23 mg/l total 
and 57.3 ng/ml unbound MPA. The IMPDH AUC was associated with CMV 
reactivation, non-relapse mortality and overall mortality. 
Extrapolation of a therapeutic concentration (3.5g/l) to mice requires a dose of 
80-100µg/g to generate similar 12-hour levels, within the range of doses shown 
in table 4.1.  Because of the lack of consensus on dose, diluent and route of 
administration, I chose to administer MMF intraperitoneally to ensure each 
recipient received the same body weight adjusted dose. I investigated the dose 
and diluent during initial experiments, with dosages used covering the range 
used in previous reports. My models required dosing to continue for several 
weeks, I therefore elected to administer drug once daily to reduce the repeated 
need for i.p. injections. 
4.2$Aims!
• To investigate toxicity and actions of MMF in a steady state mouse 
• To demonstrate selection of IMPDH2R transduced cells in MMF treated 
mice 
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4.3!Results!
4.3.1!In!vivo!dosing!and!toxicity!of!MMF!!
As can be seen from the available literature, highlighted in section 4.1, there is 
no consensus on MMF dosing in mice, or which vehicle to use for reconstitution. 
I initially used the CMC buffer described in table 4.1, to allow aliquots to be 
stored at -20˚C for up to 5 days. On thawing, a precipitate was seen that 
proved difficult to resuspend even following prolonged agitation and 
recommended gentle heating. In contrast to this, no precipitate formed when 
thawing aliquots of the buffer alone. The precipitate was not seen on initial 
reconstitution of MMF. Some mice that received MMF in CMC buffer were 
noted to have extensive adhesions within the abdominal cavity. Following 
personal communication with a group who had published protocols using this 
buffer (Dra. Mª Ángeles Ramos Barrón, Hospital Universitario Marqués de 
Valdecilla), I discovered that they had also encountered these problems often 
leading to blockage of needles used to administer drug.  
The manufacturer of MMF (Roche) supplies recommendations for use in 
humans with reconstitution in 5% Dextrose followed by administration within 3 
hours. They could not provide data on drug stability outside of 3 hours, 
following freezing or when other diluents are used for reconstitution. I 
subsequently used 5% Dextrose as diluent for all further in vivo experiments, 
with administration within 1 hour of reconstitution. 
To investigate the maximum tolerated dose of MMF, I initially used C57B6/J 
mice and administered intraperitoneal MMF at doses of 0, 200 or 400µg/g/day. 
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The dose of MMF administered, was adjusted to current body weight on a daily 
basis.  
In figure 4.1, the mean weight is plotted over time as a percentage of the 
baseline weight for mice treated with vehicle or two doses of MMF. Mice 
receiving vehicle maintained their baseline weight throughout the period of 
MMF exposure (figure 4.1A). Mice receiving 200µg/g/day lost more weight than 
vehicle treated mice. On average, this was approximately 10% of body weight 
at 2 weeks, after which they appeared to stabilise. In contrast, mice receiving 
the highest dose of MMF (400µg/g/day) rapidly lost weight and all died within 
11 days of initiation of treatment. Additionally, these mice appeared to develop 
neurological toxicity with abnormal movement patterns and behavior noted. 
Other than weight loss no evidence of gastrointestinal toxicity was seen.  
I investigated whether the addition of lymphodepletion to MMF treatment would 
increase toxicity. Lymphodepletion was by total body irradiation (TBI) 
administered immediately prior to initiation of MMF. When combined with i.p. 
injections of vehicle there was little difference between weight loss in mice 
receiving 0, 1 or 5.5Gy of irradiation (figure 4.1B). In mice receiving the 
combination of 5.5Gy irradiation and MMF 200µg/g/day, significant weight loss 
was seen resulting in death prior to day 14. These mice also exhibited 
behavioural changes shortly before death including abnormal repetitive 
movements. Mice receiving MMF and low dose irradiation (1Gy) lost similar 
amounts of weight as mice receiving MMF and no irradiation. 
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Figure 4.1 In vivo MMF toxicity is manifested as dose dependent weight 
loss and is increased when combined with lymphodepleting irradiation 
C57Bl6/J mice receiving vehicle, MMF 200µg/g/day or MMF 400µg/g/day (A) 
were weighed every 1-2 days. C57Bl6/J mice exposed to 0, 1 or 5.5Gy were 
treated with vehicle (B) or 200µg/g/day MMF (C) started on the same day as 
irradiation. A summary of weights plotted as a percentage of baseline over time 
is given. Mice were sacrificed if weight <80% of baseline. Mean and SD given.  
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4.3.2! In! vivo! administration! of! MMF! causes! reduced! lymph! node!
cellularity!in!mice!
I hypothesised that administration of MMF, in the absence of TBI, would result 
in suppression of the lymphocyte compartment. This would enable enhanced 
engraftment of transferred IMPDH2R transduced cells by the mechanisms 
described in section 1.1.6 (pp. 34) for lymphodepletion. I also hypothesised that 
the addition of low doses of TBI would enhance the effects of MMF in vivo 
compared to the steady state.  
Having identified 200µg/g/day as the maximum tolerated dose of MMF, I 
investigated the effects of a range of doses from 0 to 200µg/g/day on cells 
recovered from within the spleen, lymph nodes and bone marrow. In Figure 
4.2, total cellularity within each compartment is summarised for the highest 
dose of MMF (200µg/g/day) compared to vehicle after 7-10 days of MMF 
administration. There was no difference in overall cellularity in the spleen 
(Mann-Whitney p=0.4127; Mean Vehicle = 71 x 106, MMF = 79 x 106) or bone 
marrow (Mann-Whitney p=0.4127; Mean Vehicle = 19.8 x 106, MMF = 15.9 x 
106). Of note, the spleens from MMF treated mice subjectively appeared larger 
than those from vehicle treated mice despite no difference in cellularity. There 
was a significant difference in total lymph node cellularity between mice treated 
with vehicle and MMF (Mann-Whitney p=0.0317; Mean Vehicle= 9.74 x 106, 
MMF= 5.012 x 106). At dissection, the lymph nodes of mice in the MMF group 
were notably smaller than those in the vehicle group and were at times very 
difficult to locate.  
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Figure 4.2 MMF causes reduced lymph node cellularity. 
Mice given vehicle or MMF 200µg/g/day were sacrificed at 7-10 days and the 
cellularity of spleen (A), bone marrow (B) and lymph node (C) assessed. Mean 
and SD are plotted for the total count from each organ.  
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4.3.3!In!vivo!administration!of!MMF!reduces!B220!cell!numbers!but!not!
CD4!or!CD8!T!cells!
In addition to the clear reduction in lymph node cellularity, a repeated finding 
from these experiments was a reduction in the percentage of cells with the size 
and granularity of lymphocytes based on flow cytometric forward and side 
scatter. An experiment using a range of MMF doses from 0-200µg/g/day (figure 
4.3 A & B) showed a dose-dependent reduction in both the percentage and 
absolute number of cells within this gate when MMF doses greater than 
100µg/g/day were administered. Further investigation showed that the 
reduction in cells within this gate was due to reduction in B220 positive cells 
(Figure 4.3 C & D). The percentages and absolute numbers of CD8 and CD4 T 
cells were not reduced by 200µg/g/day in spleen (Figure 4.4 A & B) or bone 
marrow (Figure 4.4 C & D). In the lymph nodes, the percentages of CD4 and 
CD8 T cells were unchanged (Figure 4.4E) but absolute numbers were 
reduced (Figure 4.4F) reflecting the reduction in absolute cellularity (Mann-
Whitney CD8 p= 0.0079; Mean vehicle = 3.4 x 106, MMF=1.1 x 106; CD4 p= 
0.0079; Mean vehicle = 4.5 x 106, MMF= 1.4 x 106) 
 !
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Figure 4.3 MMF causes a dose-dependent reduction in lymphocytes 
within the bone marrow due to reduction in B220 positive B cells. 
Mice given vehicle or a range of MMF doses were sacrificed after 7 days and 
bone marrow harvested. Cells in a lymphocyte gate (determined by forward 
and side scatter and back-gating of CD4 and CD8) are given as a percentage 
of live cells (A) and as absolute number (B). Mice receiving MMF 200µg/g/day 
were sacrificed at 7-10 days. Cells were analysed by FACS using the B cell 
marker B220. The percentage of live cells (C) and absolute number (D) with 
mean and standard deviation are plotted for bone marrow.  
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Figure 4.4 At the maximum tolerated dose of MMF, there is no change in 
CD4 or CD8 cells percentage but absolute numbers are decreased in 
lymph nodes. 
Mice were treated with vehicle or MMF 200µg/g/day for 7-21 days. Spleen, left 
hind limb and lymph nodes (axillary, brachial and inguinal) were harvested and 
single cell suspensions counted and stained for FACS analysis. CD8 and CD4 
positive cells are presented as percentage of live gate and absolute count for 
Spleen (A and B), Bone Marrow (C and D) and lymph node (E and F).  Results 
from 5 independent experiments, mean and standard deviation are plotted. 
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Figure 4.4 !
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In!Vivo!Selection!of!IMPDH2R!
Having seen minimal effect of MMF on CD4 and CD8, I hypothesised that 
homeostatic proliferation of lymphocytes is at a rate insufficient for MMF to 
cause suppression. In order to test the in vivo effects of MMF on cells 
stimulated to proliferate, I designed the experimental protocol outlined in figure 
4.5.  
In these experiments, I stimulated proliferation by two mechanisms; 
1. Lymphopenia 
2. Cognate antigen 
Lymphopenia-induced proliferation resulted from TBI. Low doses were used to 
avoid the toxicity seen in pilot experiments when TBI and MMF were given in 
combination. Stimulation with cognate antigen within this model ensured that 
transferred but not endogenous cells would be stimulated. I used a model 
antigen system and selected donor mice transgenic for the OT1 TCR, also 
used in vitro see section 3.3.5, stimulated by administration of the cognate 
OVA peptide (SIINFEKL) given with adjuvant. 
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Figure 4.5 Overview of protocol to investigate in vivo selection of 
IMPDH2R transduced cells 
C57Bl6/J mice were exposed to low doses of irradiation (0, 1.5 or 2Gy) and 
MMF 0, 100 or 200µg/g/day started. A total of 1 x 106 transduced OT1 Rag-/- 
cells were transferred intravenously 4-6 hours later. The transferred cells 
contained a 1:1 mix of IMPDH2CS and IMPDH2R transduced cells. Both donor 
types could be differentiated from each other and the recipient using the 
congenic markers Thy1.1/1.2 and CD45.1/45.2. Mice received either 
Incomplete Freud’s adjuvant (IFA) or an emulsion of SIINFEKL in IFA on day 1 
by subcutaneous injection at the base of the tail. Weight was monitored during 
14 days of MMF administration. Mice were sacrificed at day 14 with spleen and 
draining lymph nodes (inguinal and para-aortic) harvested for FACS analysis. 
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4.3.4!Development!of!a!model!of!in!vivo!selection!
As seen in figure 4.6, there was MMF dose-dependent weight loss in both TBI 
and No TBI groups. In the absence of TBI (figure 4.6A), mice receiving vehicle 
or 100µg/g/day MMF maintained body weight throughout the experiment. Mice 
receiving MMF 200µg/g/day progressively lost weight until day 10 after which it 
stabilised at ~90% of baseline. Weight loss in all groups was greater following 
TBI. Vehicle treated mice lost <5% of baseline weight before stabilising after 4-
5 days. Mice receiving MMF lost ~10% of weight during the first week of the 
experiment with mice receiving 200µg/g/day continuing to lose weight up until 
the end of the experiment. In the higher-dose group several mice were found 
dead or required sacrifice before the end of the experiment due to weight loss. 
In the 100µg/g/day group, weight stabilised after 7 days and gradually 
increased during the second half of the experiment. 
I hypothesised that when cells were transferred under conditions to stimulate 
proliferation, IMPDH2R transduced cells would be preferentially selected over 
IMPDH2CS transduced cells. In order to detect whether selection had occurred, 
I utilised donor mice of two different types that could be distinguished from 
each other and recipient mice by the congenic markers Thy1.1 and Thy1.2 and 
CD45.1 and CD45.2.  
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Figure 4.6 Weight loss is increased at higher MMF doses and when MMF 
and TBI are combined 
The weights of mice undergoing the experimental protocol outlined in figure 4.4 
were taken every 1-2 days. Weight is given as a percentage of baseline weight 
and shown over time for recipients of no TBI (A) and TBI (B).  
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Example FACS plots of splenocyte samples from mice receiving 2Gy TBI and 
100µg/g/day of MMF or vehicle are shown in figure 4.7. Samples were initially 
gated for CD8 positive cells and then transferred cells (Thy 1.2 positive). 
Across repeated experiments, the transduction efficiency (GFP positivity) was 
between 30 and 70% of cells at transfer. The ratio between IMPDH2R and 
IMPDH2CS was set on transduced (GFP positive) cells only. In the example 
shown, just under 50% of GFP positive cells are also CD45.1 positive 
(IMPDH2R) to give a baseline ratio of 0.9. In each of the multiple experiments 
performed, the baseline ratio at transfer was close to but not exactly 1. To 
ensure that the different congenic forms of CD45 did not influence results, the 
donor type transduced with IMPDH2R was switched in different experiments.  
After 14 days, vehicle treated mice given IFA alone do not exhibit selection for 
IMPDH2R transduced cells compared to IMPDH2CS (ratio 0.639) but with 
antigen and vehicle there is selection seen (ratio 3.02). MMF treatment resulted 
in strong selection of CD45.1 positive GFP positive cells in the presence of 
antigen (ratio 23.5) but not in the absence of antigen (ratio 0.7109). Of note, in 
the plot from a mouse receiving antigen and vehicle there is a shift in the ratio 
for both transduced and untransduced cells. This was not replicated in other 
experiments. 
To summarise data from multiple experiments, the calculated ratio was 
corrected for the baseline ratio for that experiment. During initial experiments, 
spleen, lymph node and bone marrow samples were collected. The number of 
transferred cells in bone marrow was so low that data is not included for 
analysis. The results shown in figures 4.8-4.10 are combined from 9 
independent experiments using a total of 12 different injection mixes. 
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Recipient mice fell into a total of 12 groups, 6 with TBI and 6 without. With and 
without TBI groups received 0, 100 or 200 µg/g/day MMF and received either 
antigen or adjuvant alone. Mice in each of these groups had data recorded to 
demonstrate selection in spleen and lymph node samples. Because of the 
number of recipient mice required, there were only 3 available in each no TBI 
group. The data from both doses of MMF are also presented in combination in 
these groups.  
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Figure 4.7 IMPDH2R cells are selected over IMPDH2CS cells during in vivo 
MMF administration 
Example plots are shown of selection in mice receiving 2Gy irradiation and an 
MMF dose of 100µg/g/day. Samples of splenocytes are pre-gated on CD8 and 
Thy1.2 (transferred cells). Plots show CD45.1 against GFP. CD45.1 positive 
cells were transduced with IMPDH2R while IMPDH2CS transduced were CD45.1 
negative. Plots are taken at baseline of the injection mix and at day 14 from 
vehicle treated or MMF treated mice and are shown both with and without 
antigen. 
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4.3.5!Selection!of!IMPDH2R!requires!both!antigenic!stimulation!and!high!
dose!MMF!In!nonHirradiated!mice!
Summary data for mice not receiving lymphodepleting irradiation is shown for 
the spleen (figure 4.8A) and draining lymph nodes (figure 4.8C). Selection is 
summarised as a ratio of IMPDH2R:IMPDH2CS with a larger number signifying 
selection of resistant cells. Under conditions where there is no prior 
lymphodepletion, there is no MMF induced selection in the absence of antigen. 
Of note there is one outlying result from the group receiving IFA alone and 
200µg/g/day of MMF where no IMPDH2CS transduced cells could be detected.  
When proliferation of transferred cells is induced by cognate antigen there is a 
trend towards selection at 200µg/g/day MMF (Mann-Whitney IFA v IFA+OVA 
MMF 200µg/g/day p=0.1; Mean IFA=0.655, IFA+OVA=48) however as only 3 
mice were available for each group significance could not be reached in this 
experiment. If both MMF doses are combined a significant difference is seen 
(Mann-Whitney MMF IFA v IFA+OVA p=0.0411; 0.846 v 27.22).  
In draining lymph nodes from these mice exposed to cognate antigen, a similar 
pattern can be seen but this does not reach significance even when MMF 
groups are combined and outliers removed. There is a trend towards selection 
in the lymph node without MMF (Mann-Whitney Vehicle & IFA v IFA+OVA 
p=0.1; 0.692 v 5.176) and trends towards greater selection with higher doses of 
MMF (Mann-Whitney IFA+OVA 0 v 100µg/g/day and 0 v 200µg/g/day both 
p=0.1; Mean: Vehicle=5.176, 100µg/g/day=1.076, 200µg/g/day=24.06).  
  
160 
Figure 4.8 Ratio of IMPDH2R:IMPDH2CS transduced cells 
Mice treated under the protocol outlined in figure 4.4 were sacrificed 14 days 
after adoptive transfer and samples of cells from spleen and lymph nodes 
analysed for transferred cells. The ratio of IMPDH2R:IMPDH2CS transduced 
cells is given, normalised to the input ratio. Results are combined from 9 
independent experiments. Data from mice receiving no TBI are summarised for 
spleen (A), and lymph node (C) while mice receiving TBI are summarised for 
spleen (B) and lymph node (D). Mean and standard deviation are plotted. IFA 
alone = closed, SIINFEKL + IFA = Open, MMF dose in µg/g/day 
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4.3.6! Following! TBI,! selection! of! IMPDH2R! is! driven! by! antigenic!
stimulation!and!increased!by!MMF!administration!within!the!spleen!
Summary data for spleen (figure 4.8B) and draining lymph nodes (figure 4.8D) 
are shown for mice receiving low dose TBI. Following lymphodepletion, 
cognate antigen can drive selection of IMPDH2R transduced cells. This was 
independent of but enhanced by treatment with MMF. In the spleen significant 
selection was seen in vehicle treated mice when transferred cells were 
stimulated with cognate antigen (Mann-Whitney IFA v IFA+OVA Vehicle 
p=0.0356; Mean IFA=1.061, IFA+OVA= 2.492). This was also the case at both 
100µg/g/day (Mann-Whitney IFA v IFA+OVA 100µg/g/day MMF p=0.0262; 
Mean IFA=0.9609, IFA+OVA= 3.341) and 200µg/g/day of MMF (Mann-Whitney 
IFA v IFA+OVA 200µg/g/day MMF p=0.0173; Mean IFA=1.794, IFA+OVA= 
7.823). MMF at the higher dose exhibited greater selection of IMPDH2R 
transduced cells than vehicle with or without antigen (Mann-Whitney MMF 0 v 
200µg/g/day IFA alone p=0.04; IFA+OVA p=0.0103). 
Compared to the results from spleen samples, selection in lymph node 
samples from mice receiving TBI did not exhibit clear dose-response and the 
effect of antigen was less apparent. At the lower dose of MMF there was 
significant selection with antigen compared to no antigen (Mann-Whitney IFA v 
IFA+OVA 100µg/g/day MMF p=0.007; Mean IFA=1.062, IFA+OVA= 3.403). At 
the higher dose of MMF the effect of antigen was non-significant (Mann-
Whitney IFA v IFA+OVA 100µg/g/day MMF p=0.0519; Mean IFA=1.648, 
IFA+OVA= 5.578). Antigen was also not a significant driver of selection in the 
absence of MMF (Mann-Whitney IFA v IFA+OVA Vehicle p=0.1419; Mean 
IFA=1.407, IFA+OVA= 1.916). Neither dose of MMF significantly increased 
selection of IMPDH2R transduced cells over vehicle treated mice (Mann-
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Whitney IFA+OVA 0 v 100µg/g/day MMF p=0.0853, 0 v 200µg/g/day MMF 
p=0.0727; Mean Vehicle=1.916, 100µg/g/day MMF=3.403, Mean 200µg/g/day 
MMF=5.578). 
!
4.3.7!Selection!of!IMPDH2R!within!the!activated!(CD44high)!compartment!
requires!lymphodepletion!and!is!driven!by!both!antigen!and!MMF!
To investigate whether selection was increased in activated T cells, I gated for 
CD44high transferred T cells prior to calculating a ratio of transduced cells. 
These results are shown in figure 4.9 with absolute numbers of IMPDH2R cells 
shown in figure 4.10. In the absence of TBI (Figure 4.9A and C) there is no 
significant selection seen even when MMF doses are combined. In contrast, 
following TBI there is significant selection for IMPDH2R transduced cells in both 
the spleen and lymph nodes.  
Within the spleen, selection is driven by antigen (Figure 4.9B) in the presence 
of MMF (Mann-Whitney test IFA v IFA + SIINFEKL 100µg/g/day MMF 
p=0.0379, 200µg/g/day MMF p=0.0101; Means 100µg/g/day IFA = 1.436, IFA + 
SIINFEKL 4.156, 200µg/g/day IFA = 1.9, IFA + SIINFEKL 9.785) but a non-
significant trend is seen in the absence of MMF (Mann-Whitney test IFA v IFA + 
SIINFEKL Vehicle p=0.0558; Means IFA = 1.229, IFA + SIINFEKL = 2.008).  
This result is mirrored in the lymph nodes (Figure 4.9D; Mann-Whitney test IFA 
v IFA + SIINFEKL Vehicle p=0.059, 100µg/g/day MMF p=0.0169, 200µg/g/day 
MMF p=0.014; Means Vehicle IFA = 1.229, IFA + SIINFEKL = 2.008, 
100µg/g/day IFA = 1.207, IFA + SIINFEKL 3.264, 200µg/g/day IFA = 1.469, IFA 
+ SIINFEKL 5.872). 
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MMF increases the level of selection over vehicle in both spleen and lymph 
node following antigen exposure. Within the spleen this is only at the higher 
dose of MMF (Mann-Whitney test MMF Vehicle v 100µg/g/day p=0.1788, 
Vehicle v 200µg/g/day p=0.0019). In the lymph node it is increased at both 
doses (Mann-Whitney test MMF Vehicle v 100µg/g/day p=0.0268, Vehicle v 
200µg/g/day p=0.0114). 
There are significantly increased numbers of activated IMPDH2R transduced 
cells seen following addition of antigen to MMF in the absence of 
lymphodepletion (figure 4.10A and C). In general, the transduced cell numbers 
were greater following lymphodepletion (figure 4.10B and D). Within the spleen, 
IMPDH2R numbers were significantly higher with than without MMF. 
In summary in the absence of lymphodepletion, antigen driven proliferation and 
MMF are both required to select resistant cells. Following lymphodepletion, 
IMPDH2R cells are selected with antigen alone and this effect is even greater 
when MMF is given. This also results in increased numbers of activated 
resistance transduced cells following lymphodepletion, antigen and MMF than 
without. 
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Figure 4.9 Ratio of Activated (CD44high) IMPDH2R:IMPDH2CS transduced 
cells 
Mice treated under the protocol outlined in figure 4.4 were sacrificed 14 days 
after adoptive transfer and samples of cells from spleen and lymph nodes 
analysed for transferred cells. The ratio of IMPDH2R:IMPDH2CS transduced 
cells is given, normalised to the input ratio. Results are combined from 9 
independent experiments. Data from mice receiving no TBI are summarised for 
spleen (A), and lymph node (C) while mice receiving TBI are summarised for 
spleen (B) and lymph node (D). Mean and standard deviation are plotted. IFA 
alone = closed, SIINFEKL + IFA = Open, MMF dose in µg/g/day. Results 
significant by Mann-Whitney test are shown. 
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Figure 4.10 Absolute numbers of CD44high IMPDH2R transduced cells  
Mice treated under the protocol outlined in figure 4.4 were sacrificed 14 days 
after adoptive transfer and samples of cells from spleen and lymph nodes 
analysed for transferred cells. Results are combined from 9 independent 
experiments. The absolute number of CD44high IMPDH2R cells is shown. 
Summary data from mice receiving no TBI spleen (A), and lymph node (C) and 
TBI spleen (B) and lymph node (D) are shown. Mean and standard deviation 
are plotted. IFA alone = closed, SIINFEKL + IFA = Open, MMF dose in 
µg/g/day. The two columns furthest to the right of each plot contain both MMF 
doses combined. Results significant by Mann-Whitney test are shown. 
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4.4#Discussion!
The data reported in this chapter, show that daily i.p. injection of MMF in 
C57Bl6 mice results in limiting toxicity above 200µg/g/day. Toxicity is increased 
by the delivery of lymphodepleting irradiation. Mice lose weight and at higher 
doses of drug exhibit abnormal behaviour that may reflect neurological toxicity.  
A limitation of in vivo use of MMF is the half-life, approximately 12-16 hours. 
Administration in humans is therefore 2 or 3 times daily to maintain minimum 
trough levels. In the experiments shown in this chapter, MMF was administered 
for up to 21 days. Once daily dosing of MMF was used in order to limit the 
number of i.p. injections required for each mouse. Once daily dosing may result 
in several hours each day during which drug concentrations are sub-
therapeutic prior to the next dose. During this window, the inhibitor effect of 
MMF may be reduced to a point where sufficient levels of GMP can be 
produced to avoid apoptosis and initiate cell cycling. Despite this potential 
problem with dosing, protocols using MMF once daily in vivo have been 
reported that result in successful treatment of autoimmune diseases and in 
some cases suppression of tumour growth.  
The in vivo models of autoimmunity in which MMF successfully abrogated 
disease are primarily antibody mediated. This is reflected in my data that show 
that B220 positive but not CD4 and CD8 positive cells are significantly 
suppressed by MMF. This represents a B cell population. This could be 
considered surprising as B lymphocytes have been shown to possess over 
twice the activity of the salvage pathway enzyme HGPRT compared to T 
lymphocytes (Davis and Rambotti, 1982). The action of this enzyme should 
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counteract the action of MMF by ‘recycling’ guanosine nucleotides in an IMPDH 
independent fashion. The presence of HGPRT in B lymphocytes was exploited 
to select hybridomas formed between B cells and myeloma cells to produce 
monoclonal antibodies (Kohler and Milstein, 1975). Patients with Lesch-Nyhan 
syndrome (HGPRT deficiency) have apparently normal B cells, however they 
show a reduced response following mitogen stimulation (Gelfand et al., 1978). 
In humans with SLE treated with MMF, there is no difference in the frequencies 
or absolute numbers of peripheral blood B cells compared to no 
immunosuppression (Eickenberg et al., 2012). B cells from patients treated with 
MMF were less able to proliferate and form plasmablasts in response to CpG 
or anti-CD40 + IL-21. In patients receiving immunosuppression following heart 
transplantation, there was a significant decline in B cells of patient on MMF 
compared to azathioprine treated patients and a healthy control group (Weigel 
et al., 2002). The patients all also received ciclosporin and prednisolone. The 
decline in B cell numbers started 3 months after starting MMF and by 12 
months levels were nearly 50% of the other groups. This was associated with a 
reduction in CD38 a marker of activated B cells. 
A study looking at responses to sheep red blood cell vaccination in Balb/c mice 
treated with MMF, showed a reduction in B-1a cells within the spleen (but not 
B-1b or B2 cells) at 2 week but after initial reduction in IgM levels at day 5 they 
were normal by day 14 (Salinas-Carmona et al., 2009). In C3H mice, MMF was 
shown to reduce numbers of CD19+ B cells within the spleen (Padalko et al., 
2003). From the available data it appears that MMF has different effects in 
different body organs and there may be differences between species and 
depending on the underlying condition. Data from several sources supports my 
finding of a B lymphocyte depleting effect for MMF. 
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Not all published reports of MMF use in vivo have been successful. Koehl et al 
were unable to replicate anti-tumour and anti-angiogenic effects seen in vitro 
when MMF was administered once daily in vivo. They therefore investigated 
drug concentrations following dosing (Koehl et al., 2007). Figure 4.11 
reproduced from Koehl et al’s work shows MPA levels in the blood of mice on 3 
dosing strategies; 80mg/kg once daily, 50mg/kg twice daily and specially 
produced feed containing MMF. Levels achieved 2 hours after 80mg/kg MMF 
i.p. were within the range considered therapeutic in humans however after 12 
and 24 hours the levels were subtherapeutic. The lower initial dose (50mg/kg) 
produced lower peak levels and was subtherapeutic prior to the 12-hour dose. 
The twice-daily regimen did not replicate the in vitro anti-tumour effects despite 
a shorter duration of sub-therapeutic drug concentrations each day. The 
alternative strategy where drug was administered continuously in feed resulted 
in low levels of drug throughout (3mg/l) and again did not replicate in vitro 
effects. The group repeated their in vitro experiments, but only exposed cells to 
MPA for 2 hours twice a day rather than the continuous exposure used initially. 
Under these conditions the in vitro effects were lost. Their data suggest that 
once daily dosing in vivo is able to produce therapeutic peak drug levels but as 
predicted levels were sub-therapeutic for long periods of the day.  
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Figure 4.11 MPA levels in murine blood measured after various delivery 
strategies.  
Results show that although one or two bolus doses of MMF per day produce a 
relatively high early peak in MPA, levels decrease to subtherapeutic values by 
24 hr. Using MMF-containing food, levels are maintained in the therapeutic 
range. Results shown are the mean ± SEM from multiple mice.  
Adapted from Koehl et al Transplantation, 2007; 83 (5) pp. 607-614 
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Therefore the selection I have seen in the data presented here may have been 
of greater magnitude if twice daily or continuous administration of MMF is used. 
I have not investigated MMF/MPA levels during these experiments. When MPA 
levels are measured, peripheral blood serum is used and free MPA measured 
by high performance liquid chromatography. However, the action of MPA is 
intracellular and concentrations of drug within the cell may remain therapeutic 
despite lower levels in serum. In addition, repeated episodes of suppression 
may be sufficient to reduce GTP/dGTP levels to initiate apoptosis. Once 
programmed to undergo apoptosis, recovery of IMPDH function and GTP 
production will not be sufficient to reverse this programming. It has been shown 
that in K562 cells suppression of intracellular GTP by about 60% is required to 
initiate apoptosis (Meshkini et al., 2011) however the length of suppression 
required has not been investigated. 
The effect of MMF on a cell is a result of the balance between nucleotide 
requirement and the activity of functional IMPDH producing guanine 
nucleotides. The amount of GTP/dGTP required by an individual cell will 
depend on its metabolic requirement especially the rate of cell division, while 
suppression of GTP/dGTP production by MMF will depend on the intracellular 
concentrations of IMPDH and drug. When I used conditions that did not provide 
as much of a stimulus for cell division, the requirement for GTP/dGTP would be 
lower and therefore higher levels of drug would be required to reduce GTP 
levels to a point where cell cycle arrest or apoptosis would be initiated.  
This data has demonstrated a selective advantage for IMPDH2R transduced 
cells compared to IMPDH2CS transduced cells. It also demonstrates that 
transferred IMPDH2R cells can persist during MMF treatment. Data from a 
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small pilot experiment not presented here, showed persistence of transferred 
cells in mice that were left for three weeks after 1.5Gy TBI and a two-week 
period of MMF therapy (100µg/g/day). IMPDH2R cells remained strongly 
selected in mice that had received antigen and also to a lesser degree in mice 
that had not received antigen. 
The experiments presented in this chapter were not designed to demonstrate if 
transferred lymphocytes retain the ability to function or whether IMPDH2R 
transduced cells demonstrate a functional advantage for compared to control 
transduced cells during MMF treatment. As retention of function is a 
requirement for the therapeutic use of cells conferred with immunosuppressive 
drug resistance, I will present experiments designed to demonstrate 
functionality of IMPDH2R transduced T cells during MMF treatment in the next 
chapter.  
 !
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Chapter( 5:( Effects' of! MMF# post"
lymphodepleting- irradiation- and- tumour-
control'during'MMF'treatment!
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5.1!Introduction!
Having demonstrated that IMPDH2R transduced cells are selected in vivo, my 
subsequent experimental aim was to demonstrate the effect of MMF on the 
function of IMPDH2R transduced cells in vivo. I hypothesised that, as seen in 
vitro, IMPDH2R transduced cells would retain functional activity during MMF 
treatment following adoptive transfer.  
Because treatment of PTLD during immunosuppressive therapy is one of the 
suggested therapeutic targets of IMPDH2R transduced T cells, retention of 
function against tumour during MMF treatment is the focus of experiments 
presented in this chapter. The use of EL4 tumour cells, a lymphoma line 
created in C57BL6 mice exposed to 9,10-dimethyl-1,2,-benzanthracene (Gorer, 
1950), is well established as an in vivo model of localised tumour when injected 
subcutaneously in C57Bl6 recipients.  Variants of EL4 engineered to express a 
known target antigen have been developed. Having used OVA and the OT1 
TCR as a model antigen system both in vitro and to demonstrate in vivo 
selection, I elected to use an EL4 line engineered to express OVA (EG7) 
(Moore et al., 1988).  
In the initial experiments described by Gorer, injection of EL4 cells led to 
establishment of a visible tumour at day seven which then regressed 
spontaneously. This is due to rejection of the tumour by endogenous T or NK 
cells. For EG7 tumour to become established, recipient mice require 
lymphodepletion to prevent subsequent rejection. As described in chapter 4, 
when MMF and irradiation are administered together there was increased 
toxicity. I therefore designed protocols in which initiation of MMF therapy and 
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transfer of transduced therapeutic lymphocytes was delayed for several days 
after irradiation. My protocol was based on established protocols within our 
laboratory that use a single fraction of 5.5Gy total body irradiation (TBI) in 
C57Bl6 mice to successfully establish a subcutaneous EL4 tumour. 
 
 
5.2$Aims!
 
• To develop an in vivo tumour model of adoptive immunotherapy during 
MMF treatment. 
• To investigate the effects of MMF following lymphodepleting radiation. 
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5.3!Results!
 
5.3.1! Delaying! initiation! of! MMF! treatment! after! irradiation! reduces!
toxicity!
Initial experiments to initiate MMF five days following lymphodepleting 
irradiation (Single fraction, 5.5Gy) resulted in significant weight loss and death 
of recipients. To reduce the toxicity seen, the protocol was refined to use a 
reduced dose of TBI (4Gy) and to increase the window between irradiation and 
starting MMF to 10 days. This also ensured large established tumours at the 
transfer of therapeutic cells. The resulting experimental protocol is outlined 
(Figure 5.1). EG7 cells were suspended in matrigel and injected 
subcutaneously in the shaved right flank. Mice were monitored for weight loss 
and MMF started at a dose of 100µg/g/day on day 10. Mice were weighed daily 
with adjustment of the amount of MMF administered to maintain a dose of 
100µg/g/day.  
The percentage of baseline weight for all mice undergoing this protocol is 
plotted (Figure 5.2). There is no difference between MMF and vehicle treated 
groups. Two mice from the MMF treated groups and one mouse from the 
vehicle treated groups rapidly lost weight and were sacrificed on day 24 and 
day 17 respectively.  
!
 !
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Figure 5.1 Overview of in vivo tumour model 
C57Bl6/J mice were used as recipients and on day 1 were irradiated with 4Gy 
TBI. Four hours later 1 x 106 EG7 cells suspended in matrigel were injected 
subcutaneously in the shaved right flank of the mice. The mice were monitored 
for tumour growth and weight. On day 10, either MMF 100µg/g in 200µl 5% 
dextrose or 200µl of 5% dextrose was administered intraperitoneally. This was 
continued daily for 21 days with MMF dose adjusted daily for body weight. 
Additionally on day 10, 2.5 x 105 OT1 TCR Tg CD8 T cells transduced with 
either IMPDH2R or IMPDH2CS were injected intravenously via the tail vein. Mice 
were sacrificed if their weight fell below 80% of baseline or the tumour 
measured greater than 15mm in longest diameter. 
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Figure 5.2 Initiating MMF treatment 10 days after lymphodepleting 
irradiation does not result in toxicity 
Mice received 4Gy TBI, were injected subcutaneously with tumour and then 
rested until day 10 when daily MMF or vehicle injections were started. Mice 
were weighed every 1-2 days and sacrificed if weight fell below 80% of 
baseline. Plots showing the average weights for mice receiving no T cells (A), 
IMPDH2CS transduced T cells (B) and IMPDH2R transduced T cells (C) are 
shown. Results combined from 4 experiments including a total of up to 40 mice 
per group. 
 !
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5.3.2! ! !Combination!of! IMPDH2R!and!MMF!results! in! improved!survival!
compared!with!vehicle!treated!mice!
Mice that did not receive OT1 CD8 T cells exhibited rapid tumour growth and 
were sacrificed between day 16 and 20 (figures 5.3 and 5.4). The group 
receiving MMF alone demonstrated improved survival (log rank p=0.04) 
compared to mice receiving only vehicle. Both groups exhibited rapid tumour 
growth and median survival was one day longer with MMF compared to vehicle. 
In groups receiving adoptively transferred OT1 CD8 T cells and vehicle, there 
was no difference between IMPDH2CS or IMPDH2R transduced cells. Mice in 
these groups required sacrifice due to tumour size between day 20 and 34 
(Figure 5.3B).  
Mice treated with IMPDH2CS transduced OT-1 T cells and MMF exhibited 
significantly worse survival than those treated with vehicle (Figure 5.3D; log 
rank p=0.0004). There was marked variability within the vehicle treated group 
with rapid tumour growth in approximately 50% of recipients and the remainder 
surviving to similar time points as MMF treated mice. This is shown in figure 
5.4B, where at day 18 there was a significant increase in tumour size in the 
vehicle treated group (Mann Whitney p=0.0027) but at day 26 there was no 
significant difference in tumour size in surviving mice (Mann-Whitney p=0.0845).  
Unexpectedly, mice receiving IMPDH2R transduced cells survived longer when 
MMF was administered compared to vehicle treated mice (Figure 5.3E; log 
rank p<0.0001) and showed significantly increased tumour regression (Figure 
5.4C; Mann Whitney at day 18 p=0.0011; day 26 p<0.0001). I had originally 
hypothesised that this group would have similar tumour growth and survival as 
seen in vehicle treated mice. 
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Figure 5.3 Mice receiving IMPDH2R transduced T cells and MMF exhibit 
increased survival over mice receiving IMPDH2CS transduced cells or 
vehicle 
Kaplain-Meyer survival curves are shown combining results from three 
independent experiments, total of 16 mice per groups receiving T cells and 8 
mice in the no T cell groups. (A) Shows all six groups, (B) Vehicle treated 
groups, (C) MMF treated groups, (D) groups receiving IMPDH2CS transduced 
cells and (E) groups receiving IMPDH2R transduced cells. Log rank test MMF 
IMPDH2CS v IMPDH2R p<0.0001; IMPDH2R vehicle v MMF p<0.0001; 
IMPDH2CS Vehicle v MMF p=0.0004. 
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Figure 5.4 Mice receiving IMPDH2R transduced cells had significantly 
increased tumour regression when treated with MMF compared with mice 
receiving IMPDH2CS transduced cells or vehicle 
Individual plots of tumour area for each mouse are shown for (A) groups 
receiving no T cells; (B) mice receiving IMPDH2CS transduced cells and (C) 
mice receiving IMPDH2R transduced cells. Mice given MMF are shown in red 
and vehicle in blue. 
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5.3.3!Mice!receiving!MMF!and!IMPDH2R!transduced!cells!have!increased!
percentages!of!transduced!OT1!in!peripheral!blood!than!mice!receiving!
vehicle!or!IMPDH2CS!transduced!cells!
In the tumour experiments described in section 5.3.2, mice received identical 
numbers of OT-1 TCR CD8 T cells. The transduction efficiency in each 
experiment was similar for each group (IMPDH2CS and IMPDH2R) and ranged 
from 50-70% between each of the three independent experiments. Each 
recipient therefore received transduced (GFP positive) and untransduced (GFP 
negative) cells. In order to investigate the engraftment of transferred cells and 
their selection, surviving mice had peripheral blood sampled 10-14 days after 
adoptive T cell transfer (figure 5.5). Mice receiving IMPDH2R cells had 
significantly increased percentages of both total OT1 T cells (CD8, Vα2, Vβ5 
positive cells) and transduced OT1 cells than mice treated with vehicle (Mann 
Whitney p<0.0001) or IMPDH2CS and MMF (Mann Whitney p=0.0004).  
Results are given as percentages rather than absolute numbers due to the 
nature of sampling. However for similar volumes of blood taken from each 
mouse, there were notably fewer recordable events from the group receiving 
MMF and IMPDH2CS transduced T cells in comparison to the other groups. 
Following the findings presented in sections 5.3.2 and 5.3.3, I proposed the 
following hypothesis;  
MMF suppresses reconstitution of one or more endogenous cell type 
that after irradiation, in the absence of MMF, inhibits adoptively 
transferred cells.  
 !
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Figure 5.5 Mice receiving MMF and IMPDH2R transduced cells have a 
higher percentage of transduced OT1 T cells in peripheral blood than 
mice receiving vehicle or IMPDH2CS transduced cells. 
10-14 days after T cell transfer, peripheral blood was sampled from surviving 
mice. Samples were stained for CD8, TCR Vα2, TCR Vβ5 and GFP and 
analysed by FACS. Summary results combining three independent 
experiments are shown with total OT1 TCR and transduced OT1 TCR cells 
given as a percentage of live cells. 
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5.3.4! Following! lymphodepleting! irradiation,! MMF! has! varying! effects!
on!reconstitution!of!different!lymphocyte!subsets!in!different!organs!
I investigated the effects of MMF on different endogenous cell types following 
lymphodepleting irradiation. The experimental protocol, which mirrors the 
tumour model described in figure 5.1 (pp. 174), is outlined in figure 5.6 and 
consisted of 4Gy of total body irradiation and 100µg/g/day MMF starting on day 
10. Cohorts of mice were sacrificed after 5, 9 and 16 days of MMF or vehicle 
treatment and cells stained for B cell, T cell and NK cell markers. BrdU was 
added to the drinking water from day 10 to enable assessment of cell turnover. 
Cells were stimulated overnight with PMA and Ionomycin and intracellular 
staining for interferon-gamma assessed. 
As had been seen in my previous experiments, the primary effect of MMF in 
the absence of irradiation was suppression of B cells (figure 5.7A-C). This was 
seen in spleen, bone marrow and lymph nodes in terms of both percentage of 
live cells and absolute number from day 9 of treatment (Mann-Whitney 
p=0.0286). In the spleen, there was suppression of CD4 and CD8 T cell 
numbers but an increase in the absolute number of NK cells at day 16. The 
absolute number but not relative percentage of CD4 and CD8 cells was 
reduced in bone marrow on day 16.  
BrdU incorporation was similar for all CD4 and CD8 splenocytes tested at day 
16. Surprisingly, in the MMF treated group there was greater BrdU 
incorporation in NK cells than in the vehicle treated group (figure 5.8A and B). 
The number of CD8 T cells and NK cells producing interferon gamma was 
significantly reduced in MMF treated groups.   
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Figure 5.6 Overview of model to investigate effects of MMF on different 
cell subsets in mice receiving lymphodepleting irradiation 
B6 mice were given 4Gy of TBI and rested until day 10 when MMF 100µg/g or 
vehicle was administered daily via intraperitoneal injection. BrdU was added to 
the drinking water at a concentration of 0.8M. Mice were weighed daily and 
cohorts culled after 5, 9 and 16 days of MMF treatment. 
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Figure 5.7 MMF has different effects on reconstitution of several 
lymphocyte subsets and in different organs following lymphodepleting 
irradiation 
Mice were treated as per the model outlined in figure 5.6. Samples were 
stained for CD19, CD4, CD8, NK1.1 and CD335 (NKp46) and analysed by 
FACS. Results are given for (A) Spleen, (B) Bone marrow and (C) peripheral 
lymph nodes with each cell type given as a percentage of a live gate (based on 
forward and side scatter) and as absolute numbers. Gating was for B cells 
(CD19 positive), CD4 T cells (CD4 positive, NK1.1 negative), CD8 T cells (CD8 
positive, NK1.1 negative), NK cells (NK1.1 and CD335 positive) and NKT cells 
(NK1.1 positive, CD335 negative, CD4 and/or CD8 positive). Each group 
consists of four mice. Blue = vehicle treated mice; red= MMF treated mice; * = 
Mann-Whitney test p<0.05. 
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Figure 5.7 
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Figure 5.7 
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Figure 5.7 
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Figure 5.8 MMF treatment after lymphodepleting irradiation does not 
significantly reduce the number of cells incorporating BrdU but does 
reduce the number of Interferon gamma producing CD8 and NK cells in 
the spleen 
Splenocytes taken after 16 days of MMF treatment following 4Gy of total body 
irradiation were stained for CD4, CD8, NK1.1 and BrdU which had been 
present in drinking water since initiation of MMF. Percentage of BrdU positive 
cells (A) and absolute number (B) are shown. 2 x 106 cells from each mouse 
were cultured over night and stimulated with PMA and Ionomycin. The 
percentage (C) and absolute number (D) of Interferon gamma producing cells 
are shown. Each group consists of four mice. Blue = vehicle treated mice; red= 
MMF treated mice; * = Mann-Whitney test p<0.05. 
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5.3.5!Depletion!of!NK!cells!does!not!prevent! improved! tumour!control!
when!IMPDH2R!transduced!cells!and!MMF!are!combined!
NK cells are the first endogenous cells to become detectable after 
lymphodepletion. Previous work has shown that NK cells inhibit adoptive 
immunotherapy of tumour (Gattinoni, 2005). This group demonstrated that in 
vivo depletion of NK cells with PK136 antibody resulted in improved tumour 
control. I therefore hypothesised that improved tumour control seen when 
IMPDH2R and MMF were combined resulted from a suppressive effect of MMF 
on endogenous NK cells. In parallel with the experiments described in section 
5.3.4, I designed and performed the experiment outlined in figure 5.9. T cells 
were transduced with IMPDH2R for transfer to all recipients. Four treatment 
groups were included; PK136 + Vehicle, PK136 + MMF, isotype control + 
Vehicle and isotype control + MMF.  
PK136 antibody administration did not cause increased weight loss (Figure 
5.10A). Immediately prior to the final dose of PK136 antibody, peripheral blood 
was taken to assess NK cell numbers, which were significantly reduced in the 
PK136 group compared to isotype control (figure 5.10B). 
Individual tumour growth curves (figure 5.11) demonstrate that NK depletion 
did not abrogate improved tumour control with MMF. In PK136 treated mice 
(figure 5.11C) the MMF group had significantly smaller tumours (Mann-Whitney 
day 18 p=0.0012 and day 27 p=0.0006) than the vehicle treated group. 
In combination with the results described in section 5.3.4, it is unlikely that 
suppression of endogenous reconstitution of NK cell by MMF is the mechanism 
by which improved tumour control is seen in mice receiving the combination of 
MMF and IMPDH2R transduced T cells.  !
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Figure 5.9 Overview of NK depletion model 
C57Bl6/J mice were used as recipients and on day one were irradiated with 
4Gy TBI. 4 hours later 1 x 106 EG7 cells suspended in matrigel were injected 
subcutaneously in the shaved right flank of the mice. The mice were monitored 
for tumour growth and weight. On day 10, either MMF 100µg/g in 200µl 5% 
dextrose or 200µl of 5% dextrose was administered intraperitoneally. This was 
continued daily for 21 days with MMF dose adjusted daily for body weight. 
Additionally on day 10, 2.5 x 105 OT1 TCR Tg CD8 T cells transduced with 
IMPDH2R were injected intravenously via the tail vein. Mice were sacrificed if 
their weight fell below 80% of baseline or the tumour measured greater than 
15mm in longest diameter. 
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Figure 5.10 In vivo antibody depletion of NK cells does not cause 
increased toxicity 
Mice treated as per the model outlined in figure 5.5 were monitored for weight 
loss on a two-three daily basis. Average weight change from baseline is plotted 
against time (A). Immediately prior to administration of the fifth and final dose of 
PK136, peripheral blood was taken from the mice and stained for NK1.1. The 
percentage of cells in a live gate (based on forward and side scatter) that were 
NK1.1 positive is shown (B). 
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Figure 5.11 Antibody depletion of NK cells in vivo does not abrogate the 
improved tumour control seen when mice receive IMPDH2R transduced 
cells and MMF  
Mice treated as per the model outlined in figure 5.9 had tumour measured by 
callipers every two days during MMF or vehicle administration. Tumour area 
was calculated from two perpendicular diameters. Tumour growth for individual 
mice is plotted for (A) mice that received no T cells, (B) mice that received 
isotype and T cells and (C) mice that received PK136 and T cells. Each group 
consisted of seven mice. Mice were sacrificed when the maximum tumour 
diameter measured >15mm. 
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5.3.6! Tumour! control! by! IMPDH2R! transduced! cells! in! the! absence! of!
endogenous!lymphocytes!
As suppression of endogenous cells other than NK cells could result in the 
improved tumour control when MMF and IMPDH2R transduced cells were 
combined, I designed experiments using Rag knockout (Rag-/-) mice as 
recipients. Rag-/- mice are unable to develop functional receptors required for B 
and T cell maturation resulting in congenital absence of lymphocytes. In an 
initial pilot experiment, the experiment protocol used was otherwise identical to 
that outlined in figure 5.1. In this experiment tumour growth was significantly 
faster than in previous experiments requiring sacrifice of all mice within two-
three days of starting MMF. Due to the number of recipient mice available, I 
was unable to complete the experiments during my fellowship and the results 
shown are the work of Dr Pedro Velica and Sophie Ward. They followed the 
experimental plan I designed, with the protocol outlined in Figure 5.12. To 
reduce tumour growth prior to initiation of MMF, I reduced the length of time 
from tumour inoculation to MMF administration from 10 to 7 days. Only one 
mouse in the MMF alone group, who had cleared tumour, required culling due 
to weight loss. 
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Figure 5.12 Overview of Rag -/- model 
Rag-/- mice were used as recipients and on day one were irradiated with 4Gy 
TBI. Four hours later 1 x 106 EG7 cells suspended in matrigel were injected 
subcutaneously in the shaved right flank of the mice. From day seven, either 
MMF 100µg/g in 200µl 5% dextrose or 200µl of 5% dextrose was administered 
daily intraperitoneally. This was continued with MMF dose adjusted daily for 
body weight. Additionally on day seven, 2.5 x 105 OT1 TCR Tg CD8 T cells 
transduced with IMPDH2R were injected intravenously via the tail vein. Mice 
were sacrificed if their weight fell below 80% of baseline or the tumour 
measured greater than 15mm in longest diameter. 
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Significant tumour control was seen when MMF was given in the absence of 
adoptive immunotherapy compared to vehicle (Figure 5.13; Mann-Whitney 
p=0.0079, median 28.5mm2 vs 152.5mm2). In mice receiving both IMPDH2R 
transduced OT-1 T cells and MMF there was no significance in tumour control 
as in the group receiving MMF alone (Mann-Whitney p=0.0631; median 0mm2 
vs 28.5mm2). Of note, six of seven mice cleared tumour when both MMF and 
IMPDH2R transduced cells were given while only one of five cleared tumour 
with MMF alone. There was significant selection of transduced cells in mice 
receiving MMF (data not shown). 
In all mice that received vehicle, the tumour continues to grow for the first five 
to six days. In mice receiving vehicle and IMPDH2R transduced OT-1 T cells, 
tumour growth halts from day six and then regression of tumour was observed. 
The tumours remained significantly larger than in the MMF treated groups 
(Mann Whitney p=0.0017; median 0mm2 vs 66.03mm2). Mice receiving no 
immunotherapy exhibited continued tumour growth throughout. 
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Figure 5.13 MMF significantly inhibits tumour growth even in the absence 
of adoptively transduced cells when treatment is started with less 
established tumours 
Mice treated as per the model outlined in figure 5.12 were monitored for weight 
loss and tumour growth every two to three days. Individual plots of tumour area 
for each mouse are shown for (A) groups receiving no T cells and (B) mice 
receiving IMPDH2R transduced cells. (C) average tumour area for each of the 
four groups are shown with SEM. Mice given MMF are shown in red and 
vehicle in blue, hashed lines indicates groups receiving no adoptive 
immunotherapy. 
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5.4!Discussion!
The work presented in this chapter demonstrated that IMPDH2R transduced 
cells retain function in vivo during MMF treatment. Unexpectedly, when given in 
combination with MMF, IMPDH2R transduced cells demonstrate improved 
tumour control when compared to mice receiving cells and vehicle. In mice 
receiving the combination of MMF and IMPDH2R transduced cells, I have 
demonstrated an increased percentage of transduced cells in the peripheral 
blood, due to both an increase in total transferred cell percentage and selection 
for IMPDH2R.  
There are two potential reasons for this improved outcome. Firstly that MMF 
suppresses an endogenous cell type enabling the transferred cells to more 
effectively treat the tumour. Secondly, that there is synergistic activity of both 
MMF and transferred cells against the tumour. Because the number of 
transduced cells was increased in the group receiving MMF and IMPDH2R cells, 
I initially favoured the first hypothesis and designed experiments to investigate 
the role of different lymphocyte subsets.  
Because NK cells are know to act as cytokine sinks and are one of the first 
lymphocyte subsets to reconstitute following lymphodepletion, I investigated 
the role of endogenous NK cells by in vivo antibody depletion. If NK cells were 
the responsible lymphocyte subset, I hypothesised that the beneficial effect of 
MMF would be lost. NK cell depletion did not alter the improved tumour control 
seen when IMPDH2R transduced cells and MMF were combined.  
When investigating the role of MMF on the recovery of lymphocyte subsets 
following lymphodepleting irradiation, I was surprised to find that the absolute 
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number of NK cells was increased in the spleens of mice receiving MMF 
compared to vehicle. The numbers of B cells and both CD4 and CD8 T cells 
were suppressed in the spleen at the same time point. This could be a result of 
differences in cellular sensitivity to MMF i.e. NK cells being less sensitive than 
other cells. Under conditions where cell numbers are reduced, NK cells could 
then out-compete for cytokines resulting in increased numbers. While NK cell 
numbers were increased, there was significant reduction in interferon gamma 
suggesting a functional deficiency. This could reflect exposure to levels of MMF 
able to inhibit some intracellular processes but not high enough to lead to cell 
cycle arrest or apoptosis.  
To investigate the effect of other lymphocyte subsets, Rag -/- mice were used 
as recipients because they lack lymphocytes entirely. A benefit for the 
combination of IMPDH2R transduced cells and MMF compared with vehicle 
persisted in the absence of lymphocytes. The results from this experiment 
supported the second hypothesis. In all my tumour experiments, a slight 
advantage had been seen for MMF in the control groups that did not receive 
adoptive immunotherapy. This advantage was much more pronounced in the 
Rag-/- experiments and produced similar results whether cells were transferred 
or not.  
It is well established that MMF has an anti-tumour effect. This can be seen in 
my results using BK cells (sections 3.3.1 to 3.3.4, pp. 99-112) and is reviewed 
in section 1.4.6 (pp. 66). While the effect has been demonstrated easily in vitro 
against both tumour cell lines and primary malignant cells, the effect has been 
variable in vivo. Reasons for this could include the type of tumour and its 
location, the dosing of MMF used and differences in pharmacokinetics and 
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pharmacodynamics. It is possible that MMF did have a subclinical effect on 
tumour cells and that addition of a second therapy e.g. T cells can have a 
synergistic effect. 
The Rag-/- experimental protocol (Figure 5.12) differed from the others 
described in this chapter because very rapid tumour growth was seen in a pilot 
experiment. Therefore at the time of initiating MMF therapy, the tumour was 
less well established. It is likely that in my other experiments this effect would 
have also been seen if a smaller tumour inoculum or the time from irradiation to 
adoptive therapy and MMF was reduced. The data presented here support the 
hypothesis that MMF and MMF-resistant adoptive immunotherapy work in 
synergy against experimental tumour in vivo. 
MMF has clear effects on the reconstitution of endogenous cells following 
lymphodepletion. My data shows that if transferred cells are engineered with 
resistance to MMF, they engraft/persist at higher numbers at two weeks 
following transfer than both non-resistant cells given with MMF or resistant cells 
given alongside vehicle. The advantage gained by the transferred cells is likely 
due to suppression of endogenous cells, either in number or in competition for 
limiting cytokines. 
In human studies of patients receiving HSCT, efforts to reduce the incidence of 
GvHD by increasing MMF dosing from 12 to 8 hourly has been shown to delay 
the engraftment of neutrophils from 17 to 22 days if a single unit umbilical cord 
is transplanted (Okamura et al., 2011). When larger stem cell doses are 
administered e.g. double unit umbilical cord (Ponce et al., 2014) or matched 
unrelated donor PBSC (Maris et al., 2004), there is no difference in time to 
engraftment. This likely reflects the degree of lymphoproliferation required from 
202 
the transplanted cells i.e. each cell from a smaller transferred dose will need to 
proliferate more and is therefore more sensitive to MMF induced suppression. 
Despite this effect, there was continued benefit from combining MMF and 
IMPDH2R transduced CD8 T cells both in the congenital absence of 
lymphocytes and depletion of NK cells. This suggests that the effect of MMF on 
endogenous cellular reconstitution is not responsible for the results seen. 
  
203 
Chapter"6:"Discussion!
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In this work, I have demonstrated that ex vivo transduction of lymphocytes with 
IMPDH2R confers MMF resistance. This resistance enables selection in vivo 
and the selected cells retain the ability to function during on going MMF 
exposure.  
6.1! Synergy! between! IMPDH2R! transduced! adoptive! immunotherapy!
and!MMF!!
Studies using genes conferring calcineurin-inhibitor resistance have 
investigated the strategy of using drug resistance genes to enable the use of 
adoptive immunotherapy in immunosuppressed patients post transplantation 
(Brewin et al., 2009, De Angelis et al., 2009). I therefore hypothesised that 
transduction with IMPDH2R would maintain the therapeutic effect of adoptively 
transferred T cells during immunosuppression with MMF. My research not only 
supported this hypothesis but in contrast to studies utilising calcineurin-inhibitor 
resistance, the therapeutic effect during immunosuppression was greater when 
immunotherapy was combined with immunosuppression.  
IMPDH2R transduced cells worked in synergy with MMF to inhibit tumour. 
Because tumour cells utilise large amounts of guanosine nucleotides in order to 
proliferate it is unsurprising that many cancers express increased IMPDH 
(Jackson et al., 1975, Weber et al., 1981, Nagai et al., 1991, Collart et al., 
1992). It has long been established that MPA has anti-tumour activity in vitro 
(Yu et al., 1989, Carter et al., 1969, Engl et al., 2005). Because MPA reduces 
guanosine nucleotide production, an anti-tumour effect would be expected. My 
initial in vitro findings replicated this, demonstrating that MPA increased 
apoptosis and cell cycle arrest resulting in reduction in the expansion of cell 
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numbers in several tumour cell lines including BW5147 and K562 (data not 
shown).  
Having identified the beneficial synergistic effect of combining MMF with 
IMPDH2R transduced cells, I hypothesised that this effect was the result of 
MMF induced suppression of an endogenous cell population. The expanded 
numbers of IMPDH2R OT1 TCR Tg T cells in mice treated with MMF compared 
with mice given vehicle supported this hypothesis. My primary candidate for the 
endogenous cell type being suppressed by MMF were NK cells. Following 
myeloablative transplants, NK cells are the first lymphocyte subset to engraft 
and return to normal levels (Storek, 2008, Guo et al., 2003). They can act as 
cytokine sinks (Gattinoni, 2005) and directly suppress or reject transferred cells, 
reducing the efficacy of adoptive immunotherapy. 
In experiments where NK cells were depleted in vivo, the additive effect of 
MMF and adoptive immunotherapy persisted, excluding NK cells as the 
responsible cell type. The involvement of other endogenous lymphocyte 
subsets was also excluded in experiments using Rag-/- recipients, where again 
the additive effect persisted. These experiments clearly demonstrated marked 
suppression of in vivo tumour growth in mice receiving MMF without adoptive 
immunotherapy. The original tumour experiments using C57Bl6 recipient mice 
had also demonstrated a statistically significant increase in length of survival in 
mice receiving MMF alone compared with vehicle. Tumour continued to expand 
during MMF treatment resulting in a 1-2 day delay before sacrifice due to 
tumour size compared to mice treated with vehicle alone. The protocol used in 
Rag-/- recipients differed from these other tumour experiments. Rapid tumour 
growth was seen in a pilot experiment using Rag -/- recipients, resulting in the 
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need to sacrifice all recipients within 2 days of adoptive immunotherapy. I 
subsequently reduced the time period from injection of tumour until initiation of 
MMF to enable the experiment to proceed.  
In Rag-/- recipients, regression of tumour was immediate and was present at 
the first tumour measurement 2 days after starting MMF. I hypothesise that the 
effect was more marked in Rag -/- recipients because the subcutaneous 
tumours were smaller and less established at the initiation of MMF. To test this 
hypothesis, it would be of interest to repeat the original experiments in C57Bl6 
mice with the shorter window between irradiation and initiation of adoptive 
immunotherapy and MMF. 
Anti-tumour activity of MMF in vitro has not always been replicated in vivo (as 
discussed in section 1.4.6 p63). My data shows that this may potentially reflect 
the specific details of the model used particularly how well established the 
tumour is. I postulate that other tumour specific factors such as type and site of 
tumour at initiation of drug and MMF factors including diluent, dosage, route of 
administration and frequency may be the cause of the variable in vivo 
responses seen. The results I have presented here are for one tumour type in 
one model antigen system using a once daily intraperitoneal administration of 
MMF at one dose. While I have established proof of principle it would be 
important to confirm activity in different tumour models.  
MMF is not used therapeutically as an anticancer agent. My work highlights the 
potential of utilising MMF in the early post transplant period both for its 
immunosuppressive and anti-neoplastic properties, while still enabling targeted 
cellular therapy. 
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6.2! Treatment! of! postHtransplant! viral! infection! with! IMPDH2R!
transduced!adoptive!immunotherapy!
Further investigation into treatment of viral infection with IMPDH2R transduced 
cells during MMF treatment is needed. One of the main risks of 
immunosuppression is viral infection. However, in vitro MMF has been shown 
to have activity against many viruses including dengue, vaccinia, herpes 
simplex, Coxsackie, influenza, hepatitis C, hepatitis B, human 
immunodeficiency virus and synergises with antiviral agents such as 
ganciclovir in the treatment of CMV infection. These effects are not clearly seen 
in vivo. For example there is a dose dependent increased risk of CMV disease 
when taking MMF, presumably because the immunosuppressive effect 
counteracts any direct antiviral effect. Transfer of CMV specific, IMPDH2R 
transduced cells could overcome the immunosuppressive effect. There is 
therefore a rationale to hypothesise that a synergistic effect between MMF and 
IMPDH2R cells may be present in the treatment of viral infection as well as 
tumour.  
6.3!Effect!of!MMF!on!endogenous!lymphocytes!
I had originally postulated that transduction of lymphocytes with IMPDH2R 
would enable their use in adoptive immunotherapy in the absence of 
lymphodepleting irradiation or chemotherapy. I had envisaged administration of 
MMF alone to the recipient would create ‘space’ for the transferred cells 
enabling engraftment. While MMF primarily inhibits dividing cells via cell cycle 
arrest, with greater inhibition of IMPDH it disrupts cell signalling and can initiate 
apoptosis. Escalating the dose of MMF administered in vivo resulted in rapid 
weight loss and death of recipient mice. It became apparent in early 
experiments in vivo that, in the absence of lymphodepletion, the action of MMF 
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alone was insufficient to create adequate ‘space’ for engraftment either by 
reduction of cytokine sinks or suppression of endogenous TReg and NK cells 
that could suppress or kill the transferred cells.  
Several of the experiments presented in this work show clear suppression of B-
lymphocytes across all compartments analysed. This was seen both post 
lymphodepletion and when given to an otherwise untreated recipient. 
Suppression of B cells is reported in patients given MMF (Ganschow et al., 
2001) and could be the mechanism by which MMF successfully treats antibody 
mediated autoimmune disease. Post lymphodepletion, the effect of MMF on the 
numbers of T and NK cells differed with duration of treatment and varied 
between the different organs studied. Interestingly NK cell numbers were 
increased at day 16 with increased BrdU incorporation, suggesting increased 
cell division. NK cell function at this time point was suppressed as evidenced 
by reduced production of interferon gamma in response to PMA and Ionomycin. 
In vitro NK cell cultures have been shown to exhibit reduced expansion and 
activation (Ohata et al., 2011). In these experiments, the cultures only 
contained NK cells that were given sufficient levels of IL-2 and IL-15 and had 
constant MPA exposure. The in vivo environment will be significantly different 
with limiting cytokines and variable MPA levels. It has also been demonstrated 
in vitro that different levels of suppression of GTP result in different effects, with 
K562 cells undergoing differentiation with 60-70% level of GTP and induction of 
apoptosis when levels were suppressed below 40% of normal (Meshkini et al., 
2011). I hypothesise that in inhibiting T and B cell numbers, MMF removes 
cytokine sinks restricting NK cell expansion. The concentration of MMF within 
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NK cells may be sufficient to suppress function but not to achieve apoptosis or 
completely block cell cycle progression. 
The experiments designed to investigate lymphocyte recovery in mice receiving 
lymphodepleting irradiation and MMF were limited in both the number of mice 
and time points studied. It would be of potential interest to look more closely at 
different lymphocytes such as TReg and memory subsets with additional later 
time points to assess the final recovery during on-going MMF treatment. 
Another limitation was the assessment of cellular function in these experiments. 
I incubated cells overnight with PMA and Ionomycin in media that did not 
contain MPA. Cells that had been suppressed by MMF in vivo would have 
IMPDH inhibition removed for 16 hours, during which they may have sufficiently 
regenerated guanosine nucleotide pools to resume normal cellular function. 
This had the potential to overestimate function of cells from MMF treated 
recipients, however reduction in interferon gamma response was still 
demonstrated. Additionally, interferon gamma production was the only modality 
of function investigated and production of other effector molecules may not 
follow the same pattern. 
6.4!Selection!of!IMPDH2R!transduced!cells!
MMF resistance, conferred by IMPDH2R, was shown to enable selection of 
transduced cells both in vitro and in vivo confirming work from other groups. 
The combination of enhancement of the therapeutic effect and selection of 
transduced cells make IMPDH2R an exciting prospect for use in all forms of 
adoptive immunotherapy. A plasmid designed to contain IMPDH2R linked by a 
2A sequence to either a TCR or CAR could be used to enable selection of 
transduced cells either prior to or after adoptive transfer. MMF resistant cells 
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would also express the desired TCR or CAR, therefore MMF driven selection 
would result in deletion of untransduced cells of unknown specificity within the 
product. This is particularly beneficial if the source of transduced cells is an 
allogeneic donor, where the untransduced population will include cells capable 
of causing unwanted toxicity i.e. graft versus host disease.  
6.5!Safety!
A concern regarding therapeutic use of genetically engineered cells is the 
potential for leukaemic transformation as a result of genetic manipulation. This 
may be due to the position that genes are inserted within genomic DNA. An 
additional mechanism for malignant transformation could potentially arise from 
over-expression of IMPDH. By increasing the level of IMPDH within a cell, 
increased guanine nucleotides are produced increasing proliferative potential. 
This is seen physiologically, following lymphocyte activation, when a large 
number of cells need to be produced and pathologically where increased 
IMPDH copy number has been identified in many tumours. 
No evidence of malignant transformation was seen either in vitro or during in 
vivo selection experiments including where mice were left for approximately 7 
weeks after transfer. I had insufficient time to perform long-term safety 
experiments as part of this project and therefore the risk of uncontrolled growth 
of transferred cells, a potential cause of significant morbidity and mortality, 
remains to be quantified.  
Many groups have proposed the use of suicide genes or ‘kill switches’ to 
improve safety of transferred cells. By engineering cells with a gene that 
enables them to be deleted in vivo if they cause morbidity after transfer 
reduces both the consequences of uncontrolled expansion and also morbidity 
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from off target activation. Published examples of these suicide genes or ‘kill 
switches’ include CD20 (which enables rituximab to destroy transferred cells) 
(Griffioen et al., 2009, Introna et al., 2000), HSV-thymidine kinase (which 
enables ganciclovir to inhibit DNA synthesis) (Bonini et al., 1997) or inducible 
Fas or caspase (which can trigger apoptosis) (Budde et al., 2013). 
6.6!Drug!administration!
As discussed previously (section 4.1 pp136) dosing and administration of MMF 
has varied between different groups. A recent publication has suggested a new 
strategy with in vivo use of MMF contained within nanoparticles that targeted 
the drug directly to CD4 cells using monoclonal antibodies (Look et al., 2013). 
This has significant advantages over the dosing strategy I used as it enables 
once weekly, rather than daily, administration of drug thereby significantly 
reducing the number of procedures recipient mice undergo. The action of MMF 
is also targeted more specifically at the cell type of interest and therefore higher 
doses of drug can be delivered to those cells without increased toxicity. 
Additionally, higher intracellular concentrations of MMF will promote cell death 
rather than cell cycle arrest. This could allow targeted removal of cytokine sinks 
potentially enabling engraftment in the absence of lymphodepletion. 
6.7!Future!experiments!
As mentioned in the above discussion, there are several experiments that I 
have planned to carry out with cells transduced with IMPDH2R. These are split 
into three areas, further understanding of the effect of MMF following 
lymphodepleting irradiation, confirmation of IMPDH2R cellular function during 
MMF therapy and further plasmid development. 
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6.7.1!Effects!of!MMF!post!lymphodepletion!
I would repeat the experiments described in section 5.3.4 but extend the time 
points to 21, 28 and 35 days. At sacrifice, I would additionally stain cells for 
TReg markers (CD25 and FoxP3) and T memory phenotype (CD62L CCR7, 
CD127 and CD44). To further investigate cellular function I would stain cells for 
granzyme B and perform ELISA for IL2 and IFN gamma on supernate from 
cells incubated with PMA and Ionomycin. 
6.7.2! Confirmation! of! IMPDH2R! transduced! cell! function! in! other! adoptive!
immunotherapy!models!
Throughout this work, I used the model antigen system OVA/OT1 TCR and 
demonstrated proof of principle of function of IMPDH2R transduced cells during 
MMF therapy. In order to demonstrate activity against EBV+ B cell lymphomas, 
I propose using a protocol recently published in Blood using a calcineurin 
inhibitor resistance gene (Ricciardelli et al., 2014). In this model, 
NOD/SCID/IL2rγnull (NSG) mice inoculated subcutaneously with EBV-
transformed lymphoblastoid B cell lines i.e. a human EBV+ B cell lymphoma. 
The tumours were labelled with F-Luc to allow imaging of tumour response to 
CTLs transduced with immunosuppressant drug resistance genes. 
Additionally I propose studying whether IMPDH2R transduced cells retain 
function against virus using a murine model of CMV infection and T cells dual 
transduced with a CMV TCR and IMPDH2R. For these experiments I propose 
either using the MMF dosing strategy used throughout this work, namely 
100µg/g/day i.p. once daily. 
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6.7.3! Development! of! new! plasmids! H! Generation! and! testing! of! multiH
immunosuppressive!agent!resistance!plasmids!!
MMF is a commonly used immunosuppressive agent, particularly in solid organ 
transplantation. In many patients other immunosuppressive agents may be 
used either alone or in combination. As has already been shown by several 
groups, resistance to immunosuppressant will allow treatment of patients with 
post-transplant lymphoproliferative disorder whilst they are receiving 
calcineurin inhibitors. It would therefore be sensible to combine different drug 
resistance genes into one cassette which could then be used to produce cells 
resistant to all commonly used immunosuppressive drugs.  
I propose generation of a vector containing IMPDH2R, CNB30 (calcineurin 
inhibitor resistance gene) and for safety insertion of a ‘kill switch’. This will need 
in vitro validation prior to investigation in vivo to investigate whether transduced 
cells will retain therapeutic efficacy in the context of dual immunosuppression. 
Either addition of MMF to the tumour model described in section 6.7. 
(Ricciardelli et al., 2014) or calcineurin inhibitor to the tumour model I 
developed could be used. Additional activity in models of viral infection would 
be beneficial. It will be important to demonstrate that the enhanced efficacy of 
MMF-resistant cells given with MMF persists in the context of dual 
immunosuppression, albeit with resistance to both immunosuppressive agents. 
Once safety is established I would envisage translation to use in humans for 
the treatment of PTLD using either selected EBV-specific or TCR transduced T 
cells. 
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